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Abstract 
This project highlighted that Src and Src kinase family (SFK) members play a definitive 
role in breast cancer. Due to the paucity of translational studies, we investigated if SFK 
members are expressed in human breast tissue. Eight SFK members were present with 
distinct mRNA expression patterns in normal, non-malignant and malignant breast tissue. 
Immunohistochemistry was employed to investigate protein expression and activation of 
Src and SFK members. Survival analysis revealed that c-Src and activated Y419Src were 
associated with worse patient outcome, confirming current in vitro literature, whereas a 
different phosphorylation site of Src (Y215) and expression of Lck was associated with 
improved clinical outcome. Dasatinib was employed in different breast cancer cell lines to 
establish its effect on those phosphorylation sites. Decreased expression of c-Src and 
Y419Src was observed, whilst Y215Src expression stayed unchanged, providing a 
rationale for using this Src kinase inhibitor in clinical trials. 
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TGF-α ........................................  Transforming growth factor alpha  
TMA ..........................................  Tissue Microarray 
TRAM .......................................  Transverse Rectus Abdominis Muscle 
TTBS .........................................  Wash buffer for Western Blotting 
TP53 ..........................................  Tumour protein 53/ tumour suppressor gene 
Tyr .............................................  Tyrosine 
u-PAR ........................................  urokinase plasminogen activator receptor 
UQ .............................................  Upper quartile 
UK .............................................  United Kingdom 
V ................................................  Volt 
VEGFR ......................................  Vascular endothelial growth factor receptor 
w/v .............................................  weight/volume 
XR .............................................  X-rays 
Y861FAK ..................................  Focal adhesion kinase phosphorylated at tyrosine 861 
Y215Src ....................................  Src kinase phosphorylated at tyrosine site 215 
Y419Src ....................................  Src kinase phosphorylated at tyrosine site 419 
22 
Summary 
There is a paucity of translational clinical studies, to support in vitro evidence indicating a 
role for Src kinase and Src kinase family members in breast cancer.  
In vitro studies demonstrated that Src plays an important role as a regulator of cell 
proliferation and survival. Evidence from those studies also suggests that elevated c-Src 
activity promotes cellular invasion and motility in Tamoxifen resistant breast cancer cells 
providing a link between the HER family and steroid receptors. Other reports propose that 
c-Src may be implicated in aggressive ‗triple negative‘ breast cancer.  
There are at least eight other members of the Src kinase family present throughout 
mammalian cells with different expression patterns. Again there is little published data on 
the role of other Src kinase family members in breast cancer. Microarray studies have 
demonstrated that Lyn is upregulated in models of endocrine resistance and Lck is 
implicated in hypoxia induced breast cancer progression. 
Activation of Src is complicated and can occur in different ways. It either involves 
dephosphorylation of a negative regulatory domain as well as phosphorylation of an 
activation loop (classical activation pathway) and/or activation by protein interactions or 
more recently discovered by direct phosphorylation of Y215Src increasing activation by 
50fold. 
Several Src kinase inhibitors have enrolled in phase I, II even phase III clinical trials in 
breast cancer. The rationale for those trials in patients with advance breast cancer was 
mainly based on cell line studies strongly supporting the role of Src and SFK members in 
breast cancer progression and metastasis, but with very limited proof of translational 
studies indicating clinical significance of abnormal SFK expression and activation in breast 
cancer.  
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In the current study we therefore aimed to assess expression and activation of Src and SFK 
members in large patient cohorts, with full clinical data and follow-up as well as 
investigating effects of the clinically trialled Src kinase inhibitor Dasatinib on Src and its 
various activation sites, utilising fresh frozen tissue and tissue micro arrays, in conjunction 
with in vitro functional studies. 
 
Using RT-PCR we determined mRNA expression levels for all SFK members in human 
breast tissue specimens. Src and other SFK members were expressed at different levels in 
normal, non-malignant and malignant breast tissue. Src and Lyn were the most highly 
expressed SFK member in non-malignant and malignant tissue. Lck was higher expressed 
in ER negative, compared to ER positive tumours.  
This varied significantly from the expression profile of normal breast tissue specimens, 
were Fyn was the most highly expressed SFK member followed by Src and Lyn.  
Having identified which Src kinase family members were the most noteworthy in breast 
tumours, the role of Src kinase, Lyn and Lck protein expression was investigated by 
immunohistochemistry in an expanded cohort of clinical breast cancer specimens. Four 
separated Src phosphorylation sites were also incorporated in this study to explore their 
clinical relevance and impact on patient outcome. Additionally, Ki67 expression was 
examined to determine if high tumour proliferation was linked to SFK members‘ 
expression and activation. 
Increased cytoplasmic c-Src kinase expression was significantly associated with decreased 
disease specific survival. These results are in keeping with cell line studies, demonstrating 
that c-Src is associated with more aggressive growth and poor clinical outcome. c-Src 
expression also correlated with increased tumor grade, ER negativity and HER2 positivity. 
No significant associations with survival were detected with Lyn at any cellular location. 
However, membrane Lck expression was significantly associated with longer survival of 
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breast cancer patients. Even so, none of the patients expressing Lck at the cellular 
membrane died of breast cancer related causes. 
When Src kinase was activated at the classical site Y419 and located in the cellular 
membrane, it was associated with shorter disease specific survival, increasing grade, 
tumour size, ER negativity and HER2 positivity. While our results with Y419 support the 
role of Src kinase activation currently described in the literature, we found contradictory 
results with the alternative activation site Y215. Phosphorylation at this site was strongly 
associated with improved survival and was demonstrated to be independent of other known 
clinical parameters on multivariate analysis. It remains unclear why Y419Src and Y215Src 
are associated with different outcome measures. These contrasting roles may be due to 
phosphorylation at Y215 and Y419 residing in different SH protein domains. 
Phosphorylation in different domains may result in varying protein configurations, which 
might enable activation of other downstream signalling pathways. An alternative 
explanation of these results may be that the antibodies detect phosphorylation of other Src 
kinase family members (e.g. Lyn, Fyn, Yes) in addition or in preference to c-Src, as the 
phosphorylated regions are highly conserved. However we could not establish a link with 
SFK member Lck, which also showed improved patient outcome.  
Examining ER, PgR and HER2 negative breast tumours as a representation of the triple 
negative group of breast tumours, we found that high cytoplasmic Y215 Src kinase 
expression resulted again in a significant survival advantage. 
Based on our findings in clinical specimens we moved our attention to cell line studies. 
Four breast cancer cell lines, each representing one of the breast cancer subgroups, were 
studied to observe effects of Src kinase inhibitor Dasatinib on the various Src 
phosphorylation sites, SFK member Lck and downstream substrate Y861FAK. Membrane 
expression of phosphorylation site Y419Src, which was associated with decreased survival 
in the IHC study, was significantly reduced in all cell lines, yet almost abolished in the 
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triple negative cell line. Expression of downstream substrate Y861FAK, in this study 
functioning as a biomarker for Src activation and inhibition, was also diminished, whereas 
expression of activation site Y215, associated with improved clinical outcome of breast 
cancer patients, remained unchanged in all cellular compartments. 
This comprehensive study on expression and activation of Src and SFK members and their 
response to Src kinase inhibitor Dasatinib fills a gap in current literature. It strengthens the 
role of Src in breast cancer, potentially provides a diagnostic method for identification of 
patients that would respond to Src inhibitors and justifies the use of Src inhibitors in the 
clinical setting. 
 
  
 
 
 
CHAPTER 1 
 
 
 
 
INTRODUCTION 
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1.1 Breast Cancer 
1.1.1 Incidence and Survival Rates 
Breast cancer is the most common female malignancy worldwide and accounts for over 
32% of all cancer cases among women in England (1). Between 1981 and 2005, breast 
cancer incidence increased by a substantial 57% (1), with 45500 women and 300 men 
being newly diagnosed with the disease in 2005 in England (figure 1.1) and 4030 women 
and 20 men in Scotland (2). Although the incidence rates continue to increase, mortality 
has in fact decreased by almost a fifth in the last ten years. This is most likely due to earlier 
detection, minimization of risk factors and improved treatment. Survival rates in England 
have improved over the period 1999-2003. Breast cancer survival at five years was 81% 
(1) (figure 1.2). Survival from breast cancer is higher than that for cervical cancer and 
much higher than that for the other major cancers in women- lung, colorectal and ovarian. 
For women diagnosed in 2001-03, 72% are likely to survive for at least ten years. 
However, survival is still decreasing more than ten years after diagnosis, and only 64% are 
likely to survive for at least 20 years (3). 
28 
Chapter 1 Introduction 
 
Figure 1.1: Breast cancer incidence and mortality 
 
 
Figure 1.1: Diagram showing female breast cancer incidence and mortality between 
1971-2005 in England (1). 
Figure 1.2: Survival rates for selected cancers 
 
Figure 1.2: Five year relative survival rates for selected cancers for adults diagnosed 
during 1999-2003, England (1) 
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1.1.2 Risk Factors 
The risk of developing breast cancer is strongly linked to age – nearly three-quarters of 
cases occur in women over 65 (3).  
Many of the established risk factors are linked to oestrogen. The risk is increased by early 
menarche, late menopause, and obesity in postmenopausal women. Early pregnancy and 
breast feeding seems to have a protective effect (4). HRT increases the risk of breast cancer 
and reduces the sensitivity of mammography (5-8). The risk of breast cancer for current 
users of HRT is 66% higher than for never-users. The effect is substantially greater for 
oestrogen-progestagen combinations than for oestrogen only HRT. Risk also increases 
with duration of use: the risk for current users of oestrogen-progestagen combinations for 
10 or more years was 2.31 (CI: 2.08-2.56) compared to 1.74 (CI: 1.60-1.89) for one to four 
years of use. Risk decreases with cessation of use. In the UK over the past ten years, it is 
estimated that 20,000 extra breast cancer cases have occurred among women aged 50-64 as 
a result of HRT use and three quarters (15,000) of these additional breast cancers are due 
to the use of oestrogen-progestagen HRT (8). 
About 8% of breast cancer cases in the UK may be attributable to overweight and obesity 
(9). In one pooled analysis the risk of developing breast cancer was increased by around 
30% in postmenopausal women with a BMI >28kg/m
2
 compared to a BMI of less than 
21kg/m
2
 (10). After the menopause, when the ovaries stop producing oestrogen, adipose 
tissue is the primary source of endogenous oestrogen so obese and overweight women are 
exposed to higher levels of oestrogen. Obesity is also associated with lower levels of sex 
hormone binding globulin (SHBG), which increases the amount of bio available oestradiol 
(11). In premenopausal women, some but not all studies have observed that a higher BMI 
is associated with a slightly lower risk of breast cancer – possibly because it results in 
decreased exposure to endogenous oestrogens through increased anovulatory cycles. 
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A recent report from the International Agency for Research on Cancer concluded that 
physical activity has a preventive effect on breast cancer (12). This may be an indirect 
effect with exercise lowering BMI, or a direct effect on hormonal and growth factor levels. 
The magnitude of this effect varies between studies; a typical result is a 30-40% reduction 
in the risk of breast cancer with a few hours per week of vigorous activity versus none (4). 
A significant association between alcohol intake and breast cancer has been found, with an 
increase of risk of 7% for each alcoholic drink consumed on a daily basis (13). Around 4% 
of breast cancers in women in developed countries may be attributable to alcohol. 
Although alcohol and tobacco smoking are closely related social habits, there is no direct 
association between tobacco and breast cancer. 
Ionising radiation is an established risk factor for breast cancer and excessive exposure to 
radiation should be avoided. The effect of radiation on the breast is strongly related to age 
at exposure i.e. the younger the woman is exposed the greater the excess risk. A recent 
study estimated that exposure to diagnostic x-rays may be responsible for 29 cases per year 
of female breast cancer before the age of 75 in the UK, an attributable risk of 0.1%. 
Overall 0.6% of the cumulative risk of cancer to age 75 might be radiation-induced in the 
UK– approximately 700 cases of cancer each year. This was low compared to the other 
developed countries studied (14). Another group at increased risk are women treated for 
Hodgkin‘s disease by mantle irradiation where there is an approximate doubling of lifetime 
risk. Women treated in this way before age 35 are being recalled nationally and offered 
special surveillance. 
Breast cancer is one of the few cancers to have a higher incidence in the more affluent 
social classes (15). The age standardised incidence rate is 115.1 per 100,000 women in the 
least deprived quintile compared to 97.3 in the most deprived quintile. This is probably a 
reflection of other factors including reproductive history and early nutrition. 
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Benign breast disease is a generic term describing all non-malignant breast conditions. As 
such it encompasses diseases associated with an increased risk of breast cancer and others 
that do not have a raised risk. The commonest breast lump in young women is a 
fibroadenoma, which is not associated with an increased risk of breast cancer. Women in 
their 30s and 40s may develop cysts and those that suffer multiple cysts are at slightly 
increased risk of breast cancer. Women who have had biopsies that showed proliferative 
breast disease without atypia have a two-fold increased risk, while women with atypical 
hyperplasia have a two to five-fold increased risk (16-18).  
If a woman has had breast cancer, her risk of developing a second primary breast cancer is 
two to six times the risk seen in the general population of developing a primary breast 
cancer (19). 
A woman with one affected first degree relative (mother or sister) has approximately 
double the risk of breast cancer of a woman with no family history of the disease; if two 
(or more) relatives are affected, her risk increases even further (20). 
However, over 85% of women who have a close relative with breast cancer will never 
develop the disease and 85% of women with breast cancer have no family history of it 
(21). In developed countries it is estimated that hereditary factors contribute around a 
quarter of inter-individual differences in susceptibility to breast cancer, while 
environmental and lifestyle factors contribute the remaining three-quarters (4). A small 
proportion of women have a particularly strong family history of breast cancer. Mutations 
in the breast cancer susceptibility genes BRCA1 and BRCA2 account for the majority of 
families with four or more members affected (2-5% of all breast cancers) (22). Women 
carrying such a mutation have a 50-80% chance of developing the disease.  
Genetic testing for faulty BRCA genes is available on the NHS for women with a very 
strong family history. Increased susceptibility to breast cancer is also a feature of several 
rare, familial cancer syndromes (table 1.1). 
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Table 1.1: Rare familial cancer syndromes associated with breast cancer 
Gene Cancer Syndrome Associated Tumours 
BRCA1 Breast/Ovarian Predisposition Breast/Ovarian/Bowel/Prostate  
BRCA2 Breast/Ovarian Predisposition Breast (incl.male)/Ovarian/ Prostate/ 
Pancreatic 
TP53 Li Fraumeni Syndrome Childhood Sarcoma/ Leukaemia/ 
Brain/ Early Onset Breast 
PTEN Cowden‘s Syndrome Breast/GI/ 
Thyroid (benign & malignant) 
STK11/LKB1 Peutz-Jeughers Syndrome Breast/GI/Pancreatic/Ovarian 
ATM Ataxia telegiectasia Non-Hodgkin Lymphoma/ Ovarian/ 
Breast 
Table 1.1 listing up different genetic mutations of rare familial cancer syndromes 
associated with breast cancer 
Since breast cancer affects one woman in nine there will be many women who have a 
mother or sister with the disease. But only if there are several family members with early 
onset breast cancer is there a likelihood of a significant inherited predisposition to the 
disease (23). 
1.1.3 Symptoms and Detection of breast cancer 
The breast screening programme was introduced in 1988 with the aim of reducing the 
number of women dying from breast cancer. Initially breast screening was offered every 
three years to all women aged between 50 and 64. Mammography detects a large 
percentage of breast cancers early before any symptoms are noticed. By 1998, mortality 
was around 20% lower than it would have been without screening. The decrease of 
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mortality occurred in all age groups, but was greatest in women aged 55 to 69. The age 
range was stepwise extended over the years. Since 2008 proposals are in place to invite 
women between age 47 and 73 every three years (1) for breast screening. Scotland 
currently screens women between the age of 50 and 70. 
Generally women should be ―breast-aware‖. If a change in the breast has been noticed on 
regular self-examination a referral to a specialist breast clinic is necessary. Symptomatic 
patients can present with clinical signs like breast lumps, change in size or shape of the 
breast, dimpling of breast skin, nipple inversion, change in the nipple, swelling or lump in 
the axilla a blood-stained discharge from the nipple and/or rash around the nipple (Paget‘s 
disease).  
1.1.4 Malignant invasive neoplasms of the breast 
Breast cancer derives from epithelial cells, found in the terminal duct or lobular unit. Main 
pathological characteristic is breaching the basement membrane of the duct or lobules and 
dissemination of cancer cells into the surrounding adjacent normal tissue. Almost 80% of 
all breast cancers are invasive ductal carcinomas (picture 1.1). This common type of cancer 
originates from breast ducts, invades fatty breast tissue, local neural tissue and vascular 
structures. 
Approximately 10% of diagnosed invasive breast cancers are lobular. Some other tumours 
show distinct pattern of growth and cellular morphology and therefore can by identified as 
certain types of breast cancer. Less common, variants of invasive breast cancer are tubular, 
mucinous, micropapillary, cribiform and medullary carcinoma. 
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Picture 1.1: HE-staining of invasive ductal carcinoma  
 
Picture 1.1: This picture shows a Grade 3 invasive ductal breast carcinoma with HE-
staining (haematoxylin and eosin staining); original magnification × 200). 
1.1.4.1 Predictive and Prognostic Markers 
Tumour differentiation 
The grade of tumour depends on its histological appearance and reflects tissue 
differentiation associated with neoplasia. Grading of breast tumours is based on tubule 
formation (% of cancer cells composed of tubular structures), nuclear pleomorphism 
(changes in cell size and uniformity) and mitotic count (rate of cell division). 
Each of these is scored from 1 to 3. All three scores are added up to a final score, ranging 
between 3 and 9. Tumours with scores of 3-5 are considered as Grade 1, well differentiated 
tumours. Grade 2 tumours (final score 6-7) are moderately differentiated, whilst Grade 3 
poorly differentiated tumours score final count of 8-9. Patients with Grade 1 tumours have 
a better prognosis than Grade 3 tumours (24). 
Tumour stage 
Stage incorporates the tumour size and the extent of the disease spread. TNM staging is 
commonly used to classify breast cancer (table 1.2).  
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T represents tumour size of the primary, N relates to lymph node involvement and M 
correlates whether or not the disease has metastasised to other organs. Patients with stage I 
breast cancer have a better prognosis that patients with stage IV (25). 
Table 1.2: TNM classification of invasive breast cancer 
Stage Size of TU LN involvement Metastases 
I T1   < 2 cm N0    no LN involved M0   no metastases 
IIa T0   no evidence of 
primary 
N1    <4 LN involved M0 
 T1 N1 M0 
 T2   2-5 cm N0 M0 
IIb T2 N1 M0 
 T3   > 5 cm N0 M0 
IIIa T0–T3 N2   >4 LN involved and 
fixed to other structures 
M0 
IIIb T0-4 N2 M0 
IIIc T0-4 N3    incl. IM and SC LNs M0 
IV T4   any size  
and/or involving skin, 
chestwall 
N1-3 M1 distant meta-
stases 
Table 1.2: Staging of breast cancer depends on tumour size, lymph node involvement 
(axillary, internal mammary (IM) and supraclavicular (SC)) and metastasis. It ranges 
from stage I to IV. Inflammatory breast cancer is considered as at least a stage IIIb. 
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Nottingham prognostic index 
In 1982, a retrospective analysis was performed investigating prognostic potential of nine 
aspects in primary operable invasive breast cancer: age, menopausal state, tumour size and 
grade, lymph node status, cellular reaction, sinus histiocytosis and oestrogen receptor 
expression (26). Via multivariate analysis three factors remained significant. These 
independent prognostic markers (histological tumour grade, lymph node status and size) 
were combined to a formula (see below), which is known to establish the Nottingham 
Prognostic Index (NPI). 
 
NPI= histological grade + lymphnode status + (0.02 x tumours size (mm) 
Grade 1= 1 point No lymph node involvement= 1 point 
Grade 2= 2 points <4 lymph nodes= 2 points 
Grade 3= 3 points >4 lumph nodes= 3 points 
 
The NPI score is a guidance to select appropriate adjuvant therapy for each individual 
patient (table 1.3); higher the score, the worse the prognosis of the patient (24;26). 
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Table 1.3: Nottingham Prognostic Index 
NPI score Annual  
Mortality 
15 year  
survival 
Adjuvant therapy 
< 3.4 
Low risk 
3% 80% Dependant on ER/PgR status, menopausal 
status: tamoxifen for 5 years 
3.4 – 5.4 
Moderate 
risk 
7% 42% Dependant on ER/PgR status, menopausal 
status: Switch therapy tamoxifen- AI or AI 
for 5 years 
>5.4 
High risk 
30% 13% Hormonal therapy plus chemotherapy; 
depending on age and comorbidities 
Table 1.3: NPI scores are calculated using tumour grade, size and lymph node status. 
These scores group patients into low risk, moderate and high risk and determine their 
most appropriate adjuvant treatment regime. 
Steroid hormone receptors  
Oestrogen plays an important role in the development of breast cancer (27). The oestrogen 
signal is mediated by the estrogen receptor, which is a transcription factor belonging to the 
steroid hormone receptor family.  
The mechanisms through which oestrogens contribute to each phase of the carcinogenic 
process (initiation, promotion, and progression) are multifaceted. 
The classic mechanism of direct action of oestrogen on nuclear DNA involves the binding 
of the hormone to nuclear oestrogen receptors, which then binds as dimers to oestrogen-
response elements in the regulatory regions of oestrogen-responsive genes and associate 
with basal transcription factors, co-activators and co-repressors to alter gene expression 
(28). 
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Since the initial discovery and characterization of the oestrogen receptor α (ERα) in the 
1960s, research on mechanisms of oestrogen-receptor signalling has revealed its 
complexity, as represented by the discovery of oestrogen receptor β (ERβ) in 1996 and of 
signalling pathways mediated by oestrogen receptors that become associated with 
mitochondria and the plasma membrane (29;30). 
ERα and ERβ have only 53 percent homology in their ligand-binding domains; which 
accounts for different responses of the two receptors to various ligands. For example, 
tamoxifen has been reported to be both an agonist and an antagonist for ERα, but only an 
antagonist for ERβ.  
The receptors also vary in their activation domains, suggesting that they may recruit 
different proteins to the transcription complexes, thereby altering the specificity of their 
genomic transcriptional effects.  
Furthermore, oestrogen receptors interact with co-activator proteins (e.g. AP-1) to 
stimulate the activity of other transcription factors (figure 1.3). 
Finally, various tyrosine kinase growth-factor receptors can activate oestrogen receptors by 
phosphorylation in the absence of a ligand (figure 1.3). 
Non-transcriptional effects involve a membrane-bound form of ERα, ERβ, or both to 
facilitate cross-talk between the membrane oestrogen-receptor–signalling process and other 
signal-transduction pathways, such as the epidermal growth factor receptor (EGFR) and 
insulin-like growth factor 1 receptor (IGF1)–signalling pathways, suggesting oestrogenic 
control of cell proliferation and inhibition of apoptosis and possible implications for 
therapy (figure 1.3) (28;29;31).  
39 
Chapter 1 Introduction 
 
Figure 1.3: Schematic overview of Oestrogen-Receptor–Signalling Pathways 
 
Figure 1.3: Schematic overview of Oestrogen-Receptor–Signalling Pathways (27). 
cAMP= cyclic AMP, E2= oestradiol, 4-OH-E2,4-hydroxyestradiol, ER= oestrogen 
receptor, EGF= epidermal growth factor, EGFR= epidermal growth factor receptor, 
IGF-1= insulin-like growth factor 1, IGF-1R insulin-like growth factor 1 receptor, 
MAPK= mitogen-activated protein kinase, mRNA= messenger RNA, PI3K= 
phosphoinositide 3 kinase, mtProteins= mitochondrial proteins, and pShc 
phosphorylated Shc protein. 
The strongest evidence for the role of oestrogen in breast cancer has emerged from the 
experience with the selective oestrogen receptor modulator tamoxifen for the treatment and 
prevention of breast cancer. Individual trials and a meta-analysis of randomized clinical 
trials have shown that tamoxifen reduces the risk of recurrence for women of any age with 
invasive or in situ breast cancer that expresses ERα, the progesterone receptor, or both 
(32). 
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Approximately 22% of all breast cancers are oestrogen and progesterone receptor positive 
at the time of diagnosis (table 1.4).  
Table 1.4: Distribution of ER and PgR receptor status in breast cancer 
Breast Cancer Types Frequency 
ER positive PgR negative  55% 
ER positive PgR positive 22% 
ER negative PgR negative 20% 
ER negative PgR positive 3% 
Table 1.4 displays the frequency of the oestrogen receptor and progesterone receptor in 
different phenotypes of breast cancer (33). 
ER positive breast cancer patients respond and benefit from adjuvant hormonal therapy, 
which is tailored to the patient‘s risk of early relapse and menopausal status. The aim of 
endocrine therapy is to reduce the level of oestrogen; either through antagonising with 
oestrogen on the receptor (tamoxifen), downregulation of receptor (fulvestrant) or through 
inhibition of oestrogen synthesis (aromatase inhibitors). 
Most tumours initially respond to endocrine therapy, but many will eventually develop 
resistance (acquired hormone resistance). However, some tumours fail to respond to 
endocrine treatment from the beginning (constitutive resistance) despite expressing 
hormone receptors (32). 
Progesterone receptor exists as two isoforms, PRA and PRB, which are transcribed from a 
single gene under the control of distinct promoters (34). Both isoforms bind progestins and 
directly activate the expression of genes that contain progesterone response elements in 
their promoters. Alternatively, the PgRs can cooperate with other transcription factors to 
induce gene transcription.  
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PgR expression has been shown to be associated with increased benefit from adjuvant 
tamoxifen (35). In particular, ER-positive/PgR-positive patients showed a significantly 
higher reduction of relative risk of recurrence and death compared with ER-positive/PgR-
negative patients. Interestingly, analysis of data from adjuvant treatment of 
postmenopausal breast cancer patients also shows that aromatase inhibitors are 
impressively more effective than tamoxifen in ER-positive/PgR-negative patients (36). In 
this respect, it has been hypothesized that loss of PgR expression might reflect a sustained 
activation of growth factor signalling pathways (37). In fact, it has been demonstrated that 
activation of the PI3K/AKT pathway — which might be determined by either IGF-1R or 
EGFR/ErbB-2 tyrosine kinases in breast cancer cells — downregulates the transcription of 
the PgR gene (38). 
Human Epidermal Growth Factor Receptor 
HER2, initially discovered in 1985 by two independent laboratories (39;40), is a 185-kDa 
transmembrane receptor in the HER family of receptor tyrosine kinases, which also 
includes EGFR (HER1), HER3 and HER4. Each of these receptors consists of an 
extracellular binding domain, a transmembrane lipophilic segment, and (except for HER3) 
a functional intracellular tyrosine kinase domain. The tyrosine kinase domains can be 
activated by both homodimerization and heterodimerization, generally induced by specific 
ligands. Unlike the extracellular domains of the three other HER receptors, HER2 can 
adopt a fixed conformation resembling a ligand-activated state, permitting it to dimerize in 
the absence of a ligand (41) and, once activated, able to induce signalling that promotes 
proliferation and survival. 
The advent of standardized FDA-approved tests for protein overexpression is based on 
immunohistochemistry combined with gene amplification based on fluorescence in situ 
hybridization. This has led to an overall improvement in HER2 status assessment (table 
1.5). 
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Table 1.5: HER2 classification 
HER2 status IHC (HercepTest) FISH 
Negative 1+  
Negative 2+ Negative 
Positive 2+ Positive 
Positive 3+  
Table 1.5 demonstrates when HER2 is classed as positive. All IHC HercepTest HER2 
2+ tumours should undergo FISH to assess its gene amplification.  
The biological characteristics of HER2 3+ tumours probably reflect the amplification of 
HER2 as a driving event that conditions other pathological and biological features, such as 
high vascular invasion and high proliferation rates (picture 1.2).  
Picture 1.2: HER2-positive breast carcinoma 
 
Picture 1.2: Immunohistochemistry (IHC) performed by HercepTest on formalin-fixed 
paraffin-embedded section of HER2-positive breast carcinoma (HER2 3+).  
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HER2 amplification/overexpression is an early event in breast carcinogenesis. 50-60% of 
ductal carcinomas in situ are overexpressing HER2 (42) compared to only about 25% of 
invasive carcinomas. This might indicate that this alteration is relevant, but not sufficient 
to induce oncogenic transformation. p53 status greatly influences the final effect of HER2 
overexpression in tumour cells in promoting proliferation versus apoptosis and in blocking 
of proliferation. HER2 overexpression was found to be associated with proliferation when 
induced in tumour cells with mutated p53. In contrast HER2-transfected cells bearing wild-
type p53 became apoptotic shortly after transfection. Additionally, stabilization of 
apoptosis-resistant cells showed decreased proliferation (43).  
Various clinical studies have evaluated the relationship between HER2 and breast cancer 
outcome, and most have shown that women with HER2-positive tumours have a poorer 
prognosis than those with HER2-negative tumours (44;45).  
HER2-positivity has also been related to endocrine therapy unresponsiveness, even in 
hormone-receptor positive patients (46;47). The main mechanism of resistance of breast 
cancer cells to endocrine therapy is loss of expression of ER. In this regard, the levels of 
expression of EGFR, ErbB-2 and TGFα are generally higher in ER negative breast cancer 
as compared with ER-positive tumours (48). Heregulin, which can activate both EGFR 
(HER1) and HER2 through formation of heterodimers with either HER3 or HER4, has 
been shown to depress ERα or its transcriptional activity (49;50). Tamoxifen as well as 
oestrogen induces activation of EGFR/HER2 signalling, which leads to activation of both 
MAPK and AKT signal transduction pathways. 
Two major types of receptor inhibitors have been developed for therapy:  
humanized monoclonal antibodies directed against the HER2 extracellular domain, e.g. 
trastuzumab (Herceptin); and  
small-molecule tyrosine kinase inhibitors, which compete with ATP in the kinase domain 
of this receptor to impair the transmission of proliferation signal, e.g. lapatinib (Tykerb). 
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Proven survival benefit of anti-HER2 driven therapies demonstrated in clinical trials 
indicates that HER2 is one of the most promising molecules for targeted therapy (51). 
Trastuzumab, the recombinant humanized monoclonal antibody, is approved for the 
management of all metastatic and some early breast cancers with HER2 overexpression. 
Patients with advanced breast cancer, on trastuzumab treatment, can show tumour 
shrinkage. Even progressing patients can benefit from trastuzumab continuation therapy, 
most likely through the blockage of alternative HER proliferation pathways, leading to 
improved survival. However, this HER2 blockade of tumour cell growth can be 
circumvented through alternative growth signalling pathways. If trastuzumab controls 
disease progression primarily through cytostatic activity (blockade of HER2-driven 
proliferation), a combination of trastuzumab and cytotoxic agents represents future 
targeted systemic therapy for HER2 positive patients. 
1.1.4.2 Treatment Options  
National treatment guidelines (SIGN) have been published to improve and standardise the 
treatment of breast cancer in the UK.  
Surgery and radiotherapy are used to control local disease, and systemic treatments 
(chemotherapy and/or hormonal therapy) to combat frank or occult metastatic disease.  
Systemic treatments may also be administered as neoadjuvant treatment to shrink the size 
of the tumor prior to surgery.  
Nearly all patients, depending on their comorbidities and stage of their disease, have some 
form of surgery (table 1.6). The objective of surgery is to remove the disease and identify 
the extent of disease. This can be either done by either a wide local excision, removing 
only the breast lump and marginal areas of normal breast tissue, or a simple mastectomy, 
removing the entire breast. An assessment of the regional axillary lymph node is needed to 
determine the disease spread beyond the breast. Standard of surgical treatment of a small 
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invasive breast cancer is an axillary sentinel lymph node biopsy (SLNB). If this lymph 
node is positive, the surgeon proceeds to an axillary clearance (ANC), removing all of the 
axillary lymph nodes. Staging tests, ranging from simple blood tests to MRI scans, can be 
carried out to assess the extent of the disease. 
Table 1.6: Different surgical treatment options 
Breast Axilla Breast Reconstruction 
Mastectomy 
 
+/- SLNB 
+/- ANS 
+/- ANC 
 
+/- LD flap 
+/- TRAM flap 
+/- DIEP reconstruction 
+/- SIEA reconstruction  
+/- Breast Implants 
+/- Breast Prothesis 
Wide Local Excision 
 
+/- SLNB 
+/- ANS 
+/- ANC 
 
 
Table 1.6 showing various surgical treatment options for operable breast cancer 
comprising breast and axillary area plus reconstruction options offered after 
mastectomy 
In today‘s clinical practice every patient's treatment will be discussed and decided on at a 
multidisciplinary meeting integrating the stage and grade of their tumour, lymph node  
steroid hormones and HER2 receptor status, menopausal status and general health. Less 
aggressive treatment, e.g. systemic hormonal therapy for oestrogen positive breast cancer, 
may be appropriate for frail, elderly patients, avoiding mastectomy and irradiation. 
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1.1.5 In situ carcinoma 
In situ carcinoma (Roman: meaning "in the natural or normal place") is known as a 
precancerous/ pre-invasive stage of a cancer. Histopathology defines it as lesions 
composed of malignant cells that are confined to their natural basement membrane 
boundaries (52), meaning the tumour cells are still constrained to the site where they 
originated and they have neither invaded neighbouring tissues nor giving away micro-
metastasis. Two different types of carcinoma in situ can arise in the breast; lobular 
carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS). The treatment of lobular 
carcinoma in situ is mainly surveillance, whereas ductal carcinoma in situ is often treated 
by complete local excision as there is a strong possibility that it will progress to invasive 
carcinoma (53). 
The UK/ANZ DCIS trial reported on the benefit of radiotherapy over tamoxifen for 
women with completely excised ductal carcinoma in situ (54). 
1.1.6 Early breast cancer  
Early breast cancer is potentially curable. Surgery is carried out to remove the tumour with 
an increasing trend towards more conservative surgery and reconstruction of the breast. 
During surgery, axillary lymph nodes are checked to see whether cancer has spread beyond 
the breast. New techniques like axillary lymph node sampling (ANS) and/ or sentinel 
lymph node biopsy help to reduce the significant disability of lymphoedema of the arm.  
A short course of radiotherapy is given to patients who have had conservative surgery 
(wide local excision) or considered at high risk of local recurrence. High-energy radiation 
kills cancer cells. A review of clinical trials involving radiotherapy over the last 40 years 
showed a significant reduction in the number of patients relapsing following radiotherapy 
(55). Around 2% of women treated with breast conserving surgery and radiotherapy have 
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local recurrence, and if this is within the first two years they appear to have a worse 
prognosis than those with longer disease-free survival.  
Adjuvant chemotherapy is standard treatment for women with lymph node positive disease 
and for lymph node negative women with high grade, ER negative/HER2 positive tumours. 
An overview of clinical trials of adjuvant multi-agent chemotherapy in early stage breast 
cancer patients, under the age of 50, showed a 35% recurrence risk and a 27% death risk 
reduction (56). Some patients, for example young patients with large tumours with regional 
lymph node spread, may receive neo-adjuvant chemotherapy to shrink the tumour, 
allowing more conservative surgery. Chemotherapy is recommended to patients with 
moderate and poorly differentiated tumours and commonly given to women who have ER 
negative tumours. Standard treatment of the past was a CMF combination; 
cyclophosphamide, methotrexate and 5-fluorouracil. There is increasing evidence to that an 
anthracycline e.g. Epirubicin or Doxorubicin (57) should be added to the regime. Recent 
results from TACT trial showed an equivalent benefit from taxanes e.g. docetaxel for early 
stage breast cancers (58). Clinical trials are ongoing to establish the best chemotherapy 
regimens. 
Women, who have oestrogen sensitive (ER positive) tumours, can receive hormonal 
therapy to block the cancer-promoting effect of oestrogen (59). Over the past 30 years 
tamoxifen has been the gold standard and its use significantly reduced the risk of 
recurrence and increase ten year survival in women with ER positive and ER unknown 
status tumours (60);(61). Trials are ongoing to establish even more effective drugs and 
regimens for pre- and postmenopausal patients, taking into account side-effects, disease 
free and overall survival times. Results from the ATAC trial, comparing an aromatase 
inhibitor (anastrazole) alone, anastrazole plus tamoxifen, and tamoxifen alone for 
postmenopausal women, have shown benefits of anastrazole over tamoxifen in disease-free 
survival in early breast cancer (62). Most postmenopausal women receive tamoxifen for 
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five years. New switch therapies (3 years tamoxifen followed by an aromatase inhibitor) 
have been developed and trialed for women with a moderate to high Nottingham 
Prognostic Index. In premenopausal women oestrogen production may be stopped by 
surgery (bilateral oopherectomy), radiotherapy or drugs that reversibly suppress the ovaries 
(LHRH analogues such as Goserelin). 
1.1.7 Advanced breast cancer 
Minority of patients present with advanced breast cancer. Surgery and radiotherapy is 
useful in controlling local disease. Systemic treatment (e.g. Chemotherapy and/ or 
endocrine therapy) is considered to control the cancer and improve quality of life.  
High levels of HER2 are associated with ER and PR negativity and poorer prognosis. A 
monoclonal antibody treatment (Herceptin) has been shown to provide clinical benefit to 
patients with high levels of HER2 receptor (63). When Herceptin is combined with 
chemotherapy survival is significantly improved (64). Primary treatment in elderly frail ER 
positive breast cancer patients should be hormonal therapies including tamoxifen and 
aromatase inhibitors. 
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1.2 Src kinase family members 
The Src kinase family is a family of non-receptor tyrosine kinases. Src, most widely known 
and investigated, is the prototypical member of this eight-strong group of structurally 
related proteins, expressed in mammalian cells. Src family kinases are regulatory proteins, 
playing key roles in cell differentiation, motility, proliferation and cell survival (65). The 
Src family comprises Blk, Fgr, Fyn, Hck, Lck, Lyn, Src, and Yes (alphabetically listed) 
(66). Each SFK member has a different distribution in normal tissues. Src is expressed 
ubiquitously. It is found in a range of foetal and adult tissues. However neurons, 
osteoclasts, and platelets express a 5- to 20-fold higher protein level than most other cells 
(67). Blk, Hck, and Fgr are found solely within blood cells; Lck and Lyn are found in 
blood cells and brain; Yes, Fyn and Src are ubiquitously expressed (68). 
1.2.1 c-Src 
In 1911, research into chicken sarcomas led to the identification of a transmissible 
noncellular agent that could give rise to new sarcomas (69). It was a further 60 years until 
the agent responsible for this transformation process was identified as the viral SRC gene 
(v-SRC) (70). Subsequent research found that normal avian DNA contained a gene that was 
closely related to v-Src, termed cellular Src (c-SRC), which was the first human proto-
oncogene to be identified (71).  
1.2.2 Structure of Src 
The three dimensional structure of c-Src is well understood. The Src protein is a 60kDa 
tyrosine kinase. It has a N-terminal 14-carbon myristoyl sequence, a SH4 domain, an 
unique segment, a SH3 and SH2 domain, a protein-tyrosine kinase domain and a short C-
terminal regulatory tail (figure 1.4). The N-terminal myristylation of Src is required to join 
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cellular membranes and is crucial for the transformation of oncogenic Src mutants (72). In 
fibroblasts Src is bound to endosomes, perinuclear membranes, secretory vesicles and the 
cytoplasmic face of the plasma membrane by its N-terminal myristoyl group (67), where it 
can interact with a variety of growth factors and integrin receptors (73). The unique amino-
terminal domain varies between Src kinase family members. The four distinct Src-
homology (SH1-4) domains are involved in autoregulating Src kinase activity and 
interacting with substrates to form intracellular signalling complexes (73). Src activation is 
dependent on the interaction of different SH domains with each other and a carboxy-
terminal (C-terminal) domain. 
Figure 1.4: Basic structure of Src 
 
Figure 1.4 displays a one dimensional schematic overview of the basic structure of Src. 
Src kinase family members are 52-62kDa proteins composed of distinct functional 
regions. 
1.2.3 Activation of Src 
The interaction of these SH domains is highly dependent upon the phosphorylation state of 
various tyrosine residues within the protein. In the inactive state, Src kinase is 
phosphorylated at the tyrosine 530 site by the tyrosine kinases; C-terminal Src kinase (Csk) 
and Csk homology kinase (Chk). This is a highly conserved site among all Src kinase 
family members located in the C-terminal tail of the protein. In activated mutants of the 
Src kinase protein the C-terminal tyrosine is often missing or hypophosphorylated, 
producing a constitutively active protein, as is also the case with the v-Src protein. 
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Phosphorylation of the tyrosine 530 site results in a folded, inactive configuration of the 
Src kinase protein by promoting intramolecular binding of the C-terminus to the SH2 
domain (73). It is also possible that in this phosphorylated state the SH3 domain may bind 
to the SH1 domain to further fold and inactivate the protein (74). Subsequent 
dephosphorylation of the tyrosine 530 site by tyrosine phosphatases and intermolecular 
autophosphorylation of the activation loop tyrosine 419 promotes activation of Src kinase 
activity (75). It is possible that phosphorylation of the tyrosine 419 site may stabilise the 
catalytic domain in an active conformation or may facilitate substrate access to the active 
site of the kinase (70). This describes the well established classical activation pattern of Src 
kinase – dephosphorylation of tyrosine 530 and phosphorylation of tyrosine 419 to induce 
a conformational ‗unfolding‘ of the protein, permitting substrate access to the protein 
kinase domain (figure 1.5). 
Figure 1.5: Configuration change of Src 
 
Figure 1.5: Src configuration changes when activated via dephosphorylation of Tyr527 
and phosphorylation of Tyr419 (classical activation sites). 
There are further tyrosine phosphorylation sites within Src kinase; however, their roles 
have not been fully defined. In vitro studies have shown that the activated platelet-derived 
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growth factor receptor (PDGFR) will phosphorylate the tyrosine 215 site within the SH2 
domain overriding the inhibitory phosphorylated state of tyrosine 530. The suggested 
mechanism for this is a decrease in the intramolecular interaction of the SH2 domain with 
the tyrosine 530 phosphorylated C-terminal tail, thus opening the protein to its active 
conformation (figure 1.6). PDGF or HER2 driven phosphorylation of c-Src at Y215 on SH2 
has been shown to block binding to the c-terminal regulatory sequence and result in a 50-
fold activation of Src (76). 
Figure 1.6: Open configuration of Src after phosphorylation at Tyr 215 
 
Figure 1.6: Open configuration of Src when activated at Tyr215 (alternative activation 
site). 
In addition to this, the activated PDGFR has been shown to phosphorylate the tyrosine 138 
site within the SH3 domain, although the consequences are less clear. Phosphorylation at 
the tyrosine 138 site has not been shown to be required for Src kinase activation, but may 
be involved in SH3 domain interactions.  
Although Src SH3 interactions remain to be fully elucidated, the SH3 domain of the 
protein has been shown to bind to substrates containing proline-rich regions (77). The SH2 
and SH3 domains can bind to growth factor receptors that contain their own tyrosine 
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kinase activities, including EGFR, HER2, PDGFR, VEGFR and FGFR. The SH2 and SH3 
domains can also bind to and activate cytoskeletal proteins such as FAK and p130
CAS
 (66). 
This direct interaction with substrates that contain their own tyrosine kinase domains can 
activate the intrinsic tyrosine kinase activity of Src, potentially altering localisation of Src 
to sites of action (78). 
SFKs can be found at different subcellular locations. They are most abundantly localised in 
the cell cytoplasm, but are re-localised to the membrane when activated. Subcellular 
localisation has also been suggested to regulate Src activity (79). In studies examining the 
role of the SH3 domain in assembly of focal adhesions, the inactive form of Src was 
localised to the perinuclear region of cells in association with microtubules. Upon 
activation, the SH3 domain associated with actin filaments and Src was transported to the 
plasma membrane where it is recruited to focal adhesions (80). 
1.2.4 Src and its role in oncogenesis 
In normal tissue, Src acts as a signal-transduction hub, co-ordinating intracellular 
responses to extracellular stimuli. Src has a prominent role in multiple cellular processes, 
including proliferation, adhesion, and motility (65). These processes also play important 
roles in oncogenesis and cancer progression, suggesting that during oncogenesis, tumour 
cells may hijack these normal cellular processes through aberrant Src activation or 
dysregulation of Src expression (66). In vitro and in vivo studies verified this hypothesis by 
showing that overexpression or activation of Src transforms cells and induces 
tumorigenesis. c-Src overexpression in mouse fibroblasts induced transformation and 
anchorage-independent growth through an unidentified mechanism (81). 
Tumour progression from early disease to advanced or metastatic disease typically 
involves both tumour growth (cellular proliferation) and metastasis to distant sites (cellular 
migration). Metastasis is a complex multistep process involving loss of cellular adhesion, 
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increased motility, intravasation, invasion, extravasation, resistance to anoikis, colonisation 
of a site distant to the primary tumour, and angiogenesis (82). Each of these processes is 
regulated to some extent by Src (66), suggesting that Src plays a role in the advancement 
and metastasis of solid tumours. 
The involvement of Src in the metastatic process is supported by several studies. Src 
activity in the NBT-II rat carcinoma cell line promotes cell scattering in vitro. Injection of 
these cells into nude mice produced poorly differentiated primary tumours that gave rise to 
micrometastases with elevated Src expression. This suggests that Src activity correlates 
with decreased tissue organisation and increased metastatic potential compared with the 
parent line (83). Overexpression of Csk, a negative regulator of SFK activity, in a highly 
metastatic mouse colon carcinoma cell line, significantly decreased in vivo metastasis and 
in vitro invasiveness (84). The role of Src in metastasis is also supported by decreased 
occurrence of metastases in the presence of Src inhibitors (85). In addition, metastatic 
cancer models using MDA-MB-231 cells transfected with a kinase-dead Src showed a 
decrease in development of bone metastases and increased survival in female nude mice 
(86). 
The potential roles of Src in tumour proliferation and each of the various stages of 
metastasis are discussed below. 
1.2.4.1 Proliferation 
Studies using SFK inhibitors in cellular models of solid tumours have demonstrated that 
blocking Src activity inhibits proliferation by inducing cell cycle arrest (87). Activation of 
integrins or growth factor receptors also appears to involve Src-mediated phosphorylation 
of FAK at cell-matrix adhesions. Proliferation is stimulated through the 
Ras/Raf/MEK/ERK pathway (88). 
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In prostate cancer, it is well established that proliferation in primary tumours is driven by 
androgens. However, in castration resistant tumours, proliferation is dependent on growth 
factors stimulating oncogenic signals via signal transduction cascades (89). Tatarov et al. 
have recently demonstrated that Src kinase inhibitors only inhibit proliferation in castration 
resistant cells and not androgen sensitive cells. These results suggest that Src kinase only 
controls proliferation once the tumour has progressed to the more aggressive phenotype. 
This effect was not due to absence of androgens, as exposure of tumour cells to androgen 
containing medium did not rescue cells from Src kinase inhibitor induced suppression of 
proliferation (90). 
1.2.4.2 Loss of Adhesion 
Tumour cell invasion and metastasis requires a controlled disruption of interactions with 
neighbouring cells and the extracellular matrix (ECM). Src has a well-documented 
negative role in regulating cell–cell adherens junctions and cell–matrix focal adhesions. 
Activated Src destabilises focal adhesions by promoting redistribution of component 
proteins including FAK, cadherins, and catenins (91). Src also suppresses localisation of E-
cadherin to focal adhesions, further decreasing cellular adhesion (92). A recent study has 
shown that in vivo Src inhibitor treatment blocked mobilisation of E-cadherin, stabilising it 
at adherens junctions. This result supports the potential use of Src-targeted agents as anti-
invasive drugs to stabilise cell–cell adhesion (93).  
1.2.4.3 Motility and Migration 
Cell motility can be thought of as a series of well-co-ordinated detachment and 
reattachment events. During metastasis, both cell–cell and cell–matrix contacts undergo 
major changes to permit migration, which is Src signalling dependent (94). Src also 
regulates cortactin, a putative regulator of cell motility that was originally identified in Src-
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transformed cells. Cortactin is a substrate of Src that appears to play a role in reorganising 
actin filaments within the cytoskeleton at the leading edge of migrating cells (95;96). 
1.2.4.4 Invasion 
The process of invasion is dependent on two major processes: increased motility and/or 
migration, as described above and increased degradation of the ECM. In vitro, cancer cell 
invasion is associated with the formation of actin-rich membrane protrusions termed 
invadopodia, which degrade the ECM. Src interacts with FAK to regulate invadopodia 
formation by phosphorylating cortactin and altering actin assembly. Src inhibition 
decreases the formation (87;97) and inhibition of invadopodia (90). Src has also been 
shown to promote expression of both membrane-bound and secreted matrix 
metalloproteases in cancer cell lines that are important in degrading basement membrane 
and ECM during invasion (98;99). 
1.2.4.5 Intravasation and Extravasation 
Mechanisms regulating intravasation, i.e. penetration of tumour cells into blood vessels, 
remain relatively uncharacterised. However, preclinical studies in gastric and colorectal 
cancer have shown that Src signalling occurs during in vitro models of intravasation in 
association with upregulated expression of chemokine receptors (CXCR1 and CXCR2) and 
the urokinase plasminogen activator receptor (u-PAR). u-PAR expression is associated 
with poor patient survival, promotion of invasion via a Src-dependent mechanism, and 
promotion of metastasis. In a chorioallantoic membrane model, treatment with Src 
inhibitors significantly decreased invasion and intravasation (100).  
Src has also been implicated in extravasation, i.e. passage of cells from the circulation 
across the vascular walls to the target tissue stroma. The mechanism involved is distinct 
from intravasation and appears to be dependent on VEGF, a regulator of angiogenesis and 
vascular permeability. Activation of VEGFR transiently activates Src signalling in vascular 
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endothelial cells leading to disruption of cell–cell junctions and increased vascular 
permeability, allowing tumour cells to extravasate (101;102). Therefore, disrupting Src 
signalling and Src-regulated VEGF expression may protect against VEGF-induced 
increases in vascular permeability, preventing establishment of a metastatic colony of 
cancer cells in tissues distant to the primary tumour.  
1.2.4.6 Cell Survival 
Detachment of adherent cells from the ECM and loss of cell–cell adherens junctions 
typically results in a form of programmed cell death termed anoikis (103). Resistance to 
anoikis appears to occur commonly in metastatic disease and is conferred by activation of 
prosurvival pathways that allow anchorage-independent growth and survival, metastasis 
and colonisation of distant organs. Src protects from apoptosis by activating two 
antiapoptotic kinases: PI3-K and extracellular signal-regulated kinase 1 or 2 (ERK1/2) 
(104). Research in metastatic prostate cancer cells has shown that anoikis resistance is 
related to sustained ligand-independent activation and phosphorylation of EGFR caused by 
oxidation and activation of Src. This activates prosurvival signals and degrades the 
proapoptotic protein Bim, conferring increased cell survival and decreased apoptosis (105). 
The role of Src in anoikis resistance suggests that Src-targeting therapies may promote 
anoikis, decreasing the likelihood of a viable metastatic cell reaching a suitable site for 
colonisation.  
1.2.4.7 Angiogenesis 
Development of a blood supply is critical for the growth of tumours. Src activity increases 
in response to hypoxia in the inner hypoxic regions of solid tumours, inducing expression 
of VEGF to promote angiogenesis (106). Src plays a key role in regulating VEGF 
expression with Src-dependent phosphorylation of signal transducer and activator of 
transcription-3 (STAT3) being required for expression of VEGF (105). The importance of 
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Src in VEGF expression is highlighted by the finding, that Src inhibition reduces VEGF 
expression in human solid tumour cell lines, decreasing in vitro proangiogenic activity 
(107).  
Yeatman et al. is illustrating a selection of mechanisms and effects of c-Src on tumour cell 
behaviours (figure 1.7, (66)) 
Figure 1.7: Mechanisms on tumour cell behaviour mediated by Src 
 
Figure 1.7 displays a range of mechanism on tumour cell behaviour mediated by 
interactions with various substrates and binding partners. Turnover of focal adhesions 
is required for motility and invasiveness via loss of cell-cell adhesion mediated by E-
Caderin or by binding and activation of FAK, which leads to phosphorylation of other 
substrates such as paxillin, CAS and p190RhoGAP causing focal adhesion disruption. 
Activation of FAK stimulates the JNK signalling pathway resulting in increased 
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expression of matrix metalloproteinases (MMP2 and MMP9). c-Src also induces 
expression of various tissue inhibitors of metalloproteinases (TIMPs). MMPs promote 
breakdown of extracellular matrix (ECM), which is required for tumour invasion of 
surrounding tissue. STAT3 (Signal transducer and activator of transcription 3) 
activation leads to increased expression of VEGF (vascular endothelial growth factor), 
a signalling molecule that promotes tumour angiogenesis (66). 
1.2.4.8 Bone Metastases 
Bone is a common site for metastasis, particularly from breast or prostate primaries, and is 
associated with high morbidity and essentially an incurable state. In addition to its roles in 
oncogenesis and metastasis to visceral tissues, Src is essential for regulating the bone 
resorptive activity of osteoclasts in bone metastases (108). In their physiological state, 
activated osteoclasts attach to bone in an integrin-dependent manner, activating Src and 
forming a membrane structure termed the ruffled border. Osteoclasts then release hydrogen 
ions into the osteoclast–bone interface to dissolve the bone matrix (109). Src-deficient 
osteoclasts show impaired migration and ruffled border formation, and in animals with 
targeted disruption of the SRC gene, defects in bone resorption are seen, causing 
osteopetrosis (110). 
In bone metastases, Src-mediated crosstalk between tumour cells and osteoclasts can 
initiate a cycle of bone destruction, during which tumour cells activate osteoclasts by 
secretion of paracrine factors, such as parathyroid hormone-related peptide. The ensuing 
bone resorption releases matrix-bound growth factors such as transforming growth factor 
β, IGF I and II, FGFs, and PDGFs, which in turn promote growth of tumour cells (111). 
Src kinase has now been suggested to have a role in clinically dormant breast cancer 
micrometastases, where a Src activity gene expression signature was shown on 
multivariate analysis to be an independent predictor of late-onset breast cancer bone 
metastases (112). 
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1.2.5 Src in breast cancer 
A number of mainly in vitro studies have suggested a role for Src in breast cancer. But 
there has been a limited amount of in vivo studies over the past 20 years, which reported 
elevated levels of Src kinase in breast cancer tissue compared to normal tissue (113); 
(114). Translational studies investigating SFK member expression in human breast tumour 
and correlating expression and activation to clinical parameters are surprisingly limited. 
Only recently a study demonstrated an association between activated c-Src and reduced 
recurrence-free survival in DCIS (115). A larger study linked expression of activated c-Src 
in invasive breast cancer with lower proliferation indices, smaller tumour size and lower 
grade, but patient survival information was not available for this cohort (116). Further 
research on expression and activation of Src and Src family members in large patient 
cohorts with full clinical data and follow-up is needed to bridge the gap between in-vitro 
studies and clinical setting. 
1.2.5.1 Interaction with steroid hormone receptors 
It‘s well established that the oestrogenic signalling plays a critical role in promoting breast 
cancer cell growth. Characteristically, a ligand-induced activation of oestrogen receptors 
results in gene transcription. Src is able to potentiate the AF-1 (activation function 1) 
dependent gene transcription function of the oestrogen receptor by either indirect 
phosphorylation of nuclear ER via ERK1/2 (MAPK pathway) (117) and Akt (118) or 
through regulation of FAK-p130CAS-JNK pathway activity with its subsequent activation 
of co-activator molecules including CBP (CREB/EGFR binding protein) and GRIP1 
(glucocorticoid receptor interacting protein 1), which further facilitate AF-1 gene 
transcription (117). This effect can occur in the absence or presence of liganded oestrogen 
receptor. Interestingly, this ligand can be oestrogen, but also tamoxifen. 
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Regulation of numerous cellular processes such as proliferation, differentiation and 
apoptosis can be activated via the oestrogen receptor by distinct cytoplasmic protein 
cascades, initiated in the cytosolic/ membrane compartment (119). Ligand binding on the 
oestrogen receptor leads to rapid activation of the ERK and Akt pathways in a Src 
dependent manner. This can happen in ER positive breast cancer cells and in cells 
temporarily expressing oestradiol (120;121). 
Actual interaction between Src and the oestrogen receptor enhances oestrogen-mediated 
gene transcription. This may be facilitated by intermediate adapter-molecules such as the 
MNAR protein (122). 
1.2.5.2 Interaction with receptors of the HER family 
In human mammary carcinomas HER family members are involved in regulating cell 
growth, survival, migration and metastasis. EGFR (HER1) and HER2 are over-expressed 
in certain breast cancers and often associated with Src over-expression (123);(124). 
Synergism between Src and EGFR enhances neoplastic growth of breast epithelial cells 
(124). This occurs via Src-mediated phosphorylation of EGFR at tyrosine site 845. Src is 
also involved with the HER2 pathway signalling resulting in a more aggressive disease 
phenotype. HER2 signalling up-regulates Src kinase activity by enhancing its 
phosphorylation on tyrosine site 215 (125). This is associated with increased activity of 
FAK (126), promoting cell migration. Interestingly, HER2 over-expressing tumours also 
showed increased levels of phosphorylated Y215Src kinase. Cell signalling through HER2 
has also been demonstrated to boost Src expression and stability resulting in cancer 
dissemination (127). The association of Src and HER3- and HER4- mediated signalling 
pathways is less clear. Ishzawar et al. have shown that Src is able to enhance HER2/HER3 
signalling and their biological functions by promoting HER2/HER3 heterodimerisation 
(128). 
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1.2.5.3 Regulated crosstalk between steroid receptors and growth factor receptors 
by Src 
Many of the signalling molecules are found within both the growth factor- and steroid 
hormone activated pathways. Dysregulation of one of those signalling molecules could end 
in abnormal activation of both pathways, leading to uncontrolled cell proliferation and 
survival (129). Furthermore, EGFR/HER2 activation can potentiate ER signalling, 
prompting ligand-independent gene transcription and cellular proliferation. On the other 
hand the oestrogen receptor can utilise membrane-bound EGFR to signal through various 
kinase cascades influencing genomic and non-genomic actions of oestrogen in breast 
cancer cells (31). This complex crosstalk between growth factor receptors and steroid 
hormone receptors has been linked to acquisition of endocrine resistance and cancer 
progression (130). Src can play a part as a mediator of this crosstalk suggesting a role for 
Src in breast cancer. Varricchio‘s study showed that disruption of the ER-Src complex 
prevents prostate and breast cancer cell growth, suggesting that inhibition of association of 
steroid receptors with Src or inhibition of Src activity may have therapeutic applications 
for patients with ER positive tumours (131). 
1.2.6 Lyn 
Lyn is one of the members of the Src kinase family of non-receptor protein tyrosine 
kinases. It is predominately expressed in haematopoetic cells (erythroid/myeloid and B 
lymphoid origin) (132), but has been also detected in neurons, prostate and colon cells 
(133;134). Lyn's function has primarily been studied in hematopoietic cells where is 
involved in the transmission of signals from a number of receptors such as Epo, c-Kit, B 
cell antigen, and c-Mpl receptors (135;136). It is associated with the high-affinity IgE 
receptor in basophils and with p120 Ras-GAP in thrombin-stimulated platelets (137). This 
association corresponds to an increase in Lyn kinase activity.  
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It has also been implicated in the regulation of cell signalling mechanisms through 
phosphorylation of a number of signalling molecules including PI3Kinase, STAT5 and 
ERK1/2 (138). 
It was first identified in 1987 as a gene with high homology to other members if the Src 
kinase family. This gene is localised on the human chromosome 8q13. 
1.2.6.1 Lyn’s protein structure  
Lyn exists as two distinct isoforms, designated p56, containing 512 amino acids, and p53 
with 491 amino acids. As already mentioned its structure is very similar to other Src kinase 
family members. Its amino (N) terminal ending contains a sequence for attachment of the 
fatty acid myristate. During translation, the amino-terminal methionine is removed and 
myristate is attached covalently to the adjacent glycine. This modification is required for 
association of Lyn with the plasma membrane. 
Whilst this N terminus of each member is unique, the Src family shares significant 
homology in the kinase domain, as well as the SH2/SH3 protein interaction domains. 
Tyrosine phosphorylation controls the activity of Lyn in two opposing ways (139). 
Phosphorylation of the C-terminal tail at tyrosine site 508 inhibits Lyn activity through 
promoting its association with the kinases own SH2 domain. This is equivalent to tyrosine 
site 530 of c-Src. In contrast, phosphorylation of a residue within the activation loop 
(tyrosine site 397= tyrosine site 419 of c-Src) results in activation of Lyn (139). Lyn 
activity is also regulated partly by Csk (136). 
1.2.6.2 Lyn and its clinical manifesto 
Lyn plays an important role in leukaemia. This has been suggested by several studies (140-
142). Elevated Lyn kinase activity was found in primary acute myeloid leukaemia (AML) 
cells (140). Whilst in chromic myeloid leukaemia (CML) the BCR-Abl fusion protein is 
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the initiating molecule, Lyn plays a crucial downstream role in BCR-Abl-induced 
leukaemogenesis (141;142).  
Lyn is also involved in the development of certain solid tumours. Colon carcinoma cells 
utilize Lyn in the activation of the Akt (anti-apoptotic) pathway, and chemo-resistant 
colonic cancer cells displayed elevated Lyn kinase activity (134). Via signalling 
mechanisms, Lyn regulates prostate cancer cells (143). Inhibition of Lyn in prostate cancer 
cell lines resulted in reduced proliferation in vitro and in prostatic cancer xenograft models 
(133). 
Members of the Src kinase family are important targets for therapeutic intervention. 
Several small molecule inhibitors have been developed; Most of them act as ATP 
competitive inhibitors (e.g. Dasatinib). This was possible because of identification of 
crystal protein structures enabling detailed investigations of how Src family kinases are 
regulated and how small molecule inhibitors can inactivate these enzymes.  
1.2.7 Lck 
Lck (leukocyte-specific tyrosine kinase) is a 56 kDa protein found mainly in 
haematopoietic cells.  It is most commonly expressed on the cell membrane of T-cells and 
at a constant level throughout T-cell development. Activation of Lck is a required step in T 
cell activation. T-cell activation is a critical step in cell mediated immunity. Following 
binding of an antigen to the cell antigen receptor (TCR), a signalling cascade is activated 
that results in cytokine release, cell proliferation and cell survival (144). 
Immunofluorescence has shown that 50 – 90% of cellular Lck is known to be bound to 
CD4 in CD4+ cells and 10-25% to CD8 in CD8+ cells (145). A small amount is also 
known to be attached to the IL2 receptor and play a role in IL2 signalling (146). In cells, 
where none of these receptors are present, a fraction is seen to locate at the plasma 
membrane and the rest is present in peri-centrisomal vesicles (145;147). Lck‘s protein 
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structure is very similar to other SFK members apart from its unique terminal SH4 chain 
(figure 1.4). At the N-terminus is a short sequence for lipid attachment, which is involved 
in the localisation of kinases to the membrane. This attachment is mediated by either 
myristoylation (e.g. Lyn) or in case of Lck and Fyn by palmitylation (148). 
The inactive, closed conformation of Lck is stabilised by phosphorylation of the C-
terminal 505 tyrosine residue, which could be seen as equivalent to Tyrosine site 530 in 
Src. The active conformation is promoted by phosphorylation of the activation loop on 
tyrosine site 394 (equivalent of Tyr419 in Src). This is known to increase Lck‘s catalytic 
activity 2 – 4 fold (149). 
As well as being implicated in T-cell receptor (TCR) signal transduction (149;150), Lck is 
known to engage in thymocyte formation. Increasing Lck activity seems to promote CD4 
commitment, whereas decreasing activity promotes CD8 commitment (151). Lck is also 
involved in TCR-dependent homeostatic proliferation, occurring in times of lymphopenia 
(149). 
Lck may also play a role in mitochondrial apoptosis independent of its principle function in 
TCR signalling (151). Cell line experiments showed that a Lck deficiency resulted in 
resistance to apoptosis induced by anticancer drugs. 
1.2.7.1 Lck expression in cancer 
Despite Lck‘s predominance in T-cells, Lck mRNA has been observed in B-cell chronic 
leukaemia (B-CLL) (152). Lck expression is a feature of CD5(+) B1 cells.  These cells are 
the normal counterpart of CLL cells undergoing oncogenic transformation (153). 
Furthermore CD5
(-)
 B2 cells are thought to acquire the capacity to express Lck ectopically 
upon transformation by EBV (153). 
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Elevated Lck activity was seen in small cell lung cancer (SCLC), downstream of stem cell 
factor mediated Kit stimulation (150). Another study showed that high levels of Lck 
activity can cause thymic lymphomas (154). 
Studies, investigating tumour infiltrating lymphocytes, have shown that Lck expression is 
significantly decreased in breast carcinoma, renal cell carcinoma and tumour involved 
lymph nodes of patients with melanoma (155-157). For almost 20 years, it has been known 
that Lck is expressed in human breast cancer tissue. 25-30% of the tumours analyzed in 
this proto-oncogene screening study, showed significant expression of either erbB, Src, 
Raf1, Lck or H-Ras (158). Increased expression of Lck was seen in higher grade breast 
tumours (159).  
Lck interacts with Syk, another member of the family of non-receptor tyrosine kinases, via 
a cross-talk mechanism in hypoxia induced breast cancer progression (159). Syk acts as a 
negative regulator and Lck a positive regulator. Lck, activated by hypoxia/ reoxygenation, 
inhibits MelCAM, a tumour suppressor in breast carcinoma (159), which promotes breast 
cancer progression. 
 
The high homology that exists between members of this family complicates the design of 
inhibitors specific to a single isoform. 
Inhibitors with modified pyrimidine cores represent the most intensely studied group of 
compounds that inhibit SFKs. The earliest members of this family were the 
pyrazolopyrimidine inhibitors PP1 and PP2. Unfortunately these inhibitors lack specificity 
within the Src kinase family. 
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1.3 Src kinase inhibitors 
Src has many roles in regulating signal transduction during tumour cell proliferation and 
metastasis. Increasing evidence from cancer cell lines and human tumour tissue highlights 
Src as an important target for drug therapies aimed at preventing progression of disease or 
metastatic spread. 
There are two main categories of Src inhibitors currently being developed: agents that 
block substrate binding to SH2 or SH3 domains and ATP-competitive kinase inhibitors. 
1.3.1 SH2/SH3 inhibitors 
SH2/SH3 inhibitors are a class of Src inhibitors that were designed to prevent Src binding 
to and activating downstream signalling substrates. Three SH2/SH3 inhibitors are 
undergoing either preclinical or early clinical trials: UCS15A, AP22408, and KX2 391 
(figure 1.8).  
Figure 1.8: Molecular structures of SH2/SH3 inhibitors 
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Figure 1.8: Simplified compound 2D structure of the three above mentioned SH2/SH3 
inhibitors UCS15A, KX2 391 and AP22408 
 
UCS15A is a proline-rich agent that interacts with proline-rich regions of the SH3 domain. 
In preclinical studies, UCS15A inhibited SH3-mediated protein–protein interactions in 
colon cancer cells (160) and in vitro bone resorption by osteoclast-like cells (161). 
KX2 391, formerly KX 01 (Kinex Pharmaceuticals) is an orally available, non-ATP–
competitive Src inhibitor designed to target the substrate-binding pocket of Src. KX2 391 
is currently in early clinical studies in patients with solid tumours. A preclinical study in 
four liver cancer cell lines showed that KX2 391 had potent anti-proliferative activity 
(162).  
AP22408 is a nonpeptide phosphotyrosine mimic with osteoclast-targeting properties, with 
the potential to specifically target bone metastases while avoiding unwanted inhibition of 
Src-dependent activities in other cells types. AP22408 has shown anti-resorptive activity in 
models of osteoclast bone resorption (163).  
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1.3.2 ATP-competitive Src kinase inhibitors 
Each of the following three agents is an orally active small molecule, which inhibits the 
kinase activity of the SH1 domain of Src. These ATP-competitive Src kinase inhibitors 
have reached clinical application to date: dasatinib (SPRYCEL
®
, Bristol-Myers Squibb), 
saracatinib (AZD0530, AstraZeneca), and bosutinib (SKI-606, Wyeth) (figure 1.9). 
Figure 1.9: Molecular structure of ATP-competitive Src kinase inhibitors 
 
 
Figure 1.9: Simplified compound 2D structure of the three ATP-competitive inhibitors 
dasatinib, saracatinib and bosutinib, which have already reached clinical trial stage. 
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Dasatinib is a tyrosine kinase inhibitor of Abl, Src and SFKs (164;165). It is currently 
approved for the treatment of patients with certain types of leukaemia based on its potent 
inhibition of Bcr-Abl (166). Preclinical in vitro and in vivo studies have demonstrated that 
dasatinib inhibits FAK and p130
CAS
 signalling downstream of Src, cell adhesion, and 
migration in prostate cancer cell lines (167), and integrin-dependent adhesion and 
migration in colon cancer cell lines (168). Different subtypes of breast cancer cell lines 
have exhibited different sensitivities to dasatinib in vitro. Triple-negative breast cancer cell 
lines, which are considered to be equivalent to basal breast cell lines, and those 
representative of post-epithelial/mesenchymal transition cells were more sensitive to 
dasatinib-induced growth inhibition than luminal cell lines (169;170). In cells that 
overexpressed EGFR or members of the HER family, dasatinib induced cell-cycle arrest 
and caspase-mediated apoptosis and attenuated cell migration and invasion (171). 
Dasatinib also showed activity in preclinical models of EGFR-dependent sarcomas and 
lung cancers, inducing apoptosis and inhibiting downstream signalling, migration, and 
invasion (172;173).  
In vivo models of metastatic prostate cancer showed decreased growth and metastasis to 
lymph nodes following dasatinib treatment in both androgen-sensitive and -insensitive 
disease. Dasatinib was not only effective at arresting the cell cycle and preventing 
metastatic spread, but also able to inhibit formation of bone metastases. In bone metastasis 
models, dasatinib inhibited the growth of prostate tumour cells in bone (174;175). 
Saracatinib is an inhibitor of SFKs, EGFR, c-Kit, EphA2 and the Src-regulator Csk (176). 
In vitro studies of saracatinib have shown anti-proliferative, anti-migratory, and anti-
invasive activity in several cancer cell lines, including breast, prostate, colon, and non-
small cell lung cancer (NSCLC) (176-178). However, in vivo findings have been less 
consistent. In one study, saracatinib inhibited growth and metastasis of an androgen-
independent prostate cancer cell line xenograft (179), whereas other studies showed 
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moderate growth delay in four out of 10 xenografts of various types (176), and inhibition 
of in vivo tumour growth three out of 16 pancreatic tumour xenografts (180). An in vitro 
study demonstrated reversible inhibition of migration of osteoclast precursors, 
osteoclastogenesis and osteoclast-mediated bone resorption suggesting that saracatinib may 
have some activity against bone metastases (181). 
Bosutinib (formerly SKI-606) has demonstrated activity as an inhibitor of Src, SFKs and 
Bcr-Abl in leukaemia and lymphoma cell lines (182). Preclinical studies on solid tumour 
cell lines showed that bosutinib inhibited in vitro growth and motility of colorectal 
carcinoma cells (183). In NSCLC cell lines, bosutinib inhibited phosphorylation of 
downstream Src substrates and enhanced gefitinib-induced apoptosis (184). In vitro studies 
using the MDA-MB-231 metastatic breast cancer cell line showed that bosutinib inhibited 
proliferation, invasion and migration in vitro. Analogous results were observed in 
xenograft studies including a decrease in tumour size compared with control animals, in 
addition to inhibition of angiogenesis, growth factor expression and Src signalling (85). 
Other xenograft studies found that bosutinib inhibited Src phosphorylation and growth of 
subcutaneous colorectal tumour xenografts (185).  
 
Given the roles of Src in solid tumours discussed above, it is expected that Src inhibitors 
would arrest tumour growth and prevent metastasis, rather than having a cytotoxic effect. 
To fully assess the potential clinical benefits of Src inhibitors, trials need to be performed 
in patients with various stages of disease, including patients without metastases to assess 
any activity in preventing disease progression. With the aim to further improve the 
outcome of patients treated with Src-targeting agents, work is ongoing to identify gene 
signatures or pharmacodynamic markers that could predict sensitivity to Src inhibition in 
individual patients (180;186;187). The goal of this approach is to enrich study populations 
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with patients who might have an increased likelihood of response to a Src inhibitor, 
thereby providing a more definitive assessment of this class of agents.  
The potential effect of dasatinib in solid tumours may be multiple as effects on migration 
and invasion have been reported as well as inhibition of proliferation (164;167;188). It 
remains unclear, which of these mechanisms will become more relevant in the clinical 
application of dasatinib in solid tumours of epithelial origin. The introduction of 
molecularly targeted agent into the clinic has led to a re-evaluation of clinical trial design 
as many of these agents are not cytotoxic, and conventional measures of reduction in 
tumour bulk and the use of maximum tolerated dose based on toxicity do not apply. 
Phospho-specific antibodies have provided useful reagents for analysis of signalling 
pathways in clinical samples. Serrels et al. have identified autophosphorylation of Src on 
Tyrosine site 419 and phosphorylation of paxillin on Tyr118 as potential biomarkers of 
dasatinib activity in colon cancers. 
A large number of phase I and phase II clinical trials are underway with Src inhibitors 
against a range of different tumour types, both as single agent or in combination with other 
therapeutics, to determine the objective response rate of patients with advanced metastatic 
disease (189). 
One major problem still remains: how to assess which tumours will respond to Src 
inhibitors, so patient can be selected who will probably benefit most from the treatment. 
Applicability of microarray gene analysis in the clinical setting is now being tested after 
identifying a gene signature that was able to predict response to dasatinib in cell lines 
(170). Response rate with molecular target therapy in unselected patient groups have been 
so far very modest and this is most likely indicate that in most solid tumours no single 
molecular event drives tumourigensis. 
As we know Src associates with EGFR and that inhibition of Src activity in tumours 
overexpressing EGFR induces apoptosis, even in tumours resistant to EGFR therapies 
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(190). A number of clinical trials are in progress looking at combining dasatinib with 
EGFR inhibitors. Other promising preclinical data have prompted clinical evaluation with 
cytotoxic agents such as gemitabine and paclitaxel (191). 
Inhibition of Src may have a potent anti-invasive effect, which may prevent tumour 
dissemination rather reduces tumour bulk. Again remains difficult to assess efficacy of the 
drugs in the clinical setting. These agents are more likely effective in patients with pre-
invasive disease or patients with surgically resectable cancers with a high risk of recurrent 
disease due to presence of micrometastases. It is absolutely crucial to identify validated 
biomarkers to assess and monitor both target inhibition and anti-invasive efficacy to 
conduct clinical trials judiciously. 
 
Summary 
Almost 42,000 women die annually in the UK of breast cancer.  Worldwide high-profile 
public screening efforts detect breast cancer now at an early stage. These patients are 
generally treated by surgery with adjuvant endocrine therapy and radiotherapy.  A variety 
of host and tumour characteristics are used to aid decision-making in this setting including 
tumour size and grade, involvement of axillary lymph nodes, hormone receptor status and 
the presence or absence of HER2 over-expression. If breast cancer reaches advanced to 
metastatic stages further adjuvant oncological systemic treatments are available. However, 
adjuvant treatments have significant potential toxicities in addition to considerable 
economic cost.  The aim of adjuvant treatment is to reduce the risk of distant recurrences 
of cancer but accurate identification of those women at most risk of is difficult.  There is 
therefore an urgent need for novel prognostic indicators in breast cancer therapy.  
Molecular techniques and gene expression profiles have shown some value in more 
accurate identification of patients at risk. 
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Src has a well-characterised role in normal cellular functions, such as proliferation, 
adhesion and motility. These functions are also elemental for tumour growth and 
metastasis. Preclinical studies suggest that targeting Src has the potential to block multiple 
steps in the oncogenic process. Existing and emerging data in human tissues confirm that 
Src expression and/or activation are elevated in tumours compared with normal tissue, and 
levels appear to be highest in metastatic tissue.  
Nevertheless, it is also apparent that Src activity and expression varies between patients 
and tumour types, and that the subcellular localisation of Src and phosphorylation of 
different tyrosine residues might have clinical significance. This aspect of Src biology is 
being actively researched and could guide future clinical investigations. 
Preclinical and early-phase clinical studies suggest that Src inhibitors have cytostatic 
effects against tumours. Trials are ongoing to identify patient populations who might 
derive a clinical benefit from this class of drug therapy, including studies of combination 
therapy. Following encouraging early data, the potential activity of Src inhibitors in 
patients with bone metastases is also being evaluated. Parallel clinical and laboratory 
studies with a strong translational research component are needed to fully define the role of 
Src in cancer and the therapeutic potential of Src inhibitors. 
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1.4 Hypothesis and statement of aims 
It is established that Src family kinases play an important part in the develpoment and 
progression of cancer. Numerous in vitro studies have shown that elevated Src activity 
promotes cellular invasion and increases cell migration. They are also suggesting a link 
between HER and steroid receptors (ER/PgR) with Src kinase family members in breast 
cancer. Despite this, there is a paucity of translational clinical studies, to support in vitro 
evidence demonstrating a role for c-Src in breast cancer. Src kinase inhibitors have already 
entered phase II clinical trails for advanced and metastatic breast cancer without 
identification of adequate biomarkers and detailed knowledge of their effect on individual 
kinases in human breast tissue. 
 
We hypothesise that with this study we will not only advance the understanding of the role 
of Src in human breast cancer but also potentially provide the prospect of identification of 
a biomarker for patients that would respond and benefit from Src inhibitors. 
 
Aim of this project is to perform a comprehensive investigation into the clinical 
significance of Src kinase family expression and activation in human breast tumours, 
carefully noting cellular location and expression profiles of Src family members using 
already constructed tissue microarray in conjunction with in vitro cell line studies.   
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Project aims 
1. To identify which Src kinase family members are expressed in human breast tissue 
and establish if mRNA expression profiles vary between normal, non-malignant breast 
tissue and invasive breast cancer.  
2. To select and optimise antibodies for the detection of Src kinase family members and 
their activation sites in human breast cancer specimens, using paraffin-embedded tissue 
micro arrays. 
3. To link expression of Src kinase family members with clinical parameters in order to 
establish association to patients‘ outcome. 
4. To examine the effect and relevance of Src kinase inhibitor Dasatinib on expression 
and activation of Src and SFK members regards their staining intensity and cellular 
location within breast cancer cell lines representing the four different subgroups of breast 
cancer patients. 
5. To investigate the effect of Dasatinib a non-selective, clinically trialled Src kinase 
inhibitor on the expression of different Src phosphorylation sites in breast cancer cell lines. 
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mRNA EXPRESSION 
OF SRC KINASE FAMILY MEMBERS 
IN BREAST TISSUE
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2.1 Introduction 
Src kinase is implicated as a regulator of cell proliferation and survival and has a 
complex role in cell adhesion, proliferation and motility (65). In vitro studies show 
convincing evidence for a role for Src in breast cancer, but this is currently not supported 
by translational clinical studies. Additionally, there is little published evidence on the 
role of other Src family members in breast cancer. The aim of this study was to 
determine, via real time PCR, if Src and other Src kinase family (SKF) member were at 
all expressed in human breast tissue specimens, to verify if mRNA expression levels 
were different in normal, non-malignant and invasive breast cancer tissue and to 
investigate if these expression levels were associated with clinical parameters and patient 
outcome. 
2.2 Methods 
Materials used within this chapter are listed in appendix 1. 
2.2.1 Patient Cohort 
This cohort contained 139 patients in total and was subdivided into:  
Patient group 1 (M) consisted of malignant tissue samples, taken from 81 breast cancer 
patients at time of primary tumour resection. All patients were diagnosed with operable 
invasive breast carcinoma between 1987 and 2005 in the Greater Glasgow area.  
Patient group 2 (NM) included non-malignant tissue samples from 48 breast cancer 
patients taken from disease free areas of mastectomy resection specimens.  
Patient group 3 (N) comprised of 10 normal breast tissue specimens obtained from 
reduction mammoplasties.   
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All samples were taken at time of surgical resection, assessed and confirmed by a 
pathologist, then snap frozen and stored in liquid nitrogen. ER and PgR status was 
determined as a routine diagnostic measure in the local pathology department. 
Clinical and pathological characteristics, including age, tumour grade, size and histology, 
lymph node involvement, steroid receptor status and HER2 status are shown in table 2.2, 
result section of this chapter.  
2.2.2 Quantitative Reverse Transcriptase Polymerase Chain Reaction 
2.2.2.1 Tissue processing 
Following the resection of the primary tumour, representative parts of malignant (M) and 
non-malignant (NM) breast tissue were identified by a pathologist, frozen and stored in 
liquid nitrogen. Normal (N) breast tissue was selected and taken from different sites of 
breast reduction specimens. ER and PgR receptor status were determined by 
immunohistochemistry as routine diagnostic measures in the Glasgow Royal Infirmary 
Pathology Department for malignant and non-malignant breast tissue. ER and PgR were 
scored as negative when histoscore was less than 10. PgR and HER2 receptor status were 
infrequently measured on patients‘ specimen before the year 2000. Breast tumours were 
deemed as HER2 positive if scored 3+ by HERCEPT test or if 2+ by HERCEPT test and 
amplified by Fluorescent in situ hybridization (FISH) using the Pathvision test (Vysis 
Ltd, USA). 
2.2.2.2 RNA isolation 
50 – 75 mg of breast tissue was ground in a mortar and pestle in liquid nitrogen. Total 
mRNA was extracted using the TRIZOL
® 
 method according to manufacturer‘s protocol. 
RNA quantity and quality was assessed by UV spectrometry (GeneQuant machine) and 
by examination of rRNA bands after agarose gel electrophoresis.  
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Only samples, which showed both 18S band and a stronger expressed 28S band, were 
included in this study (figure 2.1).  
Figure 2.1: Agarose gel electrophoresis for RNA quality control 
 
Figure 2.1 shows an agarose gel with six invasive breast cancer rRNA samples with 
appropriate expression at 18S and 28S. After this quality control step samples were 
utilised for cDNA synthesis. L= Ladder; sample 1-6= invasive breast cancer sample 
1-6 
2.2.2.3 cDNA synthesis 
To guarantee no other DNA was present, DNA-free DNAse treatment and removal 
reagent kit was added. Samples were incubated for 30 min at 37°C. To ensure the same 
amount of cDNA being used for quantification of mRNA, a starting concentration of 
1000ng of tRNA was applied for each sample. Random hexamer primers (50ng) were 
used for First Strand cDNA Synthesis using SuperScript 
TM
 II RT according to 
manufacturer‘s instructions. Before using cDNA for PCR amplification, 2 units of RNase 
H were added to samples and incubated for 20 minutes at 37°C. Quality of cDNA was 
assessed by using a PCR control run with human ß–actin.  
Product bands were assessed by examination of agarose gel electrophoresis. Only 
samples, which showed equal product bands at 330 bp, were utilised (figure 2.2).  
 
 
28S band
18S band
L                   sample 1-6 L                   sample 1-6
Chapter 2 mRNA expression of SFK members 81 
 
Figure 2.2: Agarose gel electrophoresis for quality control for cDNA 
 
Figure 2.2 demonstrates a PCR control run with human ß-actin to assess quality of 
cDNA. An equal band of each sample, at 330 bp on agarose gel electophoresis, was 
essential for the cDNA to be used for mRNA quantification. L= Ladder, C= negative 
control, sample 1-8= invasive breast cancer sample 1-8 
2.2.2.4 Quantification of mRNA 
Real-time quantative PCR was performed using an ABI Prism 7900 Sequence Detection 
System (Applied Biosystems, UK) and TaqMan® Gene Expression Assays (table 2.1). 
For the TaqMan® Gene Expression Assays the manufacturer‘s protocol with 
recommended 40 rounds of amplification was applied. Thermal cycler condition were 
50°C for 2 min, 95°C for 10 min followed by 40x 95°C for 15 sec and 60°C for 1 min. 
Product melting curve analysis and gel electrophoresis experiments were used to ensure 
that only one product of the expected size was amplified. 
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Table 2.1: Demographic details of SKF member genes 
Gene Gene Expression 
Assay ID 
Exon boundary spanned 
according to product insert 
Amplicon 
Length 
Threshold 
value (Ct) 
SRC Hs00178494_m1 7-8 70 0.28263707 
LCK Hs00178427_m1 9-10 104 0.26297827 
LYN Hs00176719_m1 12-13 70 0.34538345 
YES Hs00736972_m1 2-3 153 0.14854589 
FYN Hs00176628_m1 3-4 99 0.27740355 
FGR Hs00178340_m1 5-6 61 0.22993330 
HCK Hs00176654_m1 6-7 64 0.37934458 
BLK Hs00176441_m1 1-2 85 0.23531063 
GAPDH 4310884E 3 118 0.26113370 
HPRT 4310890E 6-7 100 0.25742040 
Table 2.1 reveals intron-skipping primers (eight SKF member and two housekeeping 
genes) used for real-time PCR and their fixed threshold Ct values. 
Negative controls (RNAse/DNAse free H2O and negative RTPCR sample) for each 
primer were included on every 96 well PCR plate (Applied Biosystems, UK). 
Quantitative values were obtained from the threshold cycle (Ct value) at which the 
increase TaqMan® probe fluorescent signal associated with an exponential increase of 
each individual PCR product reaching a fixed threshold value. Each individual primer 
had a fixed threshold Ct value. These fixed threshold values were used for every cDNA 
sample (table 2.1). 
To enable comparison of different mRNA expression levels, their relation to the average 
expression level of two housekeeping genes (GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase and HPRT, hypoxanthine-guanine phosphoribosyl-transferase) were 
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evaluated. The housekeeping gene with the lowest standard deviation (HPRT) was used 
for evaluation of the different mRNA expression levels. Data were analysed using the 
Sequence Detection Software, which calculates the threshold cycle (Ct) value. The 
expression of the target assay was normalised by subtracting the Ct value of the 
housekeeping gene from the Ct value of the relevant target assay. The fold increase, 
relative to the control, was obtained by using the formula 2
-ΔCt
, and then expressed as a 
percentage (x100).  
Formula: 2 
-(Mean Ct target gene- Mean Ct house keeping gene) 
x100 
All samples were measured in duplicates. 
Methods were established by the author. However, supportive technical assistance was 
given by laboratory technician Fiona Jordan, who processed the last remaining 32 
samples. Result analysis of TaqMan® mRNA quantification and statistical analysis were 
performed again by the author. 
2.2.3 Statistical Analysis 
Differences in expression levels were analysed using the Mann-Whitney U test or 
Kruskal-Wallis test, including a Wilcoxon–type test for trends, when appropriate. 
Associations between continuous variables were assessed with the Spearman Rank test. 
Disease specific survival rates were generated using the Kaplan-Meier method. The log 
rank test was used to compare significant differences between subgroups using univariate 
analysis. Based on the results of the univariate analysis a multivariate analysis was then 
carried out. The multivariate stepwise Cox-regression analysis was performed to identify 
factors that were independently associated with disease specific death. A stepwise 
backward procedure was used to derive a final model of the variables that had a 
significant independent relationship with survival.  To remove a variable from the model 
the corresponding p-value had to be greater than 0.05.   
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Inter-relationships between clinical parameters, ER, PgR and HER2 status were 
calculated using the Chi square test. Nonparametric correlations between Src and other 
SFK members were determined using 2-tailed Spearman‘s rho test.  Because of the 
number of statistical comparisons, a p-value of <0.01 was considered to be significant. 
Data are expressed as median and range.  The statistical analyses were performed using a 
statistical software package (SPSS 15.0 Inc., Chicago, IL, USA). 
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2.3 Results  
2.3.1 Clinico-pathological details of cohort 
The PCR cohort consisted of 81 invasive breast cancers (M), 48 non-malignant (NM) and 
10 normal (N) breast tissue samples. Clinical and pathological characteristics of those 
three groups are shown in table 2.2.  
Median age of the breast cancer patients was 61 years (IQR 49-74 years). Median size of 
breast cancer was 30mm (IQR 20-42mm). 40% of the specimens were pathologically 
graded G2 and 48% G3. 52 breast cancer patients were ER positive compared to 29 ER 
negative patients. 55% of breast cancer patients were axillary lymph node positive. 
Median NPI was 4.6 (IQR 4.3-5.4). Patients underwent either breast conserving wide 
local excision (16%) or a simple mastectomy (67%; the rest 17% unknown). Axillary 
dissection was performed in 83% of cases. At time of analysis 37 out of 79 patients were 
deceased. 18 of those 37 patients died of breast cancer related causes. Median follow-up 
time was 5.6 years (IQR 1.8- 17.6 years). 
Median age of breast cancer patients, from whom a non-malignant specimen of breast 
tissue was obtained, was also 61 years (IQR 52-71 years). 63% of those patients were ER 
positive, 17% ER negative. ER status was not significantly different between tissue types 
(p=0.847). 
Median age of breast reduction patients supplying normal breast tissue was 37 years 
(IQR 33-48 years). 
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Table 2.2: Overview of clinico-pathological features of mRNA cohorts  
 Variables   
Cohort 1 
No: 81 
(M) 
% 
Cohort 2  
No: 48 
(NM) 
% 
Cohort 3  
No: 10 
(N) 
% 
 <= 50 20 25 11 23 8 80 
Age   > 50 61 75 37 77 2 20 
  ductal 75 93 44 92   
Histology lobular 4 5 3 6   
  others 2 2 1 2   
  unknown     10 100 
  1 5 6 6 12   
Grade 2 32 40 21 44   
  3 39 48 20 42   
  unknown 5 6 1 2 10 100 
 <20mm 10 13 10 21   
Size 20-50mm 55 68 30 63   
 >50mm 14 17 5 10   
 unknown 2 2 3 6 10 100 
Nodal status 
positive 29 36 26 54   
negative 45 55 19 40   
unknown 7 9 3 6 10 100 
  positive 29 36 18 37   
ER status negative 52 64 30 63   
  unknown     10 100 
  positive 16 20 14 29   
PgR status negative 17 21 8 17   
  unknown 48 59 26 54 10 100 
  positive 28 35 17 36   
HER2 status negative 4 5 4 8   
 unknown 49 60 27 56 10 100 
 <3.4 4 5 6 12   
NPI 3.4-5.4 49 60 29 60   
 >5.4 15 19 6 12   
 unknown 13 16 7 16 10 100 
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Table 2.2 is giving an overview of clinico-pathological features of the cohorts M= 
invasive breast tissue, NM= non-malignant breast tissue and N= normal breast tissue. 
Histology= Pathological type: Ductal= invasive ductal carcinoma; Lobular= invasive 
lobular carcinoma; others: including tubular, medullary, mucinous, and squamous; 
Grade = Bloom and Richardson grade; Size= Maximum tumour diameter; ER= 
Oestrogen receptor; PgR= Progesterone receptor; HER2= Human epidermal growth 
factor receptor 2; NPI= Nottingham Prognostic Index 
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2.3.2 mRNA expression levels in human breast tissue 
2.3.2.1 mRNA expression levels in human breast tissue 
Expression levels for SFK member were quantified in all tissue samples (table 2.3). BLK 
was the least expressed SFK member in all breast tissues. No change in the level of SRC 
expression was observed between tissue types (p=0.976) (figure 2.3). Whereas LCK, 
FYN and YES showed significant changes in expression between different breast tissue 
types (table 2.3). 
Table 2.3: Expression levels of SFK members in different breast tissue types 
Gene Expression levels 
in M 
Expression levels 
in NM 
Expression levels 
in N 
 
p-values 
SRC 9041 9252 9493 0.976 
LCK 655 217 255 <0.001 
LYN 7233 8922 10521 0.076 
FYN 2245 5293 25484 <0.001 
FGR 1144 1275 1072 0.043 
HCK 1815 2673 1712 0.070 
BLK 208 161 234 0.114 
YES 2142 499 3312 <0.001 
Table 2.3 shows expression levels of Src kinase family members in different breast 
tissue types (M= invasive breast cancer; NM= non-malignant and N normal tissue) 
are stated as medians. P-values express alterations of expression in the different 
breast tissue types (Kruskal-Wallis test). Bold typeface is used to highlight significant 
p-values. 
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Figure 2.3: SRC mRNA expression levels in normal, non-malignant and malignant 
breast specimens 
 
Figure 2.3 demonstrates different SRC mRNA expression levels in normal, non-
malignant and malignant breast specimens (p=0.976). 
 
2.3.3 Src kinase family member expression in breast cancer specimen 
SRC and LYN were the most highly expressed SFK members in malignant breast tissue 
(figure 2.4).  
Higher expression levels of LCK were observed in invasive breast cancers compared to 
non-malignant and normal breast tissue (p<0.001) (figure 2.5). Interestingly, LCK was 14 
fold less expressed than SRC. It also was the only SFK member, which showed a 
difference in expression levels between ER negative and ER positive patients. LCK was 
higher expressed in ER negative patients, compared to ER positive patients (figure 2.6).  
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Figure 2.4: Overview of all SFK member expression in malignant breast tissue 
 
Figure 2.4 shows an overview of all SFK member expression in malignant breast 
tissue. SRC and LYN are the most and BLK the least expressed SFK member. 
Figure 2.5: LCK mRNA expression in N, NM and M breast tissue 
 
Figure 2.5: LCK is highest expressed in malignant breast tissue (p<0.001). 
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Figure 2.6: LCK expression in ER negative compared to ER positive patients 
 
Figure 2.6 highlights the difference between LCK mRNA expression in ER negative 
compared to ER positive breast cancer patients (p=0.030). 
All SFK members correlated with SRC expression. The strongest correlation detected 
was with LYN (p<0.001, c.c. 0.570) (figure 2.7), the weakest with YES (p=0.030, c.c. 
0.242) (figure 2.8). An overview of those correlations is provided in table 2.4. 
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Figure 2.7: Correlation between SRC and LYN mRNA expression in the M cohort 
 
Figure 2.7 illustrates a high correlation between SRC and LYN mRNA expression in 
the malignant PCR cohort (p<0.001, c.c. 0.570). 
 
Figure 2.8: Correlation between SRC and YES mRNA expression in the M cohort 
 
Figure 2.8: SRC mRNA expression was least correlating with YES mRNA expression 
in the malignant breast patient cohort (p=0.030, c.c. 0.242). 
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Table 2.4: Non-parametric correlations between each SFK member 
 SRC  LCK LYN FGR FYN HCK BLK YES 
SRC 
Cc 
p-value 
 
1.00 
 
 
0.410 
<0.001 
 
0.570 
<0.001 
 
0.521 
<0.001 
 
0.448 
<0.001 
 
0.473 
<0.001 
 
0.316 
0.003 
 
0.242 
0.040 
LCK  
Cc 
p-value 
 
0.410 
<0.001 
 
1.00 
 
 
0.680 
<0.001 
 
0.648 
<0.001 
 
0.575 
<0.001 
 
0.613 
<0.001 
 
0.640 
<0.001 
 
0.394 
<0.001 
LYN 
Cc 
p-value 
 
0.570 
<0.001 
 
0.680 
<0.001 
 
1.00 
 
 
0.683 
<0.001 
 
0.742 
<0.001 
 
0.756 
<0.001 
 
0.527 
<0.001 
 
0.274 
0.014 
FGR 
Cc 
p-value 
 
0.521 
<0.001 
 
0.648 
<0.001 
 
0.683 
<0.001 
 
1.00 
 
0.759 
<0.001 
 
0.810 
<0.001 
 
0.543 
<0.001 
 
0.315 
0.004 
FYN 
Cc 
p-value 
 
0.448 
<0.001 
 
0575 
<0.001 
 
0.742 
<0.001 
 
0.759 
<0.001 
 
1.00 
 
0.858 
<0.001 
 
0.649 
<0.001 
 
0.323 
0.003 
HCK 
Cc 
p-value 
 
0.473 
<0.001 
 
0.613 
<0.001 
 
0.756 
<0.001 
 
0.810 
<0.001 
 
0.858 
<0.001 
 
1.00 
 
0.622 
<0.001 
 
0.382 
<0.001 
BLK 
Cc 
p-value 
 
0.316 
0.004 
 
0.640 
<0.001 
 
0.527 
<0.001 
 
0.543 
<0.001 
 
0.649 
<0.001 
 
0.622 
<0.001 
 
1.00 
 
0.349 
0.001 
Table 2.4 demonstrates non-parametric correlations between each SFK member in 
malignant breast tissue (Spearman’s Rank test). 
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Survival analysis was completed for all SFK members. Only SRC was significantly 
associated with decreased disease specific survival in ER positive breast cancer patients 
(p=0.012; figure 2.9). Patients with high SRC mRNA expression had a median survival 
of 4.5 years (IQR 2.7-6.3) compared to those with low expression with median survival 
of 11.6 years (IQR 6.9-13.3). 
Figure 2.9: Kaplan Meier survival graph for mRNA expression SRC in ER positive 
patients. 
 
Figure 2.9 shows that high mRNA expression of SRC in ER positive patients was 
significantly associated with poorer clinical outcome (p=0.012). 
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2.3.4 Src kinase family member expression in non-malignant breast 
tissue 
As observed within the invasive breast cancer specimen, SRC and LYN were the highest 
expressed Src kinase family members in non-malignant breast tissue and BLK the 
weakest expressed SFK member (figure 2.10).  
Figure 2.10: Overview of SFK member expression in non-malignant breast tissue 
 
Figure 2.10 gives an overview of SFK member expression in non-malignant breast 
tissue. Like observed within the malignant breast tissue, SRC and LYN were the 
highest and BLK the least expressed SFK member in non-malignant breast tissue. 
YES was least expressed in non-malignant breast tissue, compared to malignant and 
normal breast tissue (p<0.001) (figure 2.11). No significant difference in expression 
between the malignant and non-malignant patient group was observed with SRC, LYN, 
FGR, HCK and BLK. 
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Figure 2.11: YES mRNA expression levels in N, NM and M breast specimens 
 
Figure 2.11: YES is highest expressed in the normal breast specimen cohort 
compared to the other two cohorts (p<0.001). 
As with the invasive breast cancer specimens, all other Src kinase family members 
correlated with SRC expression. Again the strongest correlation was with LYN (p<0.001, 
c.c. 0.799) (figure 2.12) and the weakest with YES (p=0.027, c.c. 0.326) (figure 2.13). 
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Figure 2.12: Correlations between SRC and LYN expression in the NM cohort 
 
Figure 2.12 illustrates the correlation of SRC mRNA expression with LYN in the non-
malignant PCR cohort (p<0.001, c.c. 0.799). 
Figure 2.13: Correlations between SRC and YES expression in the NM cohort 
 
Figure 2.13 demonstrates a low correlation between SRC and YES mRNA expression 
in the non-malignant breast patient cohort (p=0.027, c.c. 0.326). 
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2.3.5 SFK member expression in normal/ breast reduction tissue 
FYN was the most highly expressed SFK member in normal tissue. It was significantly 
higher expressed than any other SFK members (figure 2.14); 2.7 fold higher than Src and 
100 fold higher than Lck. Highest expression levels of Fyn were observed in normal 
tissue compared to non-malignant and lowest in invasive breast cancer specimens (p< 
0.001). No correlations between Src and SFK members were observed in normal breast 
tissue (table 2.5). 
Figure 2.14: Overview of SFK member expression in normal breast tissue 
 
Figure 2.14 gives an overview of SFK member expression in normal breast tissue. 
FYN was highest expressed SFK member, followed by LYN and SRC. 
Only LCK, LYN and FYN expression correlated with SRC expression (table 2.5): LCK 
p=0.043, c.c. 0.648 (figure 2.15), LYN (p= 0.022, c.c. 0.709) (figure 2.16), FYN 
(p=0.043, c.c. 0.648) (figure 2.17).  
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Table 2.5: Correlations between SRC and other SFK members in the N cohort 
 LCK LYN FGR FYN HCK BLK YES 
SRC 
Cc 
p-value 
 
0.648 
0.043 
 
0.709 
0.022 
 
0.588 
0.074 
 
0.648 
0.043 
 
0.430 
0.214 
 
0.552 
0.098 
 
0.321 
0.365 
Table 2.5: Correlations between SRC, LCK, LYN and FYN (Spearman’s Rank test) 
were significant.  
 
Figure 2.15: Correlation between SRC and LCK expression in the N cohort 
 
Figure 2.15 displays the correlation of SRC mRNA expression with LCK mRNA 
expression in the normal breast tissue specimens (p=0.043, c.c. 0.648). 
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Figure 2.16: Correlation between SRC and LYN expression in the N cohort 
 
Figure 2.16 illustrates the correlation of SRC mRNA expression with LYN in the 
normal PCR cohort (p=0.022, c.c. 0.709). 
Figure 2.17: Correlation between SRC and FYN expression in the N cohort 
 
Figure 2.17 elicits the correlation of SRC and FYN mRNA expression in specimens, 
collected from breast reduction mammoplasties (p=0.043, c.c. 0.648). 
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2.4 Discussion 
SFK members are expressed in various cell types and tissues (192) and involved in 
cancer progression, via transduction of signals for cell growth, differentiation and 
survival, influencing cellular adhesion, migration and invasion (193). However, there is 
little translational evidence of SFK member expression in breast tissue.   
In this pilot study we used RT-PCR, a molecular quantification method, for investigating 
mRNA expression of eight SFK members. One disadvantage of this technique is the 
handling of very labile mRNA. If tissue is not instantly fresh frozen after retrieval, 
mRNA is able to degrade rapidly and quality suffers leading to faulty results. To extract 
mRNA from certain tissue, for example bladder cancer, meticulous dissection with a 
laser is needed in order to achieve purification of tumour tissue that no other tissue type 
would dampen results. Valuable information about cellular locations is lost due to the 
necessity for tissue destruction in order to facilitate quantification of specific 
biomolecules. 
Initially we used two housekeeping genes (HPRT and GAPDH) to establish which one of 
them was most suitable for evaluation of the different mRNA expression levels. Because 
of the least standard deviation with HPRT in our analysis and to use less reagent and 
materials (=financial resources) we only continued our study with HPRT. During this test 
period we also encounter difficulties with the HPRT gene assay. Its amplification plots 
suggested inhibition of the PCR reaction, preventing the PCR to amplify. After serial 
dilutions of the 100% DNA used originally, we found that a 1/10 dilution was providing 
us with the best amplification plot indicating that the real time PCR reached its full 
efficiency. 
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mRNA of all eight SFK members was investigated in normal, non-malignant and 
malignant breast tissue and confirmed to be present in all those tissue types in different 
expression levels. Interestingly, SRC expression levels were unchanged between the 
tissue types, despite being the highest expressed SFK member in malignant and non-
malignant, but not in normal breast tissue. We only conducted a survival analysis within 
the malignant breast tissue cohort. SRC was the only SFK member, which was 
significantly associated with patients‘ survival. However we sensed that the study was 
slightly underpowered. The patient number in this cohort was only 81. To gain 
trustworthy results and draw reliable conclusions we saw the necessity to increase the 
patient number for survival analysis.  
 
As SRC, LYN was also expressed at high mRNA levels in malignant and non-malignant, 
but not in normal breast tissue. It‘s unclear if the dissimilar expression profile of normal 
breast patients, with FYN being the highest expressed SFK member, is caused by the age 
discrepancy between this cohort and the others or is based on other clinico-pathological 
parameters. Nevertheless there was a significant correlation present between FYN and 
SRC expression.  
We are undecided if this finding is of any importance. It‘s well known that Fyn is 
expressed in other normal tissue (68) e.g. osteoblasts. A recent study showed that FYN 
was expressed in those cells, but had no influence on proliferation or differentiation. 
Only Src, activated at high level, was inhibited by Src kinase inhibitor Dasatinib 
enhancing osteoblast differentiation (194). This patient cohort was originally thought to 
be only a control group. For this reason we only analysed a small number of samples. 
 
LCK mRNA expression was highest in invasive breast cancer compared to the other 
groups, but was 14fold less expressed than SRC. It was not surprising to find Lck 
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expression in breast cancer specimen, a previous proto-oncogene screening study (194) 
had already recorded its presence in cancer. Increased Lck activity was also associated 
with SCLC (150) and with the development of thymic tumours (154). No data was yet 
available regarding relationship to other SFK member expression. 
LCK is known to be mainly expressed in T-lymphocytes and thymocytes (135). It‘s 
uncertain if this reflects a higher immunoreactivity of the breast tumours. Over recent 
years it has become clear that disease progression in patients with cancer is dependent on 
complex interactions between the tumour and host inflammatory response (195). There is 
increasing evidence that both local and systemic inflammatory responses play an 
important role in the progression of a variety of common solid tumours (196). Several 
studies have demonstrated the relationship between markers of the systemic 
inflammatory response and survival in advanced metastatic breast cancer (197). Up till 
now, there is no evidence if high expression of SFK members (Lck) in breast tumours, an 
association with inflammatory markers (e.g. CRP) nor even high expression of 
lymphocytes in the surrounding stroma, expressing Lck, could lead to a poor clinical 
outcome. 
 
With Src kinase inhibitors being commercially developed and made available for clinical 
trials, the lack of predictive and prognostic indicators in this area makes it more apparent 
to find an appropriate biomarker. This study established that all SFK member expression 
levels were correlating with SRC kinase expression. Additionally, SRC was the only gene 
where high mRNA expression was linked with poorer disease specific survival, 
suggesting that SRC could be used as a surrogate marker.   
 
Due to small patient numbers in the malignant breast tissue PCR cohort and the lack of 
knowledge regards transcription of mRNA into protein level, there was a need to expand 
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the investigations into the role of Src and other noteworthy SFK members (Lck, Lyn) 
into a larger cohort of patients with more detailed clinical information and mature long 
term clinical follow-up.   
With the knowledge that mRNA expression does not necessarily correlate with protein 
synthesis and protein expression, immunohistochemistry was employed to formalin fixed 
paraffin embedded breast cancer specimens to explore if observations made with mRNA 
expression regards survival, were still valid. It also would give us the opportunity to 
assess the importance of Src kinase protein activation investigating different activation 
sites of this non-receptor tyrosine kinase (next chapter).  
  
 
 
 
CHAPTER 3 
 
 
 
 
PROTEIN EXPRESSION 
OF SRC KINASE FAMILY MEMBERS 
AND THEIR ASSOCIATION WITH 
CLINICAL OUTCOME OF BREAST 
CANCER PATIENTS
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3.1 Introduction 
Having established mRNA expression and different expression levels of SFK members 
in different breast tissue types, this study aimed to prove the hypothesis that protein 
over-expression of Src, activated Src (phosphorylated and dephosphorylated tyrosine 
site 530, phosphorylated tyrosine site 419 and 215) and other most noteworthy 
expressed SFK members (e.g. Lyn, Lck,) would be associated with disease specific 
survival in breast cancer patients.  
Immunohistochemistry was employed to assess the clinical significance of Src kinase 
protein expression and activation in larger cohort of invasive breast cancer patients, to 
establish which clinical subgroups (e.g. ER/PgR positive/negative, HER2 positive, 
triple negative) are more affected by Src mediated expression and to determine if these 
are linked to clinical outcome measures. Validity/specificity of these antibodies was 
verified by Western Blotting prior to Immunohistochemistry staining. 
In addition, nuclear Ki67 expression was investigated to determine if SFK members are 
linked to high tumour proliferation. 
Chapter 3 Protein expression of SFK members 107 
 
3.2 Methods 
Materials used within this chapter are listed in appendix 2. 
3.2.1 Tissue microarray construction 
Tissue microarrays were constructed because of the large number of patients in our 
cohort (n=895). It allows rapid tumour processing under standardised conditions (198). 
There are several advantages to be listed for using TMAs. Working with tissue arrays 
instead of whole tissue sections is an extremely useful method in saving limited human 
tissue, since whole tissue sections only allow a restricted number of experiments to be 
conducted. It is also a time and money saving technique, having to apply less quantity 
of primary antibody in one experiment run. Performing all experiments at the same 
time on all the tumour tissue ensures experimental uniformity.  
Construction of the TMAs involved haematoxylin and eosin staining of the tissue 
sections of the breast cancer specimen, which was taken at time of the primary tumour 
resection. A consultant breast pathologist identified representative areas prior to coring. 
Individual tumour cores of those designated areas were then placed into a single 
recipient paraffin block.  
For our cohort six different TMAs (TMA1= 197 cores, TMA2= 80 cores, TMA3= 43 
cores, TMA4= 161 cores, TMA5= 187 cores, TMA6= 227cores) were constructed by 
Sylvia Brown. Each TMA was replicated in triplicates, using 3 * 0.6mm cores from 
each block to take into account heterogeneity of whole tumour sections. It also raises 
the possibility to gain results for all patients having three chances of obtaining 
informative cores. 
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3.2.2 Patient cohort 
The patient cohort consisted of a total of 895 patients. All patients were diagnosed with 
operable invasive breast carcinoma between 1980 and 1999 in the Greater Glasgow 
area. These patients received standard adjuvant treatment according to protocols at the 
time of diagnosis. Patients were excluded from the study if clinical follow up data was 
incomplete, tissue blocks were not available or had insufficient tumour tissue as 
determined by the pathologist. Clinical and pathological characteristics, including age, 
tumour grade, size and histology, lymph node status, ER and HER2 status are 
summarised in Table 3.3, result section of this chapter.  
The result analysis included only patients who had all clinical data, ER, PgR and HER 
status, full Src kinase, activated Src kinase, other Src kinase family member and Ki67 
expression data available. The cohort patient number was therefore reduced to 314 
patients. 
Ethical approval was granted by the Glasgow Royal Infirmary Local Ethics Committee. 
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3.2.3 Western blotting 
Western Blotting was performed to confirm antibody specificity before their usage in 
immunohistochemical staining of the TMAs. Proteins were prepared and kindly 
provided by Dr Liane McGlynn using breast cancer cell line lysates (MCF7 and 
MDAMB231). Western Blotting, also known as immunoblotting, detects and quantifies 
the amount of a specific protein in tissue or cells. Preparations for this technique 
include extracting protein samples from cultivated tissue or cells, separating the 
denaturated proteins by gel electrophoresis and transferring them to a PVDF 
membrane. This membrane is then exposed to a primary antibody specific to the 
protein of interest, followed by a secondary antibody recognising the antibody-antigen 
complex. To detect the proteins chemi-luminescent and chemi-fluorescent method is 
used. Those methods verify the specificity of all antibodies and measure the amount of 
proteins in samples from time course treatments.  
3.2.3.1 Preparation 
Determination of protein concentration 
It is essential to determine the protein concentration of each sample before starting 
immunoblotting. Using the same amount of protein from all the tested samples ensures 
experimental consistency. The method used is the Bio-Rad protein assay. It is based on 
the Bradford dye-binding procedure (Bradford 1976) and involves a colorimetric assay 
for measuring the total protein concentration. 
The protein samples were prepared as a low-concentration assay in disposable cuvettes 
(Gibo). A standard solution consisting of 200 l of Bio-Rad Reagent and 795 l dH2O 
was pipette into one cuvette, subsequently followed by 5 µl of protein sample.  
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To obtain an accurate concentration reading it is important to mix the solution 
thoroughly for even distribution of the protein. For comparison of the protein 
concentrations of each sample, protein standards were prepared using Bovine Serum 
Albumin (BSA). BSA was diluted with dH2O to 1 mg/ml. Reference samples (only 
dH20 and Bio-Rad Dye) and serial dilutions (for protein standards) from 1-50 µg/ml 
were set up afterwards. Reference sample and protein standard samples were used to 
calibrate the spectrophotometer (Bio-Rad) applying the Protein 595 Assay program.  
The Bio-Rad protein assay is based on a colour change of Coomasie brilliant blue G-
250 dye. The Coomasie dye binds to basic and aromatic acids residues of proteins. 
Protein concentration was determined via the absorbance change of the dye when 
bound to protein. Bound Coomasie blue dye has an absorption spectrum maximum at 
595nm, whereas unbound dye has an absorbance maximum at 470 nm. Consequently 
an increased absorption at 595 nm is proportional to the amount of protein within the 
sample. 
Optical density for the reference and the seven protein standard samples were measured 
at 595 nm. Optical density at 595 nm (O.D. 595) was then read for all other protein 
samples. The spectrophotometer calculated at that time the amount of protein (µg/ml) 
present in the sample, plotting a graph of absorbance at 595 nm against the protein 
concentration of the standard samples. This standard curve is used to determine the 
protein concentration of the measured sample from its O.D. 595 value. 
The initial protein concentration (µl/ml) was calculated from a diluted protein sample 
(1:200). To determine the final protein concentration in mg/ml following formula was 
used: 
Protein reading (µl/ml) x 0.2 = Final protein concentration (mg/ml) 
A standard amount of 20 µg of protein was used for western blotting, the volume of the 
sample required (µl) calculated from the final concentration. 
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Preparation of SDS-PAGE Gels 
All Western Blots were performed using the Bio-Rad Mini-PROTEAN 3 
Electrophoresis System. For the size (kDa) of all the analysed proteins it was 
appropriate to use a 10% resolving gel. 
The formation of the gels is based on polymerisation of the Acrylamide and N-N-
methylene-bis-acrylamide (Bis). Bis acts as cross-linking agent for the gel and TEMED 
and APS are the catalysts for the gel polymerisation. The separation of proteins is 
dependant on the size of the gel pores, which is determined by the amount of 
Acrylamide/Bis-Acrylamide present in the resolving gel. Increasing the volume of 
Acrylamide decreases the pore size. In general a higher percentage of resolving gel is 
used for smaller proteins. Larger proteins are more effectively separated in a lower 
percentage gel. 
Gels with 1.5 and 0.75 mm thickness, were used throughout the studies in this project. 
They were produced using either a 1.5 or a 0.75 mm spacer plate (Bio-Rad 
Laboratories) respectively. Once the 10% resolving gel was prepared, the gel plates and 
gel casting apparatus (Bio-Rad Laboratories) assembled the gel mix was titrated slowly 
between the two glass plates using a plastic pastette leaving enough space to the top for 
adding stacking gel and comb (Bio-Rad Laboratories). 
To flatten the top of the gel and to remove air bubbles, a layer of isopropanol is applied 
before the resolving gel is left for at least 30 minutes for polymerisation. 
Once set, the isopropanol is poured off from the top of the resolving gel and the already 
prepared 4.5% stacking gel is added until it reaches the top of the plates. The 
appropriate gel comb (10 well comb for 0.75 mm spacer plates and 15 well comb for 
1.5 mm spacer plates) is inserted from the top. The polymerising gel is left for about 
another 30 minutes. 
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Protein Denaturation 
Denaturation of the proteins unfolds the protein. It gives the antibody access to bind 
onto its epitope and lets the proteins run better through the gel. Protein of interest was 
60 kDa (Src and Src kinase family members) and 120 kDa (FAK) in size. 
Having measured the concentration of each protein sample a defined amount (25 or 30 
g) of protein was removed from each sample, placed into a new Eppendorf cup and 
stored on ice. To each sample a Laemmli‘s sample reducing buffer is added (2x protein 
+ 1x Laemmli‘s buffer). 
After the samples were thoroughly mixed they were boiled at 98 C for 4 minutes. 
SDS, Laemmli‘s buffer, contains a detergent with a high negative charge. It binds with 
its hydrophobic tail onto the protein, charges the protein negative and disruptes the 
tertiary structure of the protein resulting into its unfolding. Boiling the samples 
contributes to its complete unfolding. 2-Mercaptoethanol prevents the reformation of 
disulphide bonds and helps to maintain the protein in its denaturated state. The 
Biotinylated Protein Ladder, a molecular weight marker, which is used to determine the 
size of the detected protein, was also boiled for 4 minutes. All boiled samples were 
immediately stored back onto ice. 
3.2.3.2 Immunoblotting 
Gel Electrophoresis 
The proteins moved through the polyacrylamide gel, because of electrical charge. SDS 
transfers a negative charge onto the proteins allowing them to be attracted towards the 
positive anode. Smaller protein molecules travelling much faster through the 
acrylamide pores of the gel than larger molecules, therefore those can be found further 
down the gel. Gel electrophoresis separates protein by their molecular weight. 
Chapter 3 Protein expression of SFK members 113 
 
Gels were placed into the electrode assembly in a mini buffer tank. After removing the 
combs and rinsing the wells the tank was filled with running buffer (details in appendix 
2) to submerge the whole gel complex. The ladder (7 µl) and denaturated protein 
samples (x µl/ samples- depending on protein concentration) were carefully loaded into 
dedicated wells, as per protocol and Bradford Protein Assay reading, to achieve equal 
protein loading. Specific long fine tipped pipettes (alpha laboratories) were used to 
prevent overspill and contamination of other wells. Once all samples were loaded the 
gel was run at 100V for approximately 60 minutes. 
Protein Transfer 
The proteins need to be transferred from the polyacrylamide gel to a PVDF 
(polyvinylidene difluoride) membrane to enable the next step of protein detection via 
antibody exposure and binding to specific proteins molecules. Transfer was achieved 
using Mini-Trans Blot Cell tank (Bio-Rad Laboratories) to transfer the proteins onto 
the membrane over a time period of 60 minutes. 
After the gel electrophoresis is completed and the proteins have run sufficiently 
through the gel, the protein transfer onto PVDF membrane (Bio-Rad Laboratories) can 
begin. The PVDF membrane, fibre pads and 3M Whatmann paper (VWR) need to be 
cut slightly bigger than the size of the polyacrylamide gel and soaked in transfer buffer 
(details in appendix 2). For optimal transfer it‘s necessary to pre-treat the PVDF 
membrane in 100% methanol for five minute before immersing it in transfer buffer. 
The glass plates were carefully lifted, the stacking gel on the top discarded and the 
remaining gel was equilibrated in transfer buffer for approximately five minutes before 
assembling the ‖transfer sandwich‖. This step should prevent the gel from shrinking 
during the transfer process. 
The ―transfer sandwich‖ consisted of fibre pads, 3M Whatmann paper, gel and PVDF 
membrane, compiled in a gel holder cassette (figure 3.1). 
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Figure 3.1: Western blot transfer sandwich 
 
Figure 3.1 shows a schematic representation of the Western Blot “Transfer 
Sandwich”, the order and the different layers of various materials. 
Whilst building the ―transfer sandwich‖, a glass rod was used to ensure no air bubbles 
were present between the layers, by rolling over the top surface. Air bubbles prevent 
proficient transfer. The constructed sandwich was then slotted into the electrode 
assembly and positioned into the mini-tank, which was filled with transfer buffer. Bio-
Ice cooling unit (Bio-Rad Laboratories) and a magnetic stirrer were also placed in the 
tank to reduce temperature of the buffer during the transfer process and to maintain 
even buffer temperature and ion distribution. The protein transfer process from gel 
(negative/cathode) to membrane (positive/anode) was completed after approximately 
60 minutes at 100 Volts. 
Blocking of Membrane 
To avoid non-specific binding of the primary antibody to the membrane and 
consequently reduce background staining it was necessary to block the membrane by 
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incubating the membrane in 5% Non-Fat Dry Milk (Marvel) blocking solution (details 
in appendix 2) for one hour at room temperature. This step and all future steps were 
carried out on a rotatest shaker (R100/TW, Luckham), rotating at 70 rpm. 
After transferring the proteins the gel was stained with Coomassie blue solution (details 
in appendix 2) to determine how efficient the transfer was. The gel was left for 40 
minutes in Coomasie blue followed by destaining solution overnight. Any protein that 
remained on the gel was visible the next morning as blue bands. 
Incubation of Membrane with Primary Antibody 
During blocking time primary antibody solutions were prepared in 5% Non-Fat Dry 
Milk/TTBS (solution details in appendix 2) and stored at 4ºC- again to reduce non-
specific binding. After 60 minutes blocking the membrane then was incubated with the 
primary antibody overnight (approximately 18 hours) at 4ºC. For the size of membrane 
used (about 10 mm x 7 mm) 10 ml of antibody was adequate to cover the entire 
membrane. 
Incubation of Membrane with Secondary Antibody 
Following incubation with primary antibody the membrane was washed in TTBS three 
times for 10 minutes to remove any excess antibody. To detect the protein of interest a 
secondary antibody is needed to bind either to biotin or an enzyme conjugate, e.g. 
horseradish peroxidase (HRP), which was species-specific to the primary antibody. The 
secondary antibody used, was HRP-linked anti-rabbit (1:5000) or anti-mouse IgG at a 
dilution of 1:10000. As the primary antibodies all secondary antibody solutions were 
prepared in 10 mls of 5% Non-Fat Dry Milk/TTBS. Anti-biotin HRP linked antibody 
was added to detect the biotinylated ladder (details in appendix 2). The membrane was 
incubated for 60 minutes at room temperature. 
Chapter 3 Protein expression of SFK members 116 
 
Protein Visualisation 
A chemiluminescent method was employed to detect the protein of interest. 
Luminescence is the emission of light due to the dissipation of energy from a substance 
in an excited state. Horseradish peroxidase catalyzes oxidation of luminol, a 
chemiluminescent substrate, in alkaline conditions. Oxidation results in luminal being 
in an excited state, then decaying to ground state via emitting light. For this method 
ECL Plus pack was used: horse-radish peroxidase, conjugated to the secondary 
antibody, oxidases the ECL Plus chemiluminescent substrate (Lumigen PS-3 Acridan) 
producing thousands of acridinium ester intermediates per minute. These intermediates 
then interact with the peroxidase to produce a sustained high intensity 
chemiluminescence with a maximum emission at 430nm. This light is detected on 
autoradiography film (X-ray film). 
After 60 minutes of incubation with secondary antibodies the membrane was washed 
three times in TTBS for 10 minutes. During this process the ECL Plus reagents were 
warmed to room temperature. ECL reagents are sensitive to light therefore all following 
steps were performed in semi-darkness. ECL Plus solution A and solution B were 
mixed in a ratio 40:1. The use of 3 mls of the combined solution was adequate to cover 
the membrane.  
The membrane was then placed protein side up on a sheet of cellophane wrap. ECL 
solution was pipetted onto the membrane ensuring complete coverage and incubated for 
5 minutes. Excess solution was then removed and the membrane passed over onto a 
fresh sheet of cellophane wrap, in which it was enclosed. Finally the membrane was 
transferred into a film cassette. In complete darkness autoradiography films (Kodak 
Medical X-ray films, 18x24 cm) were exposed to the membrane for various times- 1, 5 
and 15 minutes. The films were then developed by passing it through X-ray developer 
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machine XOMAT 1000 (Kodak). Both marker and protein bands visualised and 
analyzed accordingly. 
3.2.3.3 Stripping of Membrane 
Restoring the membrane for further use, antibodies were removed from the probed 
membrane by incubating in 20 ml of Re-Blot Stripping Buffer at 37ºC for 15 minutes, 
followed by being washed three times for 10 minutes in TTBS. Subsequently the 
membranes were blocked again in 5% Non-Fat Dry Milk/TTBS and stored at 4ºC until 
probed with the next primary and secondary antibody, as described above. 
3.2.4 Immunohistochemistry 
The IHC method used in this study was indirect immunohistochemistry. This method 
uses another antibody (secondary antibody), already labelled with the marker, which 
recognises and binds with the primary antibody. 
The method used here for investigating the expression levels of Src kinase family 
members and their activated forms in breast tumour tissue involved rabbit and mouse 
monoclonal antibodies and the DAKO Envision System, staining and visualising 
antigenic sites with peroxidase and DAB (3,3,-diaminobenzidine). This method has 
built on dextran polymer technology. The primary antibody recognises the expressed 
protein. Applied Envision attaches itself to the secondary antibody. This is followed by 
appliance of Vector-DAB solution. Peroxidase then reacts with DAB to produce an 
insoluble yellow-brown precipitate, representing the target antigen, which can be seen 
and analysed under the light microscope (figure 3.2). 
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Figure 3.2: Indirect immunohistochemistry method 
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Figure 3.2: Schematic illustration of the indirect immunohistochemistry method 
amplifying the signal by the primary antibody. 
3.2.4.1 Preparation 
TMAs were cut into 3-4 µm thick paraffin wax sections and mounted on 3-
aminopropylethoxysilane coated slides. Slides then can be stored for 3-6 months at a 
temperature of 4ºC. Before specific slides were used for IHC, there were incubated at 
56ºC overnight. 
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3.2.4.2 Removal of Wax 
Prior to IHC staining tissue arrays were dewaxed with Xylene (2x2min) and rehydrated 
through a series of alcohol washes (100%  2x2min; 90%  2x2min, 70% 2x2min). 
3.2.4.3 Antigen Retrieval 
It‘s necessary to include an antigen retrieval step to optimise immunohistochemical 
staining. Formation of methylene bridges, which may have developed during the 
formalin fixation, can cross link proteins and mask antigenic sites. Exposure of those 
antigen binding sites is essential for primary antibodies to bind correctly. 
Two different antigen retrieval solutions were used: 10 mM Citrate Buffer (1:10 
dilution of pre-made Epitope Retrieval Buffer at pH 6.0 and TE Buffer (1 mM EDTA, 
5 mM Tris buffer at pH 8.0). Both solution were preheated in the microwave for 13.5 
min to a temperature of 96
 o
C before tissue array slides were placed into the solution 
and pressure cooked for 5 min followed by a cool down period of 20 min (table 3.1). 
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Table 3.1: Immunohistochemistry antibody information  
Protein Antibody Antigen 
Retrieval 
H2O2 
Conc. 
Horse 
Serum 
Conc. 
Antibody 
Dilutions 
Incubation 
Time and 
Temp 
Total Src Rabbit 
Cell 
Signalling 
Citrate 
Buffer 
pH 6.0 
0.3% 1.5% 1:200 60 min at 
room temp 
Anti-
clone 28 
Rabbit  
Invitrogen 
Citrate 
Buffer 
pH 6.0 
3.0% 5% 1:1500 Overnight 
at 4
o
C 
Clone 28 Mouse 
Invitrogen 
Citrate 
Buffer 
pH 6.0 
3.0% 5% 1:500 Overnight 
at 4
o
C 
Y416Src Rabbit 
Cell 
Signalling 
Citrate 
Buffer 
pH 6.0 
0.3% 5% 1:2000 Overnight 
at 4
o
C  
Y216Src Rabbit 
Santa Cruz 
Citrate 
Buffer 
pH 6.0 
3.0% 5% 1:25 Overnight 
at 4
o
C 
Lyn Mouse 
BD 
Biosciences 
TE Buffer  
pH 8.0 
1.0% 5% 1:5 Overnight 
at 4
o
C 
Lck Rabbit 
Cell 
Signalling 
TE Buffer  
pH 8.0 
3.0% 5% 1:50 60 min at 
room temp 
Ki67 Mouse 
DAKO 
TE Buffer  
pH 8.0 
3.0% 5% 1:150 60 min at 
room temp 
Table 3.1: Details of the primary antibodies used to detect total Src, its activated 
forms (Y216, Y416), the SKF protein Lyn and Lck and proliferation marker Ki67. 
Further information is given regarding antibody source, antigen retrieval method, 
blocking reagent concentrations (H2O2 and Horse Serum), antibody dilutions, 
incubation time and temperature are all listed above.  
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Citrate Buffer= 10mM Citrate buffer, TE Buffer= 1 mM EDTA, 5 mM Tris buffer at 
pH 8.0. Both solutions were preheated in the microwave for 13.5 min to a 
temperature of 96
 °
C before slides were pressure cooked for 5 min with a cool down 
period of 20 min. 
3.2.4.4 Blocking of Other Proteins 
The presence of endogenous peroxidase activity in tissue is a regular problem in IHC, 
causing background staining. To block endogenous peroxidase activity the slides were 
incubated in hydrogen peroxide (0.3% or 3.0% H2O2- depending on antibody, table 3.1) 
for ten minutes followed by a wash in running water. 
Formations of hydrophobic bonds between immunoglobulins and tissue proteins can 
cause non-specific binding of the primary and/or secondary antibody to the tissue 
sections resulting again in back ground staining. To avoid this non-specific binding 
tissue arrays were incubated in horse serum (1.5% or 5%- depending on antibody, table 
3.1) with antibody dilutent for 20 min at room temperature. 
3.2.4.5 Staining of TMA Slides 
Incubation with Primary Antibody 
Antibodies for the following proteins were used: c-Src, Lyn, Lck, phosphorylated and 
dephosphorylated Y530Src, Y419Src and Y215Src. To establish optimum conditions 
for highest quality of antigen staining, a series of investigations were performed 
varying antigen retrieval, antibody dilutions, incubation times and temperature (table 
3.1). In each experiment run a positive and negative isotype matched control was 
included to ensure no false positive staining. The positive control confirmed that the 
chosen IHC method was working whilst the negative control checked for non-specific 
binding of the antibody. 
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Incubation with Secondary Antibody 
Following incubation with antibody or no isotype matched control (negative control), 
the tissue array slides were thoroughly washed twice in TBS buffer (details in appendix 
2) for 5 minutes. A secondary antibody is required to bind onto the primary antibody to 
detect the protein of interest in the breast tissue. The DAKO Envision system was used, 
which is based on dextran polymer technology. A large number of enzyme molecules, 
including horseradish peroxidise, attach themselves to the secondary antibody via a 
dextran backbone (figure 3.2) with the advantage of increased sensitivity and decreased 
non-specific background staining. A substrate chromagen binds then to the peroxidise 
molecules producing a yellow-brown coloured product matching the quantity of the 
protein being investigated. The slides were incubated with Envision solution for thirty 
minutes at room temperature and then again thoroughly washed twice with TBS Buffer 
before Vector DAB solution was applied. Slides were left for 10 minutes at room 
temperature followed by a final wash in running water. 
Detection and Visualisation 
The chromagen used for staining the TMA slides was DAB (3,3‘-diaminobenzidine), a 
combination of 5mls dH2O, 2 drops of DAB Buffer solution, 4 drops of DAB Substrate 
solution, and 2 drops of Hydrogen Peroxidase solution. DAB was applied onto the 
slides, left for 10 minutes to permit brown staining to develop and then washed with 
running water. 
3.2.4.6 Counterstaining of TMA Slides 
TMA slides were counterstained with haematoxylin and Scott‘s Tap Water Substitute 
(S.T.W.S.). Slides were submerged in haematoxylin for around thirty seconds until a 
red colour develop on the tissue arrays; the arrays were cleared by dipping them into 
acid alcohol to remove excess colouring. Subsequently they were then immersed in 
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S.T.W.S. for about thirty seconds to produce blue staining as a contrast to the yellow-
brown staining of the antigen. 
3.2.4.7 Dehydrating and Mounting of TMA slides 
The last steps comprise dehydrating the TMAs immersing the slides through a series of 
alcohol washes with increasing percentage: 70% 1 min, 90% 1 min, 100% 2x1 min and 
2x 1 min Xylene. The slides were then mounted with coverslips using DPX mountant 
and stored away, covered at room temperature. 
3.2.5 Immunohistochemistry Scoring 
3.2.5.1 Weighted Histoscore (H-Score) 
All TMAs were scored independently by Joanne Edwards (JE) and myself (BE) for 
their nuclear, cytoplasmic and membrane protein staining within each tumour core, 
using a semi-quantitative weighted histoscore method (199;200). The intensity of 
staining was assessed and graded as negative (0), weak (1), moderate (2) and strong (3) 
staining. The percentage of tumour cells within each category was then estimated and a 
histoscore was calculated using the following formula: 
    0 * X% of negative tumour cells 
+  1 * X% of weakly stained tumour cells 
+  2 * X% of moderated stained tumour cells 
+  3 * X%    of strong stained tumour cells 
=     Y total histoscore 
 
The weighted histoscore ranged from zero (minimum) to 300 (maximum). Conformity 
of the two observers‘ scoring was assessed by calculating intra- (variation in individual 
scoring) and inter- (variation between the observers) class coefficients.  
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A scoring difference of more than 50 was considered as conflicting and resulted in re-
evaluation of those particular tumour cores by each observer. ICCC scores greater than 
0.8 are regarded as excellent. Comparison of both JE and BE scores generated ICCC 
scores between 0.84 – 1.00 as shown below in table 3.2. 
Table 3.2: ICCC scores for each protein expression analysis 
ICCC Nuclear Cytoplasm Membrane 
c-Src 0.95 0.93 0.88 
anti-Clone 28 0.91 0.83 1.00 
Clone 28 0.91 0.95 1.00 
Y416Src 0.98 0.95 0.96 
Y216Src 0.84 0.94 0.87 
Lyn 0.90 0.95 0.98 
Lck 0.99 0.95 1.00 
Table 3.2: Breast tumour cores were independently scored by two observers (BE 
and JE) for nuclear, cytoplasmic and nuclear staining of c-Src, Y419Src, Y215Src 
and SKF members (Lyn, Lck). A semi-quantitative weighted histoscore method was 
applied. Ki-67 staining was scored using the Ki-67 labeling index. Agreement 
between scores was measured using inter-class correlation coefficients. The ICCC 
scores for all primary antibodies are listed above. ICCC scores above 0.8 are 
considered as excellent. 
ICCCs were performed to verify consistency between scorers. Scattered plots for each 
antibody are displaying this data below. To confirm no bias between scorers was 
present Bland-Altman plots were constructed (figure 3.3). 
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Figure 3.3: Scattered Plots and Bland-Altman Plots for all antibodies 
c-Src 
 
 
 
 
 
 
Figure 3.3: Scattered plots and Bland-Altman plots for nuclear, cytoplasmic and 
membrane c-Src expression based on scorer-observer variation. The range and 
distribution of scores confirm appropriate scorer-observer correlation. 
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Lyn 
 
 
 
Scattered plot and Bland-Altman plot for 
nuclear Lyn expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
cytoplasmic Lyn expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
membrane Lyn expression. 
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Lck 
 
 
Scattered plot and Bland-Altman plot for 
nuclear Lck expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
cytoplasmic Lck expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
membrane Lck expression. 
 128 
 
AC 28 
 
 
Scattered plot and Bland-Altman plot for 
nuclear AC 28 expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
cytoplasmic AC 28 expression. 
 
 
 
No Scattered plot and Bland-Altman plot for 
membrane AC 28 expression available (all 
membrane histoscores 0). 
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Clone 28 
 
 
Scattered plot and Bland-Altman plot for 
nuclear Clone 28 expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
cytoplasmic Clone 28 expression. 
 
 
 
No Scattered plot and Bland-Altman plot for 
membrane Clone 28 expression available (all 
membrane histoscores 0). 
 130 
 
Y419Src 
 
 
Scattered plot and Bland-Altman plot for 
nuclear Y419Src expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
cytoplasmic Y419Src expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
membrane Y419Src expression. 
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Y215Src 
 
 
 
Scattered plot and Bland-Altman plot for 
nuclear Y215Src expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
cytoplasmic Y215Src expression. 
 
 
 
Scattered plot and Bland-Altman plot for 
membrane Y215Src expression. 
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3.2.5.2 Ki-67 scoring 
The Ki-67 antigen is a large nuclear protein (345, 395 kDa) preferentially expressed during 
all active phases of the cell cycle (G1, S, G2 and M-phases), but absent in resting cells (G0-
phase). In diagnostic histopathology and cell biology, antibodies against the Ki-67 antigen 
have proven valuable by allowing direct monitoring of the growth fraction of normal and 
neoplastic cells. 
The percentage of Ki-67-reactive tumour cells were evaluated at x400 magnification by 
scoring a minimum of 1000 tumour cells of each core of the tissue microarray (Ki67-
labelling index). 
(Number of positive cells/ Number of negative cells) x100= Y% 
 
Ki-67 scoring was performed by two independent observers (Ruth Fullerton and Alfred 
Tan, BmedScience students under my supervision). Again ICCC scores were taken to 
establish unity of scoring (Ki67nuc: 0.78). As before, Scattered plots and Bland-Altman 
plots were constructed for Ki67 double scores (figure 3.4). 
Figure 3.4: Scattered Plot and Bland-Altman Plot for Ki67 
 
 
Figure 3.4: Scattered plot and Bland-Altman plot for nuclear Ki67 expression. 
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3.2.6 Statistical Analysis of all Immunohistochemistry Studies 
The statistical analyses were performed using a statistical software package (SPSS 15.0 
Inc., Chicago, IL, USA).  
Basic descriptive statistics were performed to calculate frequencies, mean, median and 
inter-quartile ranges for all the histoscores for each antibody. These values were then used 
to establish appropriate cut-off points to define with either low or expression of the protein. 
Kaplan-Meier life table analysis (univariate analysis) was carried out to estimate 
differences in breast cancer related survival (DSS= disease specific survival) due to the 
increased or decreased protein expression in the patient‘s tumour. Only when univariate 
analysis was significant a Cox‘s multiple regression (multivariate analysis) was added. The 
log rank test was used to compare significant differences between subgroups using 
univariate analysis. Kaplan Meier survival analysis was also performed after stratification 
of the patient cohort by ER, PgR and HER2 status. Based on the results of the univariate 
analysis a multivariate analysis was then carried out.  
The multivariate stepwise Cox-regression analysis was performed to identify factors that 
were independently associated with disease specific death. A stepwise backward procedure 
was used to derive a final model of the variables that had a significant independent 
relationship with survival.  To remove a variable from the model the corresponding P-
value had to be greater than 0.05.   
For survival analysis and chi-square tests, patients were split into groups, those whose 
tumours expressed high or low levels of the protein of interest. To establish the relative 
risk of a patients dying as a result of either high or low levels of the expressed protein in 
their breast cancer, hazard ratio analysis was performed. 
Correlations between expression of different proteins and a protein‘s expression level at a 
certain cellular compartment were calculated using the Spearman Rank Test. Inter-
relationships between clinical parameters, ER and HER2 status were calculated using the 
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Chi square test. Because of the number of statistical comparisons, only a p value of <0.01 
was considered to be significant. Bonferroni phenomenon=1 out of every 10 results is 
found significant by chance. Data are expressed as median and range.   
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3.3 Results 
3.3.1 Clinico-pathological details of patient cohort 
Our cohort consisted of 314 breast cancer patients (209 ER positive/ 105 ER negative and 
149 PgR positive/ 163 PgR negative) (table 3.3). Median age was 58 years (IQR 50-65). 
46% of the cancer specimens were pathologically graded as grade 2 and 3, median size of 
the invasive cancer was 20 mm (IQR 15-30 mm). 48% of the patients were axillary lymph 
node positive. Mean patient follow-up was 7.1 years (minimum follow-up was 2.1 years 
and the maximum follow-up was 20 years). 16 patients were lost to follow-up. During this 
period, 78 patients died of their cancer and a further 33 patients died of inter-current 
disease. Correlations between the clinico-pathological characteristics of this cohort are 
shown below. 
Table 3.3: Overview of IHC patient characteristics 
Cohort  
characteristics 
Numbers  Cohort  
characteristics 
Numbers 
Age  
(<50 yr/ >50 yr) 
78/236  Lymph node  
(positive/negative) 
152/162 
Tumour type 
(duct/lob/tub/others) 
298/10/3/3  ER status  
(positive/negative) 
209/105 
Grade  
(G1/G2/G3) 
22/146/146  PgR status  
(positive/negative) 
149/163 
Size (mm) 
(<20, 20-50, >50) 
126/169/19  HER2 status  
(positive/negative) 
51/263 
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Table 3.3 gives an overview of the patient cohort used for immunohistochemistry 
studies. Histology: duct = ductal carcinoma, lob = lobular carcinoma, tub = tubular 
carcinoma, others including mucinous, mucoid and micropapillary carcinoma; Grade: 
Bloom and Richardson grade; size = maximum tumour diameter. 
3.3.2 c-Src kinase protein expression in invasive breast cancers 
The Src (36D10) Rabbit monoclonal antibody was used for this study and detects 
endogenous levels of Src proteins. Specificity of antibody was tested and confirmed by 
Western Blotting using breast cancer cell line lysates, which were kindly provided by Dr 
Liane McGlynn (figure 3.5). Each cellular location was independently assessed for c-Src 
kinase expression levels. 45% of tumours exhibited nuclear expression, 60% cytoplasmic 
and 43% membrane (figure 3.6, pictures 3.1). 
Figure 3.5: Western Blotting for specificity of c-Src antibody 
 
Figure 3.5: Western Blot with c-Src (60kDa) and β-actin (40kDa), as a protein loading 
control, demonstrating specificity of the c-Src antibody on breast cancer cell line 
lysates. ER positive (MCF-7) and ER negative (MDAMB231) breast cancer cell line 
were exposed to stimulant Oestradiol or Epidermal growth factor (E2/ EGF) and/or 
inhibitor Heregulin (HRG) at different time points. C= control, untreated cell line 
lysates. 
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Figure 3.6: Histograms for c-Src 
 
 
 
 
 
 
 
Figure 3.6: Histograms for nuclear, cytoplasmic and membrane c-Src expression 
displaying the intensity of IHC staining. 
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Picture 3.1: Immunohistochemistry staining with c-Src antibody 
 
Picture 3.1 A: Overview of a 0.6 mm 
core of the breast cancer tissue micro 
array, demonstrating, weak 
cytoplasmic, none and weak nuclear 
staining; x10 
 
Picture 3.1 C: Normal Breast tissue, 
stained with c-Src antibody (Cell 
Signalling); magnification x100 
 
Picture 3.1 B: demonstrates weak 
cytoplasmic, none and weak nuclear 
and negative membrane staining, x100 
 
 
 
 
Picture 3.1 D: Negative staining of 
stroma and tumour tissue, 
magnification x100. Negative IHC 
control. 
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3.3.2.1 Cellular distribution of nuclear, cytoplasmic and membrane c-Src expression 
For statistical analysis tumours were split into those with high (above the median) or low 
(below or equal to the median) expression (table 3.4). Therefore patients separated into two 
groups; those with low expression (negative subgroup) and those with higher expression 
(positive subgroup) (table 3.5). 
Table 3.4: Descriptive statistics of c-Src histoscores 
c-Src 
Histoscores 
Minimum Maximum Median LQ UQ 
nuclear 0.0 190 0.0 0.0 10.0 
cytoplasmic 0.0 190 0.0 0.0 40.0 
membrane 0.0 123 0.0 0.0 10.0 
Table 3.4 provides an overview of descriptive statistics of c-Src nuclear, cytoplasmic 
and membrane histoscores. With the median being 0, patients were grouped into two 
subgroups: patients with no c-Src expression and with c-Src expression. 
 
Table 3.5: c-Src expression in patient subgroups 
c-Src expression Nuclear Cytoplasm Membrane 
Positive (Patient No) 139 139 135 
Negative (Patients No) 175 175 179 
Table 3.5 shows the distribution of patients in each subgroup. 
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3.3.2.2 Correlation of clinic-pathological features of the patient cohort and c-Src 
expression 
Chi square analysis was employed to determine if increasing level of protein expression 
was linked to histopathological features of the breast tumours, e.g. tumour size, grade, 
steroid receptor status.  
Table 3.6 demonstrates that grade, PgR and HER2 status positively correlate with 
cytoplasmic c-Src expression; meaning that patients with invasive breast cancers, 
overexpressing c-Src in the cytoplasm, were more likely to have high grade (G3, χ2 
p<0.001), PgR and HER2 positive (both χ2 p<0.001) breast tumours. ER status correlated 
negatively with cytoplasmic (χ2 p<0.001) and membrane (χ2 p=0.001) c-Src expression 
(table 3.6); highlighting that patients with higher c-Src protein expression in the cytoplasm 
and membrane were most likely patients with ER negative breast cancers.  
c-Src expression in the membrane correlates positively with PgR (χ2 p<0.001) and HER2 
status (χ2 p=0.001, table 3.6). 
Nuclear c-Src expression does not significantly correlate patients‘ age, tumour type, grade, 
size, axillary lymph node steroid receptor and HER2 status (table 3.6). 
Expression levels of c-Src at each cellular location correlate positively with each other (c-
Src nuc, cyto and memb χ2 p<0.001, table 3.6). 
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Table 3.6: The interrelationships between c-Src expression and the clinico-pathological characteristics of patients  
Total Patient Cohort: 314 Chi-squared p-values 
Variables Tumour 
type 
Grade Size LN 
status 
ER  
status 
PgR  
status 
HER  
status 
c- Src 
nuc 
c-Src 
cyto 
c-Src 
memb 
Age  0.910 0.728 0.261 0.950 0.260 0.947 0.173 0.527 0.369 0.705 
Tumour type  0.007 0.964 0.680 0.012 0.453 0.512 0.904 0.717 0.761 
Grade    <0.001 0.301 <0.001 <0.001 0.003 0.019 <0.001 0.017 
Size (mm)    <0.001 0.048 0.169 0.010 0.695 0.177 0.029 
Lymph node      0.555 0.812 0.016 0.937 0.329 0.607 
ER status       <0.001 <0.001* 0.037 <0.001* 0.001* 
PgR status        0.001 0.237 <0.001 <0.001 
HER2 status         0.031 <0.001 0.001 
c- Src nuc         <0.001 <0.001 
c-Src cyto          <0.001 
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Table 3.6 shows the interrelationship between c-Src expression at different cellular levels and clinico-pathological characteristics of patients with breast 
cancer; c-Src = total Src kinase, Y416Src = Src kinase phosphorylated at Tyrosine site 416, Y215Src = Src kinase phosphorylated at Tyrosine site Y215; 
c-Src nuc = c-Src nuclear expression, c-Src cyto = c-Src cytoplasmic expression, c-Src memb = c-Src membrane expression; *negatively correlated, 
significant results are highlighted in bold. p-values of >0.01 were considered as non-significant due to the large number of statistical comparisons 
(Bonferroni phenomenon). 
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3.3.2.3 Effects of c-Src overexpression on patients’ clinical outcome 
Patient outcome was measured in disease specific survival, where death from breast cancer 
or breast cancer related illness was used as endpoint respectively. On univariate analysis 
neither nuclear nor membrane c-Src expression were associated with disease specific 
survival (c-Src nuc p=0.328, c-Src memb p=0.784), whereas cytoplasmic c-Src kinase 
expression (IHC Histoscore > 0) was significantly associated with shorter disease specific 
survival (p 0.028) (figure 3.7, table 3.7). Those patients with cytoplasmic c-Src expression 
had a median survival of 12.6 years (IQR 10.8-14.5) compared to those with no expression 
with median survival of 14.6 years (IQR 12.8-16.5).  
Figure 3.7: Kaplan Meier survival curve for cytoplasmic c-Src expression 
 
Figure 3.7: Kaplan Meier survival curve demonstrates that cytoplasmic c-Src 
expression is significantly associated with decreased disease specific survival (p=0.028, 
respectively).  
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However, there was no statistical evidence on multivariate Cox-regression analysis that 
cytoplasmic c-Src expression was independent of tumour size, grade and axillary nodal 
status in influencing disease specific survival. Only tumour size (p<0.001, respectively), 
lymph node (p=0.013, respectively), ER (p=0.027, respectively) and PgR status (p=0.040, 
respectively) proved to be independent markers of patients‘ disease specific survival in this 
cohort. 
Table 3.7: Impact of clinico-pathological factors and c-Src expression on patient survival   
Total Patient 
Cohort:  
 Univariate  
Analysis 
Multivariate 
Analysis 
314 patients Numbers P value HR IQR P value HR IQR 
Age  
(<50yr/>50yr)  
78/236 0.351 1.2 0.7-2.2    
Tumour type 
(duct/lob/tub/others) 
298/10/3/3 0.714 0.6 0.2-1.4    
Grade  
(G1/G2/G3) 
22/146/146 0.014 1.8 12.-2.7    
Size (<20 , 20-50, 
>50mm) 
126/169/19 <0.001 3.1 2.1-4.8 <0.001 6.7 3.2-14.2 
Lymph node  
(positive/negative) 
152/162 0.001 2.1 1.3-3.3 0.013 1.9 1.1-3.1 
ER status  
(positive/negative) 
209/105 <0.001 2.3 1.5-3.6 0.027 1.8 1.1-3.0 
PgR status 
(positive/negative) 
149/163 0.006 1.9 1.2-3.0 0.040 1.7 1.0-2.7 
HER2 status 
 (positive/negative) 
51/263 0.010 1.9 1.6-3.2    
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c-Src nuc  
(positive/negative) 
139/175 0.328 1.2 0.7-2.0    
c-Src cyto  
(positive/negative) 
139/175 0.028 1.6 1.1-2.6 0.103 0.7 0.4-1.1 
c-Src memb  
(positive/negative) 
135/179 0.784 0.94 0.6-1.5    
Table 3.7: Each clinical and pathological parameter was correlated to disease specific 
survival. Cytoplasmic c-Src expression is associated with disease specific survival 
(p=0028), but not independent in multivariate analysis (p=0.103). HR= Hazard Ratio 
(95% Confidence Interval (CI)), IQR= interquartile range. Significant results are 
highlighted in bold.  
 
3.3.3  Src kinase family member expression in invasive breast cancer 
We had observed from PCR results that LYN was the second highly expressed SFK 
member in malignant tissue besides SRC and that LCK was higher expressed in ER 
negative, compared to ER positive tumours. This guided our interest and we focused on 
investigating protein expression of those Src kinase family members in a larger cohort to 
determine if Lyn and Lck had similar expression pattern as Src and if there were any 
association to clinical outcome of breast cancer patients. 
 
Both antibodies are monoclonal. Lyn is Mouse antibody, which sometimes can be 
observed on Western Blots as a doublet of about 56 kDa and 53 kDa. The Lck (D88) XP™ 
Rabbit antibody detects endogenous levels of total Lck protein. These antibodies do not 
cross-react with other Src family members. 
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3.3.3.1 Patient Cohort 
The patient cohort consisted of 314 patients. Clinico-pathological details are shown in 
table 3.3. The same patient cohort was used for c-Src analysis. 
3.3.3.2 Lyn protein expression in invasive breast cancer specimens 
Prior to optimisation of the antibody for immunohistochemistry, its specificity was 
determined by Western Blotting using the ER positive breast cancer cell line MCF-7. 
Protein lysates were again provided by Dr Liane McGlynn, as residual time course lysates 
from previous cell line experiments (figure 3.8). 
Figure 3.8: Western Blotting for specificity of Lyn antibody 
 
Figure 3.8: Western Blot with Lyn (56 kDa) and β-actin (48kDa), as a protein loading 
control. Using ER positive (MCF-7) breast cancer cell lines exposed to stimulant 
oestradiol or epidermal growth factor (E2/ EGF) and/or inhibitor heregulin (HRG), 
time point 5 min. C= control, untreated cell line lysates. 
Due to tissue limitations only 57.3% of the tumours previously available for analysis were 
able to be stained for Lyn expression (180/314).  37% of Lyn expression was observed in 
the nucleus, 33% in the cytoplasm and only 4.4% in the membrane.  
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The cellular distribution of nuclear, cytoplasmic and membrane Lyn expression is 
demonstrated as histograms (figure 3.9) and displayed in pictures 3.2.  
Figure 3.9: Histograms for Lyn expression 
 
 
 
 
Figure 3.9: Histograms for nuclear, cytoplasmic and membrane Lyn expression 
displaying the intensity of IHC staining. 
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Picture 3.2: IHC staining with Lyn antibody 
 
Picture 3.2 A: Overview of a 0.6 mm core 
of the breast cancer TMA, showing no 
membrane, weak cytoplasmic, none and 
weak nuclear staining; x10 
 
Picture 3.2 C: demonstrates weak 
cytoplasmic, weak and moderate nuclear 
and negative membrane staining, x100 
 
 
Picture 3.2 B: Normal Breast tissue, 
stained with Lyn antibody (BD 
Biosciences); magnification x100 
 
 
Picture 3.2 D: Negative staining of 
stroma and negative to greyish tumour 
tissue (nuclear histoscore 0), x100 
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Again tumours were split into high (above median) and low expression (below or equal to 
the median) (table 3.8), separating patients into patient group with high (positive subgroup) 
and low expression (negative subgroup) (table 3.9). 
Table 3.8: Descriptive statistics of Lyn histoscores 
Lyn 
Histoscores 
Minimum Maximum Median LQ UQ 
nuclear 0.0 140 0.0 0.0 10.0 
cytoplasmic 0.0 200 0.0 0.0 10.0 
membrane 0.0 100 0.0 0.0 0.0 
Table 3.8 provides an overview of descriptive statistics of Lyn nuclear, cytoplasmic and 
membrane histoscores. With the median being 0, patients were grouped into two 
subgroups: patients with no Lyn expression and with Lyn expression. 
Table 3.9: Lyn expression in patient subgroups 
Lyn expression Nuclear Cytoplasm Membrane 
Positive (Patient No) 67 59 8 
Negative (Patients No) 113 121 172 
Table 3.9: shows the distribution of patients in each subgroup. 
To determine interrelationships between Lyn, Src and clinic-pathological features of the 
cohort, chi square analysis was performed. The only significant correlations between Lyn 
expression and clinico-pathological features of the cohort were observed between Lyn 
nuclear expression, grade and size of breast cancer specimens (p=0.019, p=0.029, table 
3.10). Higher nuclear Lyn expression occurred in more aggressive and larger breast 
tumours. No significant correlations between Lyn and Src kinase expression levels and 
locations were evident.  
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Lyn nuclear expression correlated with Lyn cytoplasmic expression and Lyn cytoplasmic 
expression correlated significantly with Lyn membrane expression (table 3.10). 
Table 3.10: Interrelationship between clinico-pathological characteristics and Lyn 
expression of breast cancer patients 
Total Patient Cohort:  Chi-squared p-values 
314 
Variables 
Numbers Lyn 
nuc 
Lyn 
cyto 
Lyn 
memb 
Age 78/236 0.259 0.027 0.297 
Tumour type 298/10/3/3 0.642 0.547 0.492 
Grade 22/146/146 0.019 0.632 0.991 
Size (mm) 126/169/19 0.029 0.832 0.115 
Lymph node 152/162 0.123 0.200 0.247 
ER status 209/105 0.133 0.122 0.876 
PgR status 149/163 0.339 0.115 0.058 
HER2 status 51/263 0.733 0.836 0.772 
c- Src nuc 139/175 0.163 0.646 0.917 
c-Src cyto 139/175 0.621 0.579 0.780 
c-Src memb 135/179 0.691 0.497 0.410 
Lyn nuc 67/113  <0.001 0.345 
Lyn cyto 59/121   <0.001 
Table 3.10 shows the interrelationship between Lyn expression at different cellular 
levels and clinico-pathological characteristics of patients with breast cancer; Lyn nuc = 
Lyn nuclear expression, Lyn cyto = Lyn cytoplasmic expression, Lyn memb = Lyn 
membrane expression; c-Src nuc = c-Src nuclear expression, c-Src cyto = c-Src 
cytoplasmic expression, c-Src memb = c-Src membrane expression; significant results 
are highlighted in bold. 
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On univariate analysis there was no association noticed between Lyn expression and 
disease specific survival at any cellular location (table 3.11).   
Table 3.11: Impact of clinico-pathological factors and Lyn expression on patient survival   
Total Patient 
Cohort:  
 Univariate  
Analysis 
314 patients Numbers P value HR IQR 
Lyn nuc  
(positive/negative) 
67/113 0.545 1.2 0.7-2.0 
Lyn cyto  
(positive/negative) 
59/121 0.980 1.6 1.1-2.6 
Lyn memb 
(positive/negative) 
8/172 0.728 0.94 0.6-1.5 
Table 3.11:  Expression of each cellular location was correlated to disease specific 
survival. None of the protein expressions were associated with disease specific survival 
and independent in multivariate analysis. HR= Hazard Ratio (95% Confidence Interval 
(CI)), IQR= interquartile range. Significant results are highlighted in bold.  
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3.3.3.3 Lck protein expression in invasive breast cancer specimens 
As before with the antibodies of c-Src and Lyn, specificity of the Lck (D88) XP™ Rabbit 
antibody was determined by Western blotting, using HeLa (cervical cancer) cell line and 
ER negative breast cancer cell line lysates- MDAMB231 (figure 3.10). 
Figure 3.10: Western Blotting for specificity of Lck antibody 
 
Figure 3.10: Western Blot with Lck and β-tubulin antibody, as a protein loading 
control. Using cervical cancer (HeLa) and ER negative breast cancer cell lysates (MDA 
MB231). Positive band expression for Lck antibody is noticed at about 58 kDa. β-
tubulin antibody was used as protein loading control. 
83.8 % of the tumours previously available for analysis were able to be stained for Lck 
expression (263/314). Each cellular location was independently assessed. 42 % of Lck 
expression was observed in the nucleus, 42 % in the cytoplasm and only 5 % in the 
membrane (table 3.12).  
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Descriptive statistical analysis revealed a median histoscore of 0. Therefore tumours were 
divided into expressing Lck or not expressing Lck (table 3.12), separating patients into a 
positive and negative patient subgroup (table 3.13). 
Table 3.12: Descriptive statistics for Lck histoscores 
Lck 
Histoscores 
Minimum Maximum Median LQ UQ 
nuclear 0.0 93 0.0 0.0 10.0 
cytoplasmic 0.0 85 0.0 0.0 10.0 
membrane 0.0 15 0.0 0.0 0.0 
Table 3.12 provides an overview of descriptive statistics of Lck nuclear, cytoplasmic 
and membrane histoscores. With the median being 0, patients were grouped into two 
subgroups: patients with no Lck expression and with Lck expression. 
 
Table 3.13: Lck expression in different patient subgroups 
Lck expression Nuclear Cytoplasm Membrane 
Positive (Patient No) 111 111 12 
Negative (Patients No) 152 152 251 
Table 3.13 shows the distribution of patients in each subgroup. 
Histograms and IHC pictures below exhibit the cellular distribution and intensity of 
nuclear, cytoplasmic and membrane Lck expression (figure 3.11, picture 3.3). 
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Figure 3.11: Histograms for Lck expression 
 
 
Figure 3.11: Histograms for nuclear, cytoplasmic and membrane Lck expression 
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Picture 3.3: IHC staining with Lck antibody 
 
Picture 3.3 A: Overview of a full section 
of a tonsil, strong staining of 
inflammatory cells; x10. Positive control. 
 
Picture 3.3 C: Normal Breast tissue, 
stained with Lck antibody (Cell 
Signalling); x100. 
 
 
Picture 3.3 B: Negative staining of 
stroma and tumour tissue, x100. 
Negative IHC control. 
 
Picture 3.3 D demonstrates weak 
cytoplasmic and membrane, weak and 
negative nuclear staining. Interstitial 
inflammatory cells stained, x100. 
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On chi square analysis the only significant positive correlation between protein expression 
and clinico-pathological characteristics of the cohort was with nuclear Lck expression and 
ER status (χ2 p=0.001). Lck expression at all cellular locations correlated strongly with 
each other (table 3.14).   
Table 3.14: Correlations between SFK member and clinico-pathological characteristics of 
breast cancer patients 
Total Patient Cohort Chi-squared p-values 
314 
Variables 
Numbers Lck 
nuc 
Lck 
cyto 
Lck 
memb 
Age  
(<50yr/>50yr)  
78/236 0.639 0.927 0.024 
Tumour type 
(duct/lob/tub/others) 
298/10/3/3 0.375 0.032 0.842 
Grade  
(G1/G2/G3) 
22/146/146 0.034 0.543 0.741 
Size  
(<20 , 20-50, >50mm) 
126/169/19 0.892 0.580 0.926 
Lymph node  
(positive/negative) 
152/162 0.957 0.308 0.311 
ER status  
(positive/negative) 
209/105 0.001 0.600 0.118 
PgR status 
(positive/negative) 
149/163 0.097 0.036 0.090 
HER2 status 
 (positive/negative) 
51/263 0.168 0.085 1.000 
c-Src nuc  
(positive/negative) 
139/175 0.328 0.461 0.701 
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c-Src cyto  
(positive/negative) 
139/175 0.299 0.508 0.934 
c-Src memb  
(positive/negative) 
135/179 0.274 0.064 0.017 
Lyn nuc 
(positive/negative) 
67/113 0.016 0.975 0.534 
Lyn cyto 
(positive/negative) 
59/121 0.424 0.067 0.032 
Lyn memb 
(positive/negative) 
8/172 0.282 0.726 0.053 
Lck nuc 
(positive/negative) 
111/152  <0.001 0.001 
Lck cyto 
(positive/negative) 
111/152   <0.001 
Table 3.14 shows the interrelationship between Lck expression at different cellular 
levels and clinico-pathological characteristics of patients with breast cancer; Lck nuc = 
Lck nuclear expression, Lck cyto = Lck cytoplasmic expression, Lck memb = Lck 
membrane expression; Lyn nuc = Lyn nuclear expression, Lyn cyto = Lyn cytoplasmic 
expression, Lyn memb = Lyn membrane expression; c-Src nuc = c-Src nuclear 
expression, c-Src cyto = c-Src cytoplasmic expression, c-Src memb = c-Src membrane 
expression; significant results are highlighted in bold. p-values of >0.01 were 
considered as non-significant due to the large number of statistical comparisons 
(Bonferroni phenomenon). 
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Patient outcome was measured in disease specific survival, where death from breast cancer 
or breast cancer related illness was used as endpoint respectively. On univariate analysis 
neither nuclear nor cytoplasmic Lck expression were associated with disease specific 
survival (p=0.140, p=0.935). Whereas membrane Lck expression (IHC Histoscore > 0) was 
associated with longer disease specific survival (p 0.039) (figure 3.12, table 3.15).  
Figure 3.12: Kaplan Meier survival curve for membrane Lck expression 
 
Figure 3.12: Kaplan Meier survival curve demonstrates that membrane Lck expression 
is associated with improved disease specific survival (p=0.039, respectively).  
None of patients expressing Lck on the cell membrane died of breast cancer.  Median 
follow-up for patients with positive Lck staining of the membrane was 7.8 years (IQR +/- 
4.5), for patients without staining 6.0 years (IQR +/- 3.5). 
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Table 3.15: Impact of Lck expression on breast cancer patient survival 
Total Patient 
Cohort:  
 Univariate  
Analysis 
Multivariate 
Analysis 
263 out of 314 
patients 
Numbers P value HR IQR P 
value 
HR IQR 
Lck nuc  
(positive/negative) 
111/152 0.140 1.5 0.9-2.5    
Lck cyto  
(positive/negative) 
111/152 0.935 1.0 0.6-1.7    
Lck memb 
(positive/negative) 
12/251 0.039 0.1 0.01-4.0 0.972 0.0  
Table 3.15: Expression of each cellular location was correlated to disease specific 
survival. None of the protein expressions were associated with disease specific survival 
and independent in multivariate analysis. HR= Hazard Ratio (95% Confidence Interval 
(CI)), IQR= interquartile range. Significant results are highlighted in bold.  
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3.3.4 Protein Expression of various activation sites of Src kinase in 
breast cancer specimens 
As described in more detail in the introductory chapter, c-Src is activated by a number of 
pathways. Known as the classical activation pathway, dephosphorylation of Y530 is 
needed to initiate a configuration change of the protein allowing autophosphorylation of 
tyrosine site 419 at the SH2 protein domain leading to full activation of the protein.  
Two antibodies were used to investigate those different stages of Src kinase activation and 
to link these to patient outcome: Clone 28 antibody is a monoclonal Mouse antibody, 
which recognises the semi-active form of Src when not phosphorylated at Y530. Whereas, 
the Y416Src polyclonal Rabbit antibody was applied to determine protein expression of the 
fully activated Src kinase. It detects endogenous levels of Src only when phosphorylated at 
tyrosine 419 and does not cross-react with Src phosphorylated at tyrosine 530. 
More recently, a different activation pathway has been described (76). Direct 
phosphorylation of tyrosine site 215 can lead to a more powerful activation of Src. A 
polyclonal Rabbit antibody was used to assess if there would be significant differences in 
protein expression and patients‘ clinical outcome. 
Phosphorylation of the tyrosine residual 530 on the c-terminal tail by Csk tyrosine kinase 
acts as a negative regulatory protein binding site, keeping Src kinase in a closed 
confirmation. To evaluate protein expression of inactivated Src kinase a polyclonal Rabbit 
antibody, named by Invitrogen as anti-Src family negative regulatory [pY] site and re-
named in our laboratory as anti-Clone28, was utilised for detecting phosphorylated 
tyrosine site 530. 
Investigating the role of the Src kinase in breast cancer at each activated phosphorylation 
site (Y530, Y419, Y215) and inactivated status (pY530) is thought to be necessary to 
determine its clinical significance for breast cancer patients.  
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Immunohistochemistry for the different activation sites of Src (anti-Src family negative 
regulatory [pY] site/ anti-Clone 28, Clone 28, Y419Src and Y215Src) was performed on 
the same mixed breast cancer patient cohort (314 patients, table 3.3) used for previous 
immunohistochemistry staining of SFK members (Src, Lyn and Lck). 
 
3.3.4.1 Inactivated Src kinase (AC 28) protein expression in invasive breast cancer 
Before optimising the antibody for immunohistochemistry staining, the specificity of the 
anti-Src family negative regulatory [pY]/ anti-Clone 28 (AC28) antibody was tested via 
Western Blotting. Various commercially available cell lysates were used as different 
protein sample loadings (figure 3.13). 
Figure 3.13: Western Blotting for specificity of anti-Clone 28 antibody 
 
Figure 3.13: Western Blot with anti-Src family negative regulatory site (pAb) antibody 
(60kDa) and tubulin (48kDa), as a protein loading control, using, Jurkat (human 
lymphoma cell line), HeLa (cervical cancer cell) and MDAMB231(ER negative breast 
cancer cell) lysates. 
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Only 53 % of the tumours, previously available for SFK member analysis, were able to be 
stained for AC28 expression (165/314). This effect was due to tissue limitation after 
extensive section cutting of the TMA. 
Each cellular location was again independently assessed. 50 % of anti-Clone 28 expression 
was observed in the nucleus, 44 % in the cytoplasm and only 3.6 % in the membrane (table 
3.17). The following histograms and IHC pictures exhibit the cellular distribution and 
intensity of nuclear, cytoplasmic and membrane anti-Clone 28 expression (figure 3.14, 
picture 3.4). 
Figure 3.14: Histograms for anti-Clone 28 expression in invasive breast carcinoma 
 
 
 
Figure 3.14: Histograms for nuclear, cytoplasmic and membrane AC28 staining 
revealing the distribution of IHC intensity staining. 
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Picture 3.4: IHC staining with AC28 antibody 
 
Picture 3.4 A: Overview of a 0.6 mm 
core of the breast cancer TMA, 
showing nuclear, cytoplasmic and peri-
nuclear staining; magnification x10. 
 
Picture 3.4 C demonstrates weak 
cytoplasmic and membrane, negative 
weak and moderate nuclear staining. 
x100. 
 
 
Picture 3.4 B: Normal Breast tissue 
stained with anti-Clone 28 antibody 
(Invitrogen); x100. 
 
 
Picture 3.4 D: Negative and weak 
staining of nuclei, negative cytoplasm, 
membrane and stroma tissue staining, 
magnification x100. 
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Tumours were split into high (above median) and low expression (below or equal to the 
median) (table 16), separating patients into patient group with high (positive subgroup) and 
low expression (negative subgroup) (table 3.17). With the membrane anti-Clone 28 median 
being 0, patients were grouped into two subgroups: patients with no anti-Clone 28 
expression and with anti-Clone 28 expression. Median of nuclear, cytoplasmic and 
membrane anti-Clone 28 was used for statistical analysis. 
Table 3.16: Descriptive statistics for anti-Clone 28 histoscores 
AC28 
Histoscores 
Minimum Maximum Median LQ UQ 
nuclear 0.0 180.0 30.0 10.0 60.0 
cytoplasmic 0.0 140.0 10.0 0.0 40.0 
membrane 0.0 15.0 0.0 0.0 0.0 
Table 3.16 provides an overview of descriptive statistics of AC28 nuclear, cytoplasmic 
and membrane histoscores. 
Table 3.17: anti-Clone 28 expression in patient groups 
AC28 expression Nuclear Cytoplasm Membrane 
Positive (Patient No) 82 72 6 
Negative (Patients No) 83 93 159 
Table 3.17: shows the division into positive and negative expression group. 
Associations between anti-Clone 28, Src and clinico-pathological features of the cohort 
were examined performing Chi square analysis. There was only one significant correlation 
between clinico-pathological features and AC28 expression. ER status negatively 
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correlated with nuclear expression of AC28 (χ2 p<0.001) meaning that patients with ER 
negative breast cancers were more likely not to express inactive Src in the nucleus.  
Interestingly cytoplasmic AC28 correlated negatively with membrane c-Src expression (χ2 
p=0.008), pointing out that breast cancer patients with higher expression of inactive Src in 
the cytoplasm were more likely not to express c-Src at the membrane.  
No significant correlations were noted with AC28 membrane expression.  
Interrelationships between the different AC28 cellular locations were insignificant. 
However, the negative correlation between AC28 cytoplasmic and AC28 membrane 
expression was close to reach significance (χ2 p=0.015, table 3.18). 
Table 3.18: Interrelationship between clinico-pathological features of the cohort, c-Src and 
anti-Clone 28 expression 
Total Patient Cohort Chi-squared p-values 
314 
Variables 
Numbers AC28 
nuc 
AC28 
cyto 
AC28 
memb 
Age  
(<50yr/>50yr)  
78/236 0.114 0.306 0.924 
Tumour type 
(duct/lob/tub/others) 
298/10/3/3 0.614 0.528 0.974 
Grade  
(G1/G2/G3) 
22/146/146 0.250 0.068 0.273 
Size  
(<20 , 20-50, >50mm) 
126/169/19 0.202 0.038* 0.227 
Lymph node  
(positive/negative) 
152/162 0.870 0.923 0.114 
ER status  
(positive/negative) 
209/105 0.008* 0.196* 0.712 
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PgR status 
(positive/negative) 
149/163 0.020* 0.552 0.883 
HER2 status 
 (positive/negative) 
51/263 0.488 0.030* 0.797 
c-Src nuc  
(positive/negative) 
139/175 0.102 0.300 0.845 
c-Src cyto  
(positive/negative) 
139/175 0.380 0.040* 0.340 
c-Src memb  
(positive/negative) 
135/179 0.075 <0.001* 0.080 
AC28 nuc  
(positive/negative) 
82/83  0.902 0.510 
AC28 cyto  
(positive/negative) 
73/92   0.015* 
Table 3.18 shows the interrelationship between AC28 expression at different cellular 
levels and clinico-pathological characteristics of patients with breast cancer; 
Histology: duct = ductal carcinoma, lob = lobular carcinoma, tub = tubular 
carcinoma, others including mucinous, mucoid and micropapillary carcinoma; Grade: 
Bloom and Richardson grade; c-Src = total Src kinase, Y416Src = Src kinase 
phosphorylated at Tyrosine site 416, Y215Src = Src kinase phosphorylated at Tyrosine 
site Y215; AC 28= anti-Src family negative regulatory [pY] site, re-named in our 
laboratory as anti-Clone28, Src kinase phosphorylated at Tyrosine site 530 (inactive); 
*negatively correlated; significant results are highlighted in bold. p-values of >0.01 
were considered as non-significant due to the large number of statistical comparisons 
(Bonferroni phenomenon). 
 
On univariate and multivariate analysis there was no significant association noticed 
between anti-Clone 28 expression and disease specific survival at any cellular location 
(table 3.19).   
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Table 3.19: Impact of AC28 protein expression on patient survival 
Total Patient 
Cohort:  
 Univariate  
Analysis 
314 patients Numbers P value HR IQR 
AC28 nuc  
(positive/negative) 
82/83 0.192 1.5 0.8-3.0 
AC28 cyto  
(positive/negative) 
72/93 0.294 1.4 0.7-2.8 
AC28 memb 
(positive/negative) 
6/159 0.748 1.3 0.2-9.6 
Table 3.19: No impact of AC28 protein expression is detected on patient survival. 
Expression of each cellular location was correlated to disease specific survival. None of 
the protein expressions were associated with disease specific survival and independent 
in multivariate analysis. HR= Hazard Ratio (95% Confidence Interval (CI)), IQR= 
interquartile range. Significant results are highlighted in bold.  
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3.3.4.2 Partially activated Src kinase (Clone 28) protein expression in invasive breast 
cancer 
Specificity of the Clone 28 (Cl28) antibody was routinely tested via Western Blotting. 
Commercially available cell lysates were used as protein samples (figure 3.15). 
Figure 3.15: Western Blotting for specificity of Clone 28 antibody 
 
Figure 3.15: Western Blot with Clone 28 antibody (60kDa) and β-tubulin (48kDa), as a 
protein loading control, using, Jurkat (human lymphoma cell line), Akt control cell 
lysates (Jurkat cell line) and MDAMB231 (ER negative breast cancer cell) lysates. 
Only 48 % of the tumours, previously available for SFK member analysis, were able to be 
stained for Clone 28 expression (149/314). This effect was due to tissue limitation after 
extensive section cutting of the TMA. 
Nuclear, cytoplasmic and membrane staining was independently assessed. Perinuclear 
staining was also included in this analysis 50 % of Clone 28 expression was observed in 
the nucleus, 46 % in the cytoplasm and a remarkable 53 % in the membrane and 55 % 
perinuclear (table 3.21).  
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Histograms and IHC pictures below demonstrate the cellular distribution and intensity of 
nuclear, cytoplasmic and membrane Clone 28 expression (figure 3.16, picture 3.5). 
Figure 3.16: Histograms for Clone 28 expression 
 
 
 
Figure 3.16: Histograms for nuclear, cytoplasmic and membrane Clone 28 staining 
displaying the distribution of IHC intensity staining. 
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Picture 3.5: IHC staining with Clone 28 antibody 
 
 
Picture 3.5 A: Overview of a 0.6 mm 
core of the breast cancer TMA, 
showing, cytoplasmic, membrane and 
peri-nuclear staining; magnification 
x10. 
 
Picture 3.5 C demonstrates weak 
cytoplasmic and membrane, negative 
weak and moderate nuclear staining. 
x100. 
 
Picture 3.5 B: Normal Breast tissue 
stained with Clone 28 antibody 
(Invitrogen); magnification x100. 
 
 
Picture 3.5 D: Negative staining of 
nuclei, but strong perinuclear staining 
with Clone 28, x120. 
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Tumours were split into high (above median) and low expression (below or equal to the 
median) (table 3.20), separating patients into patient group with high (positive subgroup) 
and low expression (negative subgroup) (table 3.21). Median of nuclear, cytoplasmic and 
membrane Clone 28 was used for statistical analysis. 
Table 3.20: Descriptive statistics for Clone 28 histoscores 
Clone 28 
Histoscores 
Minimum Maximum Median LQ UQ 
nuclear 0.0 80.0 5.0 0.0 15.0 
cytoplasmic 0.0 227.0 40.0 10.6 74.3 
membrane 0.0 110.0 2.5 0.0 10.0 
Table 3.20 provides an overview of descriptive statistics of Clone 28 nuclear, 
cytoplasmic and membrane histoscores. 
Table 3.21: Clone 28 expression in patient subgroups 
Clone 28  
expression 
Nuclear Cytoplasm Membrane Perinuclear 
Positive (Patient No) 74 69 78 82 
Negative (Patients No) 85 80 70 67 
Table 3.21 shows the division into positive and negative expression group. 
Chi square analysis was performed to identify associations between Clone 28, anti-Clone 
28, Src and clinico-pathological features of the cohort (table 3.22). No significant 
correlations were noted between clinico-pathological features and any of the Clone 28 
expression sites.  Nuclear and membrane Clone 28 expression showed no significant 
correlations with any of the other c-Src and anti-Clone 28 expressions. Interrelationship 
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analysis of individual cellular locations demonstrated a positive correlation between 
nuclear and cytoplasmic Clone 28 expression (χ2 p<0.001) and a negative correlation 
between nuclear and perinuclear Clone 28 expression (χ2 p<0.001). Interestingly 
cytoplasmic Clone28 correlated negatively with membrane c-Src expression (χ2 p<0.001) 
and cytoplasmic AC28 (χ2 p=0.001), highlighting that breast cancer patients with partially 
activated Src in the cytoplasm were less likely to express c-Src at the membrane (site of 
activation) or inactivated Src in the cytoplasm. Perinuclear Clone 28 expression correlated 
negatively with cytoplasmic AC28 (χ2 p<0.001), nuclear Clone 28 (χ2 p<0.001) and 
cytoplasmic Clone 28 (χ2 p<0.001) (table 3.22). 
Table 3.22: Correlations between clinico-pathological features of the cohort, c-Src, AC28 
and Clone 28 expression 
Total Patient 
Cohort 
Chi-squared p-values 
314 
Variables 
Numbers Cl28 
nuc 
Cl28 
cyto 
Cl28 
memb 
Cl28 
perinuc 
Age  
(<50yr/>50yr)  
78/236 0.027* 0.906 0.547 0.239 
Tumour type 
(duct/lob/tub/others) 
298/10/3/3 0.307 0.304 0.394 0.269 
Grade  
(G1/G2/G3) 
22/146/146 0.312 0.010* 0.655 0.204 
Size  
(<20 , 20-50, >50mm) 
126/169/19 0.901 0.030 0.565 0.016 
Lymph node  
(positive/negative) 
152/162 1.0 0.747 0.811 0.420 
ER status  
(positive/negative) 
209/105 0.055 0.535 0.806 0.645 
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PgR status 
(positive/negative) 
149/163 0.461 0.635 0.926 0.975 
HER2 status 
 (positive/negative) 
51/263 0.628 0.038 0.306 0.181 
c-Src nuc  
(positive/negative) 
139/175 0.105 0.066 0.678 0.046 
c-Src cyto  
(positive/negative) 
139/175 0.740 1.0 0.811 0.629 
c-Src memb  
(positive/negative) 
135/179 0.841 <0.001* 0.393 0.002* 
AC28 nuc  
(positive/negative) 
82/83 0187 0.428 0.848 0.406 
AC28 cyto  
(positive/negative) 
73/92 0.282 0.001* 0. 703 <0.001* 
AC28 memb  
(positive/negative) 
6/159 0.388 0.802 0.241 0.707 
Cl28 nuc  
(positive/negative) 
74/85  <0.001 0.037 <0.001* 
Cl28 cyto  
(positive/negative) 
69/90   0.081 <0.001* 
Cl28 memb  
(positive/negative) 
78/70    0.770 
Table 3.22 shows the interrelationship between Clone 28 expression at different 
cellular levels and clinico-pathological characteristics of patients with breast cancer; 
Histology: duct = ductal carcinoma, lob = lobular carcinoma, tub = tubular 
carcinoma, others including mucinous, mucoid and micropapillary carcinoma; Grade: 
Bloom and Richardson grade; c-Src = total Src kinase, AC 28= anti-Src family 
negative regulatory [pY] site, re-named in our laboratory as anti-Clone28, Src kinase 
phosphorylated at Tyrosine site 530 (inactive); Cl 28= Clone 28, Src kinase 
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dephosphorylated at Tyrosine site 530, partially activated. *negatively correlated; 
significant results are highlighted in bold. p-values of >0.01 were considered as non-
significant due to the large number of statistical comparisons (Bonferroni 
phenomenon). 
 
On univariate and multivariate analysis there was no significant association noticed 
between Clone 28 expression and disease specific survival at any cellular location (table 
3.23).   
Table 3.23: Impact of Clone 28 protein expression on patient survival. 
Total Patient 
Cohort:  
 Univariate  
Analysis 
314 patients Numbers P value HR IQR 
Cl28 nuc  
(positive/negative) 
74/85 0.313 1.4 0.7-2.5 
Cl28 cyto  
(positive/negative) 
69/90 0.810 0.9 0.5-1.7 
Cl28 memb 
(positive/negative) 
78/70 0.568 0.8 0.5-1.5 
Cl28 perinuclear 
(positive/negative) 
75/74 0.625 1.2 0.6-2.2 
Table 3.23:  No impact of Clone 28 protein expression on patient survival was 
observed. Expression of each cellular location was correlated to disease specific 
survival. None of the protein expressions were associated with disease specific survival 
and independent in multivariate analysis. HR= Hazard Ratio (95% Confidence Interval 
(CI)), IQR= interquartile range. Significant results are highlighted in bold.  
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3.3.4.3 Activated Y419Src kinase protein expression in invasive breast cancers 
Specificity of the antibody detecting phosphorylation at Tyrosine site 419 was confirmed 
using a ER negative (MDAMB231) and ER positive (MCF7) cell line (figure 3.17). Time 
course cell lysates were kindly provided by Dr Liane McGlynn. 
Figure 3.17: Western Blotting for specificity of Y416Src antibody 
 
Figure 3.17:  Western Blots with Y416Src (60kDa) and β-actin (40kDa), as a protein 
loading control. Using ER positive (MCF7) and ER negative (MDA MB231) breast 
cancer cell lines exposed to stimulant oestradiol or epidermal growth factor (E2/ EGF) 
and/or inhibitor Heregulin (HRG) at different time points. C= control, untreated cell 
line. 
Activated phosphorylated Src kinase expression, at the classical activation site Y419, was 
predominately observed in the nucleus (39%) and cytoplasm (45%). 51% of tumours 
expressed Y419Src kinase in the membrane (table 3.24). 
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Table 3.24: Y419Src expression in patient subgroups 
Y419Src (no. 314) Nuclear Cytoplasm Membrane 
Positive (Patient No) 122 140 161 
Negative (Patients No) 192 174 153 
Table 3.24 shows the distribution of patients in each subgroup. 
For statistical analysis tumours were split into those with high (above the median) or low 
(below or equal to the median) expression (table 3.25). Therefore patients separated into 
two groups; those with low expression (negative subgroup) and those with higher 
expression (positive subgroup) (table 3.24). 
 
Table 3.25: Descriptive statistics for Y419Src histoscores 
Y419Src 
Histoscores 
Minimum Maximum Median LQ UQ 
nuclear 0 245 32 10 70 
cytoplasmic 0 213 20 3 60 
membrane 0 135 0 0 5 
Table 3.25 provides an overview of descriptive statistics of Y419Src nuclear, 
cytoplasmic and membrane histoscores. With the membrane Y419Src median being 0, 
patients were grouped into two subgroups: patients with no Y419Src expression and 
with Y419Src expression. 
Histograms and IHC pictures below exhibit the cellular distribution and intensity of 
nuclear, cytoplasmic and membrane Y419Src expression (figures 3.18, picture 3.6). 
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Figure 3.18: Histograms for Y419Src expression 
 
 
Figure 3.18 demonstrates the intensity of IHC staining for nuclear, cytoplasmic and 
membrane Y419Src expression 
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Picture 3.6: IHC staining with Y416Src antibody 
 
Picture 3.6 A: Overview of a 0.6 mm 
core of the breast cancer TMA, 
showing nuclear, cytoplasmic and 
membrane staining; magnification 
x10.  
 
Picture 3.6 C demonstrates weak 
cytoplasmic and membrane, weak and 
negative nuclear staining. 
magnification x100. 
 
Picture 3.6 B: Normal Breast tissue, 
stained with Y416Src antibody (Cell 
Signalling); magnification x100. 
 
 
 
Picture 3.6 D: Negative/greyish 
staining of stroma and tumour tissue, 
magnification x100. 
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With chi square analysis we tried to evaluate if clinico-pathological features of the patient 
cohort correlated with high Y419Src expression (table 3.26). We found that cytoplasmic 
Y419Src expression positively correlated with HER2 status; meaning that patients with 
invasive breast cancer over-expressing Y419Src in the cytoplasm, were more likely to have 
HER2 positive breast cancers (χ2 p<0.001). Membrane Y419Src expression positively 
correlated with grade (χ2 p<0.001), size (χ2 p=0.002) and HER2 status (χ2 p<0.001) and 
inversely correlated with ER status (χ2 p<0.001). Nuclear Y419Src expression did not 
correlate with any known clinico-pathological features or other c-Src location (table 3.26).  
Cytoplasmic and membrane Y419Src expression correlated significantly with c-Src cyto 
and membrane expression (χ2 p<0.001). Expression levels of Y419Src at each cellular 
location strongly positively correlated with each other (table 3.26).  
Table 3.26: Interrelationship between clinico-pathological features of the cohort, c-Src and 
Y419Src expression 
Total Patient Cohort Chi-squared p-values 
314 
Variables 
Numbers Y419Src 
nuc 
Y419Src 
cyto 
Y419Src 
memb 
Age  
(<50yr/>50yr)  
78/236 0.622 0.391 0.287 
Tumour type 
(duct/lob/tub/others) 
298/10/3/3 0.753 0.293 0.416 
Grade  
(G1/G2/G3) 
22/146/146 0.627 0.069 <0.001 
Size  
(<20 , 20-50, >50mm) 
126/169/19 0.061 0.044 0.002 
Lymph node  
(positive/negative) 
152/162 0.127 0.211 0.392 
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ER status  
(positive/negative) 
209/105 0.143 0.108 <0.001* 
PgR status 
(positive/negative) 
149/163 0.412 0.042 <0.001 
HER2 status 
 (positive/negative) 
51/263 0.053 <0.001 <0.001 
c-Src nuc  
(positive/negative) 
139/175 0.058 0.268 0.376 
c-Src cyto  
(positive/negative) 
139/175 0.687 <0.001 <0.001 
c-Src memb  
(positive/negative) 
135/179 0.370 <0.001 <0.001 
Y419Src nuc 
(positive/negative) 
122/192  <0.001 0.004 
Y419Src cyto 
(positive/negative) 
138/174   <0.001 
Table 3.26 shows the interrelationship between Y419Src expression at different cellular 
levels and clinico-pathological characteristics of patients with breast cancer; c-Src = 
total Src kinase, Y419Src = Src kinase phosphorylated at Tyrosine site 419, *negatively 
correlated, significant results are highlighted in bold. p-values of >0.01 were 
considered as non-significant due to the large number of statistical comparisons 
(Bonferroni phenomenon). 
Patients‘ clinical outcome was analysed using Kaplan Meier survival analysis. Only 
Y419Src membrane expression was associated with shorter disease specific survival 
(p=0.023, table 3.27) on univariate analysis (figure 3.19).  
However, as with cytoplasmic c-Src expression, it was not independent in multivariate 
analysis (table 3.27).  
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Table 3.27: Impact of Y419Src expression on patient survival 
Total Patient 
Cohort:  
 Univariate  
Analysis 
Multivariate 
Analysis 
314 patients Numbers P value HR IQR P value HR IQR 
Y419Src nuc  
(positive/negative) 
135/179 0.585 0.9 0.5-1.4    
Y419Src cyto  
(positive/negative) 
122/192 0.625 0.9 0.6-1.4    
Y419Src memb 
(positive/negative) 
138/174 0.023 1.7 1.1-2.7 0.614 1.1 0.7-1.8 
Table 3.27:  Expression of each cellular location was correlated to disease specific 
survival. Membrane Y419Src protein expression was associated with poorer clinical 
outcome, but was not independent in multivariate analysis. HR= Hazard Ratio (95% 
Confidence Interval (CI)), IQR= interquartile range. Significant results are highlighted 
in bold.  
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Figure 3.19: Kaplan Meier survival curve for membrane Y419Src expression 
 
Figure 3.19: Kaplan Meier survival curve illustrates that membrane Y419Src 
expression is significantly associated with decreased disease specific survival (p=0.023, 
respectively). 
Patients with high membrane Y419Src expression had a median survival of 12.8 years 
(IQR 11.1-14.6) compared to those with low expression with median survival of 14.8 years 
(IQR 12.1-16.8). 
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3.3.4.4 Activated Y215Src kinase protein expression in invasive breast cancers 
Despite the only recent discovery of the activation site Y215, there are already several 
antibodies commercially available. Specificity of the Y216Src Santa Cruz antibody was 
confirmed using a ER negative (MDAMB231) and HEK293 (human embryonic kidney) 
cell line lysates (figure 3.20).  
Figure 3.20: Western Blotting for specificity of Y216Src antibody 
 
Figure 3.20:  Western Blot with Y216Src and β-tubulin (48kDa), as a protein loading 
control. Using Human Embryonic Kidney cell lysates (HEK293) and ER negative (MDA 
MB231) breast cancer cell line lysates. No band detected in non-phosphorylated HEK 
293 cells with Y216Src antibody (Santa Cruz). 
Phosphorylated activated Y215Src kinase expression was predominately observed in the 
nucleus (49%) and cytoplasm (50%). No more than 4% of tumours expressed Y215Src 
kinase in the membrane. (table 3.28). Likewise the statistical analysis of Y419Src tumours 
was split into those with high (above the median) or low (below or equal to the median) 
expression (table 3.29).  
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Therefore patients separated into two groups; those with low expression (negative 
subgroup) and those with higher expression (positive subgroup) (table 3.29). 
Table 3.28: Descriptive statistics for Y215Src histoscores 
Y215Src 
Histoscores 
Minimum Maximum Median LQ UQ 
nuclear 0 230 5 0 35 
cytoplasmic 0 235 8 0 43 
membrane 0 38 0 0 0 
Table 3.28 provides an overview of descriptive statistics of Y215Src nuclear, 
cytoplasmic and membrane histoscores. With the membrane Y215Src median being 0, 
patients were grouped into two subgroups: patients with no Y215Src expression and 
with Y215Src expression. 
 
Table 3.29: Y215Src expression in patient subgoups 
Y215Src (no. 314) Nuclear Cytoplasm Membrane 
Positive (Patient No) 154 158 14 
Negative (Patients No) 160 156 299 
Table 3.29 shows the distribution of patients in each subgroup. 
 
Histograms and IHC pictures below exhibit the cellular distribution and intensity of 
nuclear, cytoplasmic and membrane Y215Src expression (figure 3.21, picture 3.7). 
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Figure 3.21: Histograms for Y215Src expression in invasive breast carcinoma 
 
 
Figure 3.21: Each histogram displays the distribution of nuclear, cytoplasmic and 
membrane Y215Src expression and its IHC staining intensity. 
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Picture 3.7: IHC staining with Y215Src 
 
Picture 3.7 A: Overview of a 0.6 mm 
core of the breast cancer TMA; 
showing areas of nuclear and 
cytoplasmic mixed with no nuclear 
staining, x10.  
 
Picture 3.7 C: demonstrates weak and 
moderate cytoplasmic, weak and 
negative nuclear and no membrane 
staining, x100. 
 
Picture 3.7 B: Normal Breast tissue, 
stained with Y216Src antibody (Santa 
Cruz); magnification x100. 
 
 
 
Picture 3.7 D: Negative staining of 
stroma and tumour tissue, 
magnification x100. Negative control. 
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Correlations between Y215Src expression and clinico-pathological features of the patient 
cohort were assessed with Chi square analysis. Nuclear Y215Src expression positively 
correlated with grade and ER status (table 3.30), meaning that patients with invasive breast 
cancer over-expressing Y215Src in the nucleus, were more likely to have high grade, ER 
positive breast cancers (χ2 p=0.006 and χ2 p<0.001). The only correlation observed with 
cytoplasmic Y215Src expression and clinico-pathological features was a positive 
correlation with HER2 status (table 3.30).  
Table 3.30: Correlations between pathological features of cohort and Y215Src expression 
Total Patient Cohort: 314 Chi-squared p-values 
Variables Numbers Y215Src nuc Y215Src cyto Y215Src memb 
Age  
(<50yr/>50yr)  
78/236 0.332 0.649 0.861 
Tumour type 
(duct/lob/tub/others) 
298/10/3/3 0.015 0.515 0.424 
Grade  
(G1/G2/G3) 
22/146/146 0.006 0.674 0.372 
Size  
(<20 , 20-50, >50mm) 
126/169/19 0.061 0.921 0.399 
Lymph node  
(positive/negative) 
152/162 0.504 0828 0.217 
ER status  
(positive/negative) 
209/105 <0.001 0.902 0.972 
PgR status 
(positive/negative) 
149/163 0.014 0.266 0.087 
HER2 status 
 (positive/negative) 
51/263 0.161 <0.001† 0.075 
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Table 3.30 shows the interrelationship between Y215Src expression at different cellular 
levels and clinico-pathological characteristics of patients with breast cancer. 
Histology: duct = ductal carcinoma, lob = lobular carcinoma, tub = tubular 
carcinoma, others including mucinous, mucoid and micropapillary carcinoma; Grade: 
Bloom and Richardson grade; Y215Src nuc = Y215Src nuclear expression, Y215Src 
cyto = Y215Src cytoplasmic expression, Y215Src memb = Y215Src membrane 
expression.  †cytoplasmic Y215Src kinase expression independent on multivariate 
analysis (p=0.005, table 3) as HER2 being displaced from the Cox-regression model. 
 
Interestingly all significant relationships between Y215Src expression and other Src 
phosphorylation sites were negatively correlated (table 3.31). Most of the correlations were 
with cytoplasmic Y215Src expression, apart from one Y215Src nuclear expression, which 
correlated negatively with AC 28 nuclear expression (χ2 p=0.004). Cytoplasmic Y215Src 
expression correlated negatively with all Y419Src expression sites (Y419Src nuc χ2 
p=0.005, Y419Src cyto χ2 p<0.001, Y419Src memb χ2 p<0.001), cytoplasmic and 
membrane c-Src (χ2 p=0.009 and p<0.001), cytoplasmic AC 28 (χ2 p<0.001) and 
cytoplasmic Clone 28 expression (χ2 p=0.004), meaning that patients with invasive breast 
cancer over-expressing cytoplasmic Y215Src, were more likely to have low protein 
expression of the other Src phosphorylation site. No significant correlations were noted 
with membrane Y215Src expression. Interrelationship between different Y215Src 
locations only highlighted a positive correlation between nuclear and cytoplasmic Y215Src 
expression. 
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Table 3.31: The interrelationships between c-Src and all activation sites 
Total Patient Cohort:314 Pearson Chi-squared p-values 
Variables Numbers c-Src 
cyto 
c-Src 
memb 
Y416 
Src  
nuc 
Y416 
Src 
cyto 
Y416 
Src 
memb 
Y215 
Src 
nuc 
Y215 
Src 
cyto 
Y215 
Src 
memb 
AC  
28 
nuc 
AC  
28 
cyto 
AC  
28 
memb 
Clone  
28 
nuc 
Clone  
28 
cyto 
Clone  
28 
memb 
c-Src nuc 
(pos/neg) 
139/175 <0.001 <0.001 0.058 0.268 0.376 0.902 0.297 0.048 0.102 0.330 0.845 0.038 0.027 0.678 
c-Src cyto  
(pos/neg) 
139/175  <0.001 0.687 <0.001 <0.001 0.745 0.009* 0.682 0.380 0.044 0.340 0.200 0.873 0.811 
c-Src memb  
(pos/neg) 
135/179   0.370 0.001 <0.001 0.147 <0.001* 0.054 0.075 <0.001 0.080 0.650 <0.001 0.393 
Y416Src nuc  
(pos/neg) 
122/192    <0.001 0.004 0.042 0.005* 0.120 0.001 0.074 0.054 0.154 0.787 0.308 
Y416Src cyto  
(pos/neg) 
138/174     <0.001 0.294 <0.001* 0.489 0.058 <0.001 0.002 0.952 0.522 0.718 
Y416Src memb 
(pos/neg) 
138/174      0.690 <0.001* 0.141 0.702 0.141 0.064 0.521 0.008 0.157 
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Y215Src nuclear 
(pos/neg) 
154/160       <0.001 0.063 0.004* 0.176 0.640 0.761 0.659 0.366 
Y215Src cyto 
(pos/neg) 
158/156        0.022 0.515 <0.001* 0.077 0.485 0.004* 0.502 
Y215Src memb 
(pos/neg) 
14/299         0.430 0.323 0.263 0.423 0.101 0.174 
AC 28 nuclear 
(pos/neg) 
82/83          0.902 0.510 0.015* 0.449 0.848 
AC 28 cyto  
(pos/neg) 
72/93           0.015* 0.192 <0.001* 0.703 
AC 28 memb  
(pos/neg) 
6/159            0.305 0.696 0.241 
Clone 28 nuclear  
(pos/neg) 
74/85             0.007* 0.144 
Clone 28 cyto  
(pos/neg) 
69/80              0.410 
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Table 3.31 gives on overview of interrelationships between all Src and Src phosphorylation sites. c-Src = total Src kinase, Y416Src = Src kinase 
phosphorylated at Tyrosine site 416, Y215Src = Src kinase phosphorylated at Tyrosine site Y215; AC 28= anti-Src family negative regulatory [pY] site, 
re-named in our laboratory as anti-Clone28, Src kinase phosphorylated at Tyrosine site 530 (inactive), Clone 28= dephosphorylated at Tyrosine site 530 
(partially active); c-Src nuc = c-Src nuclear expression, c-Src cyto = c-Src cytoplasmic expression, c-Src memb = c-Src membrane expression, Y416Src 
nuc = Y416Src nuclear expression, Y416Src cyto = Y416Src cytoplasmic expression, Y416Src memb = Y416Src membrane expression, Y215Src nuc = 
Y215Src nuclear expression, Y215Src cyto = Y215Src cytoplasmic expression, Y215Src memb = Y215Src membrane expression; AC 28 nuc = anti-Clone 
28 nuclear expression, AC 28 cyto = anti-Clone 28 cytoplasmic expression, AC 28 memb = anti-Clone 28 membrane expression; Clone 28 nuc = Clone 
28 nuclear expression, Clone 28 cyto = Clone 28 cytoplasmic expression, Clone 28 memb = Clone 28 membrane expression; pos= positive, neg= 
negative; *negatively correlated; significant results are highlighted in bold. p-values of >0.01 were considered as non-significant due to the large number 
of statistical comparisons (Bonferroni phenomenon). 
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In contrast, to the observations made with total c-Src (associated with poor prognosis), 
high nuclear and cytoplasmic Y215Src kinase expression was strongly associated with 
improved disease specific survival (nuc Y215Src p=0.001, cyto Y215Src p=0.001 (figure 
3.22) (table 3.32).  
Figure 3.22: Kaplan Meier survival curve for nuclear and cytoplasmic Y215Src expression 
 
Figure 3.22: Kaplan Meier survival curve shows that nuclear and cytoplasmic Y215Src 
expression is significantly associated with decreased disease specific survival (p=0.001, 
respectively). 
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Table 3.32: Impact of Y215Src expression on patient survival 
Total Patient 
Cohort:  
 Univariate  
Analysis 
Multivariate 
Analysis 
314 patients Numbers P value HR IQR P value HR IQR 
Y215Src nuc  
(positive/negative) 
154/160 0.001 0.43 0.2-0.7 0.203 0.7 0.4-1.2 
Y215Src cyto  
(positive/negative) 
158/156 0.001 0.45 0.3-0.7 0.002 0.4 0.3-0.7 
Y215Src memb 
(positive/negative) 
14/299 0.601 0.74 0.2-2.3 0.764 1.2 0.4-4.0 
Table 3.32:  Expression of each cellular location was correlated to disease specific 
survival. Nuclear and cytoplasmic Y215Src protein expression was associated with 
better clinical outcome. Only cytoplasmic Y215Src was independent in multivariate 
analysis. HR= Hazard Ratio (95% Confidence Interval (CI)), IQR= interquartile range. 
Significant results are highlighted in bold.  
 
Patients with high nuclear Y215Src kinase expression had a median survival of 15.0 years 
(IQR 13.1-16.8) compared to those with low expression with a median survival of 12.3 
years (IQR 10.5-14.2). Patients with high cytoplasmic Y215Src kinase expression had a 
median survival of 14.9 years (IQR 13.1-16.7) compared to those with low expression with 
a median survival of 12.5 years (IQR 10.6-14.4).  
Although cytoplasmic Y215Src kinase expression and HER2 status correlated on chi 
square analysis (table 3.32), only cytoplasmic Y215Src kinase expression was independent 
on multivariate analysis (p=0.002) with a hazard ratio 0.4 (IQR 0.3-0.7), as HER2 was 
displaced from the Cox-regression model. 
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3.3.4.5 Relationship of Src kinase expression to disease specific survival in patients 
stratified by ER status 
Expression of Src kinase, SFK members and all activation sites of Src kinase was stratified 
by ER status (105 ER negative and 209 ER positive tumours). The only significant results 
were observed with Y215Src expression. 
Patients with ER negative tumours and high cytoplasmic Y215Src kinase expression had 
significantly improved disease specific survival (p=0.003) (figure 3.23). As in the full 
cohort, this association was also independent on multivariate analysis (p=0.009, table 3.33) 
with a hazard ratio of 0.4 (IQR 0.2-0.8).  No association was observed in the ER positive 
cohort (p=0.051). 
Figure 3.23: Kaplan Meier Survival Curve for cytoplasmic Y215Src in ER negative 
patients compared to ER positive patients 
 
Figure 3.23: Kaplan Meier Survival Curve for cytoplasmic Y215Src in ER negative 
patients and ER positive patients. Significant survival advantage is present in ER 
negative patients. 
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Table 3.33: Survival analysis in ER negative patient cohort with all Src and SFK members 
ER negative  
patients:  
 Univariate 
Analysis 
Multivariate  
analysis 
 Numbers P value HR IQR P value HR IQR 
Grade  
(G1/G2/G3) 
1/23/81 0.062 1.7 0.9-3.1    
Size  
(<20, 20-50, >50mm) 
35/61/9 <0.001 5.4 2.1-14.0 0.004 4.5 1.6-12.3 
Lymph node  
(positive/negative) 
54/51 0.010 2.4 1.2-4.6 0.001 3.2 1.6-6.7 
HER2 status  
(positive/negative) 
30/75 0.475 1.3 0.6-2.5    
c-Src nuc 
(positive/negative) 
56/49 0.570  1.2 0.6-2.3    
c-Src cyto 
(positive/negative) 
65/40 0.090 1.8 0.9-3.7    
c-Src memb 
(positive/negative) 
58/47 0.982 1.0 0.5-1.9    
Y419Src nuc 
(positive/negative) 
35/70 0.740 1.1 0.6-2.2    
Y419Src cyto 
(positive/negative) 
53/50 0.730 1.1 0.6-2.1    
Y419Src memb 
(positive/negative) 
67/38 0.715 1.1 0.6-2.2    
Y215Src nuc 
(positive/negative) 
37/68 0.345 1.1 0.7-2.8    
Y215Src cyto 
(positive/negative) 
54/51 0.003 0.4 0.2-0.7 0.009 0.4 0.2-0.8 
Y215Src memb 
(positive/negative) 
5/100 0.866 1.1 0.3-4.8    
AC 28 nuc 
(positive/negative) 
19/33 0.665 1.2 0.5-3.0    
AC 28 cyto 
(positive/negative) 
26/26 0.444 1.4 0.6-3.3    
Chapter 3 Protein expression of SFK members 196 
 
AC 28 memb 
(positive/negative) 
2/50 0.303 0.05 0.0-33    
Clone 28 nuc 
(positive/negative) 
21/25 0.533 1.3 0.5-3.2    
Clone 28 cyto 
(positive/negative) 
24/22 0.961 1.0 0.4-2.3    
Clone 28 memb 
(positive/negative) 
24/21 0.781 0.9 0.4-2.1    
Lyn nuc 
(positive/negative) 
15/42 0.926 1.0 0.4-2.6    
Lyn cyto 
(positive/negative) 
23/34 0.956 1.0 0.5-2.3    
Lyn memb 
(positive/negative) 
3/54 0.893 1.1 0.2-8.5    
Lck nuc 
(positive/negative) 
26/65 0.577 0.8 0.4-1.7    
Lck cyto 
(positive/negative) 
40/51 0.650 0.9 0.4-1.7    
Lck memb 
(positive/negative) 
2/89 0.316 0.05 0.0-37    
Table 3.33 gives an overview of survival analysis in ER negative patient cohort with all 
Src and SFK antibody used. Only significant association was with Y215Src cytoplasmic 
expression and was also independent on multivariate analysis. c-Src = total Src kinase, 
Y416Src = Src kinase phosphorylated at Tyrosine site 416, Y215Src = Src kinase 
phosphorylated at Tyrosine site Y215; AC 28= anti-Src family negative regulatory [pY] 
site, re-named in our laboratory as anti-Clone28, Src kinase phosphorylated at 
Tyrosine site 530 (inactive), Clone 28= dephosphorylated at Tyrosine site 530 (partially 
active); c-Src nuc = c-Src nuclear expression, c-Src cyto = c-Src cytoplasmic 
expression, c-Src memb = c-Src membrane expression, Y416Src nuc = Y416Src nuclear 
expression, Y416Src cyto = Y416Src cytoplasmic expression, Y416Src memb = Y416Src 
membrane expression, Y215Src nuc = Y215Src nuclear expression, Y215Src cyto = 
Y215Src cytoplasmic expression, Y215Src memb = Y215Src membrane expression; AC 
28 nuc = anti-Clone 28 nuclear expression, AC 28 cyto = anti-Clone 28 cytoplasmic 
expression, AC 28 memb = anti-Clone 28 membrane expression; Clone 28 nuc = Clone 
28 nuclear expression, Clone 28 cyto = Clone 28 cytoplasmic expression, Clone 28 
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memb = Clone 28 membrane expression;  Lyn nuc = Lyn nuclear expression, Lyn cyto 
= Lyn cytoplasmic expression, Lyn memb = Lyn  membrane expression; Lck nuc = Lck 
nuclear expression, Lck cyto = Lck cytoplasmic expression, Lck memb = Lck membrane 
expression. Significant results are highlighted in bold. 
 
In contrast, it was nuclear Y215 Src kinase expression that was significantly associated 
with improved disease specific survival (p=0.003) (figure 3.24) in the patients with ER 
positive tumour and this was also independent on multivariate analysis (p=0.009, table 
3.34) with a hazard ratio of 0.4 (IQR 0.2-0.8).  No association was observed in the ER 
negative cohort (p=0.345) (figure 3.24). 
Figure 3.24: Kaplan Meier Survival Curve for cytoplasmic Y215Src in ER negative 
patients compared to ER positive patients 
 
Figure 3.24: Kaplan Meier Survival Curves for nuclear Y215Src in ER negative 
patients and ER positive patients. ER positive patients with high nuclear Y215Src 
expression have a significantly better clinical outcome. 
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Table 3.34: Survival analysis in ER positive patient cohort with all Src and SFK members 
ER positive 
patients:  
 Univariate 
Analysis 
Multivariate  
analysis 
 Numbers P value HR IQR P value HR IQR 
Grade  
(G1/G2/G3) 
21/123/65 0.004 6.4 1.0-48.3    
Size  
(<20,20-50, >50mm) 
91/108/10 <0.001 22.0 7.4-69.6 <0.001 7.0 5.3-54.8 
Lymph node  
(positive/negative) 
98/111 0.091 1.7 1.0-3.3    
HER2 status  
(positive/negative) 
21/188 0.040 2.2 1.0-4.9    
c-Src nuc 
(positive/negative) 
83/126 0.317 1.4 0.7-2.7    
c-Src cyto 
(positive/negative) 
74/135 0.932 1.0 0.5-2.0    
c-Src memb 
(positive/negative) 
77/132 0.176 1.6 0.8-3.2    
Y419Src nuc 
(positive/negative) 
87/122 0.501 1.3 0.6-2.5    
Y419Src cyto 
(positive/negative) 
85/124 0.288 1.4 0.7-2.9    
Y419Src memb 
(positive/negative) 
87/122 0.099 1.7 0.9-3.3    
Y215Src nuc 
(positive/negative) 
117/92 0.003 0.4 0.2-0.7 0.009 0.4 0.2-0.8 
Y215Src cyto 
(positive/negative) 
104/105 0.051 0.5 0.3-1.0    
Y215Src memb 
(positive/negative) 
10/199 0.693 0.7 0.1-4.9    
AC 28 nuc 
(positive/negative) 
63/50 0.586 1.3 0.5-3.6    
AC 28 cyto 
(positive/negative) 
67/46 0.178 2.0 0.7-6.3    
AC 28 memb 4/109 0.424 0.4 0.06-3.4    
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(positive/negative) 
Clone 28 nuc 
(positive/negative) 
53/50 0.174 1.8 0.8-4.5    
Clone 28 cyto 
(positive/negative) 
45/58 0.596 1.3 0.5-3.0    
Clone 28 memb 
(positive/negative) 
54/49 0.629 0.8 0.3-1.9    
Lyn nuc 
(positive/negative) 
52/71 0.797 0.9 0.4-2.2    
Lyn cyto 
(positive/negative) 
36/87 0.420 1.6 0.5-4.7    
Lyn memb 
(positive/negative) 
5/118 0.556 0.6 0.1-2.8    
Lck nuc 
(positive/negative) 
85/87 0.570 1.2 0.6-2.5    
Lck cyto 
(positive/negative) 
71/101 0.536 1.3 0.6-2.6    
Lck memb 
(positive/negative) 
10/162 0.124 0.04 0.0-19    
Table 3.34 gives an overview of survival analysis in ER positive patient cohort with all 
Src and SFK antibody used. Only significant association was with Y215Src cytoplasmic 
expression and was also independent on multivariate analysis. c-Src = total Src kinase, 
Y416Src = Src kinase phosphorylated at Tyrosine site 416, Y215Src = Src kinase 
phosphorylated at Tyrosine site Y215; AC 28= anti-Src family negative regulatory [pY] 
site, re-named in our laboratory as anti-Clone28, Src kinase phosphorylated at 
Tyrosine site 530 (inactive), Clone 28= dephosphorylated at Tyrosine site 530 (partially 
active); Significant results are highlighted in bold. 
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3.3.4.6 Relationship of Src kinase expression to disease specific survival in patients 
stratified by ER and HER2 status 
When patients with ER/HER2 negative tumours were analysed (n=75), cytoplasmic Y215 
Src kinase was yet again strongly associated with improved disease free survival (p=0.007) 
(figure 3.25) and this was again independent on multivariate analysis (p=0.040) with a 
hazard ratio of 0.3 (IQR 0.2-0.8) (table 3.35).  This observation held when ER/PgR/HER2 
negative tumours were analysed (n=69) (univariate analysis p=0.015, multivariate analysis 
p=0.021, table 3.35). 
Figure 3.25: Kaplan Meier Survival Curve for cytoplasmic Y215Src in ER/HER2 negative 
patients. 
 
Figure 3.25: High cytoplasmic Y215Src is associated with better disease specific 
survival in ER/HER2 negative patients.  
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Table 3.35: Overview of the ER/HER2 negative patient and ER/PgR/HER2 negative 
patient subgroup and their survival analysis with Y215Src expression 
ER /HER2 negative patients:  
75 patients 
Univariate 
Analysis 
Multivariate 
Analysis 
 Numbers P value HR IQR P value HR IQR 
Grade  
(G1/G2/G3) 
1/13/61 0.214 2.0 0.9-4.5    
Size  
(<20,20-50, >50mm) 
31/37/7 <0.001 5.2 1.9-14.7 0.030 5.1 1.7-15.0 
Lymph node  
(positive/negative) 
35/40 0.021 2.4 1.1-5.4 0.005 3.3 1.4-7.5 
Y215Src nuc 
(positive/negative) 
22/53 0.590 1.3 0.5-3.0    
Y215Src cyto 
(positive/negative) 
30/45 0.007 0.3 0.1-0.8 0.040 0.3 0.1-0.9 
Y215Src memb 
(positive/negative) 
3/72 0.771 1.3 0.2-10.1    
ER/PgR/HER2 negative patients:  
69 patients 
Univariate 
Analysis 
Multivariate 
Analysis 
 Numbers P value HR IQR P value HR IQR 
Y215Src nuc 
(positive/negative) 
18/51 0.937      
Y215Src cyto  
(positive/negative) 
25/44 0.015 0.3 0.2-0.7 0.021 0.2 0.1-0.9 
Y215Src memb 
(positive/negative) 
3/66 0.679      
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Table 3.35 shows an overview of the ER/HER2 negative patients’ characteristics. Each 
clinical and pathological parameter was correlated to disease specific survival (p-
values). Grade = Bloom and Richardson grade. Y215Src = Src kinase phosphorylated 
at Tyrosine site Y215; Y215Src nuc = Y215Src nuclear expression, Y215Src cyto = 
Y215Src cytoplasmic expression, Y215Src memb = Y215Src membrane expression. In 
the ER/HER2 negative and triple negative patient cohort Y215Src was significantly 
associated with improved disease specific survival, and this was also independent in 
multivariate analysis. 
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3.3.5 Ki67 expression and its association with Src kinase expression 
Ki67 antigen MIB-1 (DAKO, UK) was used to determine proliferation status of the 
tumours. This antibody has been validated previously in our department and used in 
different studies (201). As before with other antibodies, nuclear Ki67 
immunohistochemistry was obtained from 71% (194/274) of the TMA tumours of the 
initial patient cohort. This was due to tissue limitation through previous extensive section 
cutting. 
Median Ki67 score was 3.8 (IQR: 0-9.8, table 3.36). Scores were classified into three 
groups (low-medium-high).  54% of the tumour specimens had a low proliferation rate, 
with a Ki67 score of <5, 30% had a medium proliferation rate of 5-20 and only 9% of the 
tumours had a high proliferation >20 (Table 3.37).   
Table 3.36: Descriptive statistics for Ki67 expression in patient cohort 
Ki67 scores Minimum Maximum Median LQ UQ 
nuclear 0.0 111 3.8 0.0 9.8 
Table 3.36 provides an overview of descriptive statistics of Ki67 nuclear histoscores.  
 
Table 3.37: Distribution of patients in each Ki67 subgroup 
Ki67 expression Low (<5%) Moderate (5-20%) High (>20%) 
Patient No 105 58 17 
Table 3.37 Majority of breast cancers of this cohort had a low to moderate shows 
proliferation index 
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Histogram and IHC pictures below exhibit the different expression intensity of nuclear 
Ki67 (figure 3.26, pictures 3.8). 
Figure 3.26: Histogram for Ki67 histoscores 
 
Figure 3.26 displays the staining intensity with Ki67 within the cohort 
Picture 3.8: IHC staining with Ki67 
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Picture 3.8 shows Ki67 staining of invasive breast cancer specimens (1:150), A= 
negative staining of stroma and tumour tissue, B= Ki67 staining classed as weak 
staining, C= Ki67 staining classed as moderate staining, D= Ki67 staining classed as 
strong staining, magnification x100 
 
On chi square analysis the only significant positive correlation between Ki67scores and 
clinico-pathological characteristics of the cohort was with tumour grade (χ2 p=0.006), 
nuclear c-Src (χ2 p=0.001) and nuclear Y419Src (χ2 p=0.008) (table 3.38). 
 
On univariate analysis Ki67 score was not associated with disease specific survival (p= 
0.254, HR1.0 range 0.5-1.9) (figure 3.27). 
Figure 3.27: Kaplan Meier survival curves for all three Ki67 subgroups 
 
Figure 3.27 demonstrates no association with patients’ disease specific survival and 
Ki67 expression (p=0.254). 
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Table 3.38: Correlations between Ki67, clinico-pathological features of the cohort and all Src and SFK expressions 
Total Patient Cohort:314 Pearson Chi-squared p-values 
Variables 
(pos/neg) 
Age Tumour  
type 
Tumour 
grade 
Tumour 
size 
LN 
status 
ER 
status 
PgR 
status 
HER2 
status 
c-Src 
nuc 
c-Src 
cyto 
c-Src 
memb 
Y416 
Src nuc 
Y416 
Src cyto 
Y416 
Src memb 
Ki67 nuc 
180/194 
0.965 0.360 0.006 0.186 0.590 0.997 0.280 0.200 0.001 0.110 0.110 0.008 0.055 0.781 
Total Patient Cohort:314 Pearson Chi-squared p-values 
Variables 
(pos/neg) 
Y215 
Src nuc 
Y215 
Src cyto 
Y215 
Src memb 
AC 28 
nuc 
AC 28 
cyto 
AC 28 
memb 
Clone 28 
nuc 
Clone 28 
cyto 
Clone 28 
memb 
Lck 
nuc 
Lck 
cyto 
Lck 
memb 
Lyn 
nuc 
Lyn 
cyto 
Lyn 
memb 
Ki67 nuc 
180/194 
0.766 0.948 0.258 0.523 0.199 0.658 0.889 0.450 0.014 0.045 0.572 0.506 0.081 0.598 0.010 
Table 3.38 shows the interrelationship between Ki67scores, Src, phosphorylated Src sites, SFK members and clinico-pathological characteristics of 
patients with breast cancer. 
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3.4 Discussion 
Histopathology continues to be a very important tool in the world of surgical oncology. 
Decisions regarding patients‘ treatments are founded on the appearance of cell and tissue 
morphology and its interpretation by the observer. A breast cancer patient‘s prognosis can 
currently alone be determined by grading and sizing of the tumour and lymphatic 
involvement (NPI). Immunohistochemistry has enhanced the spectrum and aspects of 
morphological appearances by providing additional information of the molecular 
constitution of the specimen. Hormonal adjuvant therapy is now being administrate based 
on a steroid receptor immunohistochemistry score. Human Epidermal Growth Factor 
Receptor analysis, in particular HER2 for breast cancer patients, has broadened treatment 
options by targeting and blocking this membrane-bound receptor, when overexpressed, 
with now commercially available antibodies; known as trastuzamab/ herceptin for HER2 
and lapatinib/ Tykerb for HER1/HER2. To test for HER2 positivity/ overexpression of 
HER2, a hercept score of 3+ in IHC or 2+ in IHC and positive gene amplification in FISH 
is at present the standardised method/ recommendation worldwide (202). Breast cancer 
specimens should now undergo routinely an assessment of their steroid and HER2 
receptors done to increase the amount of information available for clinicians to 
individualise therapies for the best possible outcome of their patients. It‘s been shown that 
ER and PgR positive patients have a higher risk of relapsing on tamoxifen therapy and 
increase benefit from a aromatase inhibitor (203). We also know that HER2 positivity is 
associated with increased mortality, a higher rate of disease recurrence and could predict 
resistance to certain systemic therapy (204).  
 
Indirect immunohistochemistry is used widely to examine cell signalling processes in 
cancer using paraffin embedded tissue sections. Our laboratory has extensive experience in 
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optimising conditions for usage of primary antibodies in immunohistochemistry (205-207). 
Different techniques to achieve best antigen retrieval were trialled for each individual SFK 
antibody. We established that the procedure was best performed when the TMA slides 
were submerged in preheated buffer (Citrate or TE) at a certain pH (6.0-9.0) in pressure 
cooker placed in a microwave for 5 minutes (details in material and methods section). 
Different concentrations of horse serum were tested to avoid non-specific protein binding 
of individual primary antibodies. Accurate application time and concentration of the 
primary antibody is essential to accomplish not just true differential IHC staining, but also 
consistent and replicable immunostaining. Only c-Src, Lck and Ki67 were applied for 60 
minutes at room temperature. All other antibodies were left overnight at 4 ºC. Secondary 
antibodies were chosen depending on the species the primary antibody was raised (rabbit 
or mouse).  
 
Compared to RT-PCR, this method allowed us to retrieve important information about the 
intensity and cellular location of the expressed protein. Thorough evaluation was 
performed of each cellular (nuclear, cytoplasmic, membrane and peri-nuclear) expression 
of every antibody. Significant results were seen when activated Src (pY419) was expressed 
at the membrane, the site of activation, whereas the majority of inactivated Src expression 
(anti-Clone 28) was observed in the nucleus and cytoplasm. Interestingly, partially 
activated Src (Clone 28) was found to a larger extent in the peri-nuclear region. It remains 
unclear if this hints an intention to be activated/ recruited. 
 
It may seem that IHC scoring is a subjective method and would need a standardised 
approach for clinical routine medical practice to prevent inaccurate results leading to 
erroneous treatment decisions. Individual protein expression was assessed using the 
weighted histoscore technique, also known as H-score. This has been shown to be a robust, 
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reproducible scoring method to interpret immune-reactivities of signalling molecules. 
Protein expression is quantified objectively by means of continuous variable (199;200). 
Each tumour was assessed and scored respectively by two independent, histoscore trained 
observers. Quality and standard of inter-observer variation can be determined by inter class 
correlation coefficients (ICCC). It‘s defined as the variance between subjects relative to the 
sum of the variance components for subjects, observers and random error (199). ICCCs 
were calculated to ensure intra and inter-scorer consistency and reproducibility. ICCC 
scores above 0.8 are considered as excellent and certifying a sufficient data interpretation. 
Another way of visualising a validated range and distribution of histoscores is through 
Scattered (X and Y axis: Each axis representing each scorer‘s histoscores for a core) and 
Bland-Altman plots (X-axis: average between Histoscores of each scorer, Y: difference 
between scorer‘s Histoscore). These were presented in the material and method section for 
each individual antibody confirming appropriate scorer-observer correlation. 
 
Due to small patient numbers in the PCR cohort (previous chapter), we transferred our 
interest towards a larger cohort to investigate the role of Src and Src kinase family 
members in breast cancer in formalin fixed paraffin embedded specimens (IHC cohort). 
Clinical details of the IHC cohort were retrospectively collected by Dr Sylvia Brown 
during her investigations into the association of deprivation and breast cancer incidence 
between 1980s and 1990s in the area of Greater Glasgow (208). This cohort represents a 
large heterogenic group of patients from one geographical region with mature clinical 
follow-up. But because of the long duration of time, tissue specimens were collected by 
different individuals during these years, pathology laboratory fixation protocols were 
altered and even more aromatase inhibitors were commenced routinely in clinical practice. 
These inconsistencies could influence and alter results.  
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HE sections from each breast cancer specimen were examined by Consultant Pathologist 
Dr Elizabeth Mallon and marked for tissue microarray construction. Oestrogen-, 
progesterone- and HER2 receptor status (IHC and FISH) were the first investigations 
performed for each specimen to achieve a uniform database (209). Kaplan Meier Survival 
analyses were carried on all clinico-pathological patients‘ details to ensure the collected 
data of this cohort were validated (table 3.3). Initially 895 patients were identified and 
recruited through Dr. Brown‘s study. However, due to the retrospective collection of data 
only 314 patients/ tumour specimens were eligible for this project. For a rounder and more 
detailed interpretation of the protein expression results further data on recurrence of 
disease or even more particularized adjuvant treatment received by patients would have 
been of interest and we currently constructing retrospectively an expanded cohort with 
more detailed patient information.  
It is known from the literature that certain fixation methods or/ and duration of fixation 
could affect quality of the specimen and variability of IHC staining results. Tissue 
microarray construction allows rapid tumour processing under standardised conditions and 
has been extensively validated in breast cancer. Up to 100-200 (0.6-2mm diameter) 
individual tumour cores can be placed into a single recipient block enabling simultaneous 
multiple tumour analysis and increase cost effectiveness by using less antibody. Three 0.6 
mm cores from each block were taken to account for biological tumour heterogeneity. 
Each immunohistochemistry run included a positive and negative control to ensure no false 
positive staining. Full sections and normal breast tissue specimens were added to evaluate 
significant staining differences.  
Initially we were able to analyse Src expression data of 314 patients. Over time and 
extensive section cutting of the tissue microarray, tissue/ cores vanished, resulting to an 
expression analysis of 48% of the original tumour with the Clone 28 antibody.  
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Src kinase has been investigated for a long time in a variety of solid tumours. Data from 
human cancer tissues have further defined the role of Src in tumour development in a more 
clinically relevant setting. Elevated levels of Src or SFKs have been detected in a range of 
human solid tumours, including glioblastoma (210), cancers of the prostate (90), breast 
(114), pancreas (211), and lung (212). Either overexpression or increased activity of Src is 
responsible for oncogenesis in different tumours. For example, in colon carcinoma lysates, 
Src activity was elevated compared with normal human colon mucosa cells, which 
appeared to be as a result of increased kinase signalling by Src, rather than increased 
protein levels (213;214). 
This differs to breast cancer. In vitro evidence for a role for c-Src in breast cancer is 
convincing, but currently not supported by translational clinical studies. Elevated c-Src 
activity promotes cellular invasion and motility in Tamoxifen resistant breast cancer cells 
and provides a link between the HER family and steroid receptors (215). Other Src family 
members have also been linked with breast cancer. Microarray studies have demonstrated 
that Lyn is induced in models of endocrine resistance (216) and Lck is implicated in 
hypoxia induced breast cancer progression (159). Again, there is little published evidence 
on the role of other Src family members in clinical breast cancer specimens. Translational 
studies, investigating human breast tumour Src kinase expression and correlating 
expression and Src activation to clinical parameters including survival, are surprisingly 
limited. Only three in vivo studies have been published so far (114-116). Two of those 
clinical studies used immunohistochemistry (IHC) method to show that Src is associated 
with aggressive disease studies in breast cancer. Additionally, they noted that Src 
expression was higher in malignant tissue compared with normal tissue (114;116). 
Elevated Src kinase activity has also been witnessed in metastatic disease. Compared with 
primary tumour tissue, Src activity is increased in metastatic tissue and in cells with a high 
metastatic potential (217;218). A study in colorectal cancer has demonstrated that 
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increasing Src expression and activity correlated with the progression of colorectal cancer 
from colonic polyps to primary lesions and liver metastases. With each step in disease 
progression, an increase in Src activity was seen. This was confirmed within individual 
patients by comparing Src activity in metastatic lesions with synchronous primary and 
metastatic tumour excisions at the same time (217). 
Increased Src activity has been associated with poor prognosis in patients with colon 
carcinoma showed that when Src expression correlated with patient survival, Src activity 
was an independent indicator of poor prognosis at each stage of colon carcinoma. This 
suggests that measurement of Src activity may help in selecting patients most suitable for 
adjuvant therapy (219). 
It‘s well known that advanced breast cancer has the tendency to develop bone metastasis. 
Araujo et al. described the role of Src in normal bone cells and bone remodelling in 
metastatic disease (108). Abnormal Src signalling may contribute to the increased 
osteoclastic activity associated with bone metastases. This implies that Src kinase 
inhibitors could not only be used for early stage high risk breast cancer to prevent 
metastatic spread, but also in the advanced or even palliative setting to limit growth of 
established metastasis sites and reduction of patients‘ symptoms. 
 
This is currently the largest published study investigating the role of Src kinase expression 
and its different phosphorylation status in a cohort of clinical breast cancer specimens. Our 
study suggests that Src kinase expression and phosphorylation status may be employed as 
prognostic markers in breast cancer. 
Increased cytoplasmic c-Src kinase expression is significantly associated with decreased 
disease specific survival. Most of the existing in vitro literature provides compelling 
evidence that c-Src activation is associated with high tumour proliferation, increased 
invasion and increased migration in breast cancer cells (65;220). 
 
This has been supported 
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by an in vivo study, carried out by Nigel Bundred‘s group, where Src kinase expression in 
ductal carcinoma in situ (DCIS) breast tumors correlated with HER2 positivity, high tumor 
grade, comedo necrosis and elevated epithelial proliferation. In addition, high c-Src levels 
were associated with lower recurrence free survival (115). The results obtained from our 
study are in keeping with cell line studies, too, demonstrating that c-Src is associated with 
more aggressive growth and poor clinical outcome. c-Src expression not only correlated 
with decreased survival, but also with increased tumor grade, ER negativity and HER 
positivity. In breast cancer, Src activity and distribution might impact on resistance to 
endocrine therapy in patients with oestrogen receptor/progesterone receptor (ER/PgR)-
positive disease. A recent study of our group illustrated in a hundred per cent ER positive 
cohort that activated Src localised to the nucleus was significantly associated with 
improved overall survival and a lower recurrence rate during tamoxifen treatment of 
ER/PgR-positive tumours (221).  
Parallel to this finding Src kinase was investigated in a cohort of castrate resistant prostate 
cancer and an increase in Src activity within tumour tissue with the development of 
hormone resistance was observed. Patients within this subpopulation had a significantly 
shorter overall survival than those with tumours that had a decrease or no change in Src 
activity (90), again, suggesting that increased Src activity may play a role in resistance to 
endocrine therapies in more than one type of cancer. 
 
Although it is important to assess c-Src protein levels, it is of equal importance to 
determine the activation status of Src kinase. Ito el al. reported that high activated c-Src 
expression was frequently observed in breast tumors with lower aggressiveness as 
indicated by low Ki-67, absence of lymph node spread, small size and a low histological 
grade.  This suggests that activation of Src is associated with early stages of breast 
carcinoma, but there was no correlation made with patient outcome measures (116). 
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However, Src activation in this study was determined using an antibody (Clone 28) to 
tyrosine site 530 and was classed as activated if un-phosphorylated at this site. Clone 28 is 
a marker for partial activation of c-Src, detecting dephosphorylated Y530Src at first 
protein configuration change before phosphorylation of Y419Src leading to full activation. 
It has previously been suggested, that a more appropriate biomarker for prediction of 
clinical response to Src kinase inhibitors would to be to measure phosphorylation of the 
protein at a site associated with activity (213;222). Currently there are two sites within c-
Src known to be associated with activation. Tyrosine site 419 (Y419Src) in human, is 
known as the classical site, which is most commonly utilised in cell line studies 
investigating the functional relevance of Src kinase activation (169). Src kinase when 
activated is moved to the membrane (65).  
Indeed in our study, when Src kinase is activated at the classical site Y419 and located in 
the cellular membrane, it is associated with shorter disease specific survival, increasing 
grade, tumour size, ER negativity and HER2 positivity. Whilst our results with Y419 
support the role of Src kinase activation, currently described in the literature.  
 
The other site of activation is at tyrosine 215 (Y215Src). Stover et al. reported a 50-fold 
increase in activation of Src kinase associated with Y215Src phosphorylation (76). We 
obtained contradictory results with this alternative phosphorylation site.  
Interestingly our study observes poor prognosis associated with membrane expression of 
phosphorylated Y419Src, but good prognosis with cytoplasmic expression of 
phosphorylated Y215Src. These results suggest that location and not only phosphorylation 
site influences downstream effectors of Src kinase.  
Phosphorylation at Y215Src was strongly associated with improved survival (high nuclear 
and cytoplasmic Y215Src expression) and was demonstrated to be independent of other 
known clinical parameters on multivariate analysis (only seen with high cytoplasmic Y215 
Chapter 3 Protein expression of SFK members 215 
 
Src kinase expression). It is of note, that all significant associations between cytoplasmic 
Y215Src, c-Src and Y419Src were all negatively correlated. 
It is unclear why Y416Src and Y215Src are associated with different outcome measures. 
These contrasting roles may be due to phosphorylation at Y215 and Y419 residing in 
different SH domains. Phosphorylation in different domains may result in varying protein 
configurations, which might enable activation of other downstream signalling pathways. 
An alternative explanation of these results may be that the antibodies detect 
phosphorylation of other Src kinase family members (e.g. Lyn, Lck, Yes) in addition or in 
preference to c-Src, as the phosphorylated regions are highly conserved (76). 
Activated phosphorylated Y215Src kinase was independent in multivariate analysis 
(tumour grade, tumour size, axillary lymph node involvement, ER and HER2 status), 
providing evidence that Y215Src could be utilised as a prognostic marker to determine 
which subgroup of breast cancer patients should not be targeted with Src kinase inhibitors. 
Although Y215Src was independent on multivariate analysis, there was a positive 
association observed between cytoplasmic Y215Src kinase expression and HER2 status. 
These results support the observation that HER2 may phosphorylate Src kinase at Y215 
(125). Vadlamudi et al. suggested that the interaction with HER2 would result in a more 
aggressive phenotype of cancer (125).  
This is in direct contrast with results obtained in the current study. Further investigations, 
to determine the underlying molecular interactions between HER2 and Src kinase, are 
therefore warranted. 
Approximately 10-15% of breast cancers fall into the receptor negative or triple negative 
group of breast cancers as defined by the absence of ER, PgR and HER2 receptors. This 
group of breast tumours are currently the focus of much attention because of their poor 
prognosis and the lack of an effective treatment target (72;223). In vitro studies, using gene 
expression profiling, have identified triple negative breast cancer tumours to be sensitive to 
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dasatinib, a non-receptor tyrosine kinase inhibitor. A reduction in cell proliferation was 
demonstrated (169). When we examined the ER, PgR and HER2 negative breast tumours 
as a representation of the triple negative group of breast tumours, we found that high 
cytoplasmic Y215 Src kinase expression resulted again in a significant survival advantage. 
With this in mind further investigations are urgently needed to determine what effect the 
Src inhibitor Dasatinib has on this phosphorylation site. 
 
To conclude the assessment of the various phosphorylation sites we studied 
phosphorylated and dephosphorylated tyrosine site 530, using an antibody called anti-Src 
family negative regulatory antibody (anti-Clone 28) and Clone 28. These antibodies should 
represent c-Src in its inactive form and partially activated appearance. Clone 28 has been 
used in previous studies (116;224;225) to determine whether c-Src plays a role in 
colorectal, hepatocellular or mammary tumorigenesis. Intense staining was frequently 
observed in colonic adenomas and in well- and moderately differentiated hepatocellular 
carcinomas and colonic adenocarcinomas at an early stage, suggesting that expression of 
Clone 28 was linked to an early event in carcinogenesis in situ before invasive and 
metastatic elements manifest.  
Therefore it is not surprising that none of the expression patterns of both antibodies were 
significantly associated with disease specific survival of mixed breast cancer patient 
cohort.  
Anti-Clone 28 and Clone 28 were more or less equally expressed in the nucleus and 
cytoplasm. However, there was a noteworthy divergence of their expression at the cell 
membrane. Anti-Clone 28 was rarely detected in the membrane compared to Clone28. 
Clone 28 was mainly expressed in the membrane and perinuclear, which corresponds with 
features seen in Sakai‘s colonic tissue immunohistochemistry study (224).  
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Interestingly, cytoplasmic anti-Clone 28 and Clone28 correlated negatively with membrane 
c-Src expression (χ2 p=0.008, χ2 p<0.001), confirming the validity of the results regarding 
functional and cellular location e.g. cell membrane being site of Src activation.  
Another negative correlation was observed between nuclear expression of anti-Clone 28 
and ER status (χ2 p<0.001), suggesting that ER negative breast cancer patients are more 
likely to express anti-Clone 28 in the nucleus, valued as the site of inactivation. In vitro 
experiments with c-Src showed that the oestradiol receptor can activate c-Src, proposing 
that c-Src is an initial and integral part of the signalling events mediated by the oestradiol 
receptor (120). 
 
No significant associations were noted between Lyn protein expression, clinico-
pathological features and survival. Other studies report that Lyn plays a part in developing 
chemo-resistance of colon cancer (134), progression of prostate tumours (226) and 
leukaemia (227).  The latter is not surprising, since Lyn is associated as with a number of 
haematopoietic cell surface receptors, cytokine receptors and is a key mediator in several 
pathways of B cell activation (228). These observations are congruent with a role for Lyn 
associated with the development of chemo-resistance.  
Our study does not utilise any hormone resistant, or chemo-resistant tumours; only 
operable tumours obtained at primary diagnosis.  However, a recently published study 
elicit that Lyn was associated with shorter overall survival and that RNAi- knockdown of 
Lyn in breast cancer cell lines inhibited cell migration and invasion, but not proliferation 
(229). The same observation was made in ovarian cancer cell lines. Cell lines with high 
expression of Lyn were particularly sensitive to Dasatinib. Dasatinib inhibited invasion 
significantly, but caused less cell-cycle arrest suggesting Dasatinib should be used in 
combination with other systemic cytotoxic agents (230). 
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Surprisingly, Lck protein expression showed similar results like activated Src kinase 
expressed at tyrosine site 215. Membrane Lck was associated with improved disease 
specific survival in the IHC cohort and not associated with patient mortality.  This was the 
reverse to the observation made with c-Src and activated Y419Src. 
With the knowledge that phosphorylation antibodies are able to detect other Src kinase 
family members, hypothesis was stated that the Y216Src antibody used, could have 
identified Lck as the other SFK member associated with good clinical outcome.  However, 
this observation with Lck membrane expression and good prognosis was only observed in 
a small number of patients and there was no significant correlation detected on chi square 
analysis between membrane Y215Src and membrane Lck expression. Therefore further 
analysis in a much larger cohort is required to verify these results. 
Nevertheless, the positive findings are consistent with results reported by Rody et al. (231).  
Gene array analysis showed that Lck was associated with improved disease free survival 
within an ER positive and ER/ HER2 positive breast cancer subgroup. Though, this study 
proposed that the survival benefit associated with the Lck metagene was at least partly 
related to predicting response of certain breast cancer subgroups to chemotherapeutic 
treatment (231). 
Since Lck is known to be involved in T-cell proliferation (149), it was hypothesised that 
expression of this gene was linked with the presence of lymphocyte infiltration within the 
tumour and interacting with it.  Results of the current study demonstrated that Lck is 
expressed within the tumour, providing evidence that Lck itself may be involved with 
signal transduction in the tumour. Other studies suggest that Syk, a member of another 
non-receptor tyrosine family, is involved in hypoxia driven tumour progression via cross-
talk to Lck in the nucleus (159).  
Lck has been implicated in the mitochondrial apoptosis pathway by controlling the 
expression of pro-apoptotic factor Bak (151). Cell line experiments have shown that a Lck 
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deficiency resulted in resistance to anticancer drugs induced apoptosis.  T-lymphoma cells 
lacking Lck have shown marked resistance to apoptosis reduction upon ionizing radiation 
(232).  A more recent study from the same group adjusted their previous findings that not 
just the lack of Lck caused pronounced apoptosis resistance in response to stimuli of the 
intrinsic pathway; the additional loss of Bak was responsible for reduced sensitivity (233). 
Decreased levels of other pro-apoptotic Bcl-2 family members, e.g. Bax, have been shown 
to correspond to shorter survival in women with metastatic breast cancer.  However, as yet 
no significant correlation between Bak and clinical outcome has been seen within breast 
cancer (234).  
 
Correlations between Ki67 proliferation index, clinical parameters, c-Src, activated Src 
kinase and other Src kinase family members, were also analysed.  Varied evidence exists 
for the association of Ki67 score and other prognostic variables. Some studies show no 
significant association, whereas other report links with patient age, grade, lymph node 
status, tumour size, ER, PgR and EGFR status (235).  Some associations with survival 
have also been seen (236). To measure cell proliferation objectively is difficult and there 
are a number of limitations to Ki67 scoring.  First of all there is no formal agreement on 
the scoring method. Secondly it doesn't account for tumour heterogeneity.  In order to 
address these issues, each tumour was stained and scored each in triplicates as well as 
double scored to ensure reliability of the results. 
The Bloom-Richardson method of grading takes into account tumour proliferation in terms 
of mitotic count.  Not surprising that Ki67 score, a marker of proliferation, highly 
correlated with tumour grade of the breast cancer patients.   
It could be argued that Ki67 should have also correlated with HER2 status. HER2 receptor 
when activated stimulates downstream signalling pathways promoting cellular 
proliferation. Therefore we would expect an increased proliferation rate in tumours with 
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HER2 over-expression. This observation wasn‘t made nor was there a correlation between 
ER and PgR status seen.  
These results demonstrated that Ki67 is a good predictor of clinical prognostic variables 
within the ER positive patient subgroup, where cells are stimulated for proliferation by the 
normal expected pathways whereby oestrogen binds to the ER stimulating cell division.  
Ki67 score was not shown to predict patient outcome even within the ER positive group.   
It is well established that Src kinase plays a fundamental part in controlling cell 
proliferation (237).  Ki67 correlated highly with c-Src and activated Y419Src kinase 
expression in the nucleus. Increased proliferation could possibly confer the poorer survival 
associated with high expression of c-Src and activated Y419Src. However, no significant 
association was detected between Ki67 and disease specific survival. 
 
With this all-round IHC study we demonstrated in a large mature cohort that the protein 
Src kinase and its activated forms are expressed in invasive breast cancer in every cellular 
compartment. We determined that not only protein activation, but also site of activation 
and cellular location play an important role in breast cancer survival outcome. Cytoplasmic 
c-Src and membrane Y419Src expression were associated with poor clinical outcome, 
whereas nuclear and cytoplasmic Y215Src expression was associated with longer disease 
specific survival. Only Y215Src kinase was independent on multivariate analysis and 
seemed promising as a potential biomarker. Inactive or partially active Src kinase 
expression had no association with survival at any cellular location, nor did SFK member 
Lyn. However, membrane Lck expression was significantly associated with improved 
disease specific survival. Ki67 expression revealed that Src kinase was higher expressed in 
patients with less differentiated, more aggressive tumours. 
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Evaluation of the consequences Src inhibitor may have on Src expression, its location and 
activation sites, is of importance to ensure none of these molecular bio-agents is used 
unsafely in the clinical setting. 
  
 
 
 
CHAPTER 4 
 
 
 
 
EFFECTS OF SRC INHIBITOR DASATINIB 
ON SRC KINASE FAMILY MEMBER 
EXPRESSION AND PHOSPHORYLATION 
STATUS IN BREAST CANCER CELL LINES
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4.1 Introduction 
The previous chapter elicits that clinical outcome of breast cancer patients was linked to 
protein expression of Src kinase family members. Elevated cytoplasmic c-Src and 
membrane Y419Src kinase expression was associated with shorter disease specific 
survival, whereas high cytoplasmic Y215Src and membrane Lck expression was associated 
with longer disease specific survival. These results highlight not only that over-expression 
of different activation sites can be associated with different clinical outcome, but also over-
expression on different cellular locations could influence downstream effectors of Src 
kinase. 
Additionally it was noticed that cytoplasmic Y215Src kinase expression had a potentiated 
effect on good prognosis in triple negative breast cancer subgroup. 
With Src inhibitors being trialled clinically, there is a requirement to establish which 
phosphorylation site they target. If subsequent experimental data demonstrate Src kinase 
inhibitors target Y215, these drugs could be potentially harmful to the specific subgroup of 
patients, who express phosphorylation at this site. Caution should therefore be applied 
before these drugs are administered.  
We therefore utilised four different breast cancer cell lines representing the breast cancer 
patients‘ subgroups (ER pos/HER2 neg, ER pos/HER2 pos, ER neg/HER2 neg, ER 
neg/HER2 pos) to investigate the effects of the Src kinase inhibitor Dasatinib on 
expression levels and cellular location of Src, activated Y419Src, activated Y215Src, Lck 
and activated Y861 FAK, a downstream effector of c-Src. 
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4.2 Methods 
4.2.1 In-vitro studies 
Materials used within this chapter are listed in appendix 3. 
4.2.1.1 Culturing of breast cancer cell lines 
MCF-7, MDAMB 231 and MDAMB453 (American Tissue Culture Collection (ATCC), 
European Tissue Culture Collection (ETCC), Sigma) and MCF-7HER2 (Rachel Schiff, 
USA) were the cell lines utilised in the current study. Compared to MCF-7 cell line, HER2 
was transfected and upregulated, which is clearly demonstrated by Western blotting (figure 
4.1). 
Figure 4.1: Upregulated HER2 receptor in MCF-7 cell line 
 
Figure 4.1 clearly demonstrates by Western Blotting an absent/low HER2 expression in 
MCF-7 cell line (left) compared to upregulated HER2 expression (right). This Western 
Blot was kindly provided by Jaclyn Long. 
Chapter 4 Effects of Src inhibitor Dasatinib 225 
 
These four cell lines were chosen to represent each subgroup of breast cancer patients (ER 
positive/ HER2 negative, ER positive/ HER2 positive, ER negative/ HER2 negative and 
ER negative/ HER2 positive). Each cell line varies in different expression levels of the 
human epidermal growth factor receptor group (HER1-4) as listed in table 4.1. 
Table 4.1: Breast cancer cell lines and their ER/HER2 status 
Cell line ER status HER1 status 
(EGFR) 
HER2 status HER3 
status 
HER4 
status 
MCF-7 Positive Negative Negative (weak positive) Positive Negative 
MCF-7HER2 Positive Negative Positive (up-regulated) Positive Negative 
MDAMB231 Negative Positive (weak) Negative Negative Negative 
MDAMB453 Negative Negative Positive Positive Negative 
Table 4.1 displays all breast cancer cell lines used in this study and their oestrogen 
(ER) and human epidermal growth factor receptor (HER) status. 
Cell lines MCF-7, MDAMB231 and MDAMB 453 were cultivated in Dulbecco‘s 
Modified Eagle Media (DMEM/FM) with additional heat-inactivated foetal calf serum 
(10%) (FS), 2mM L-glutamine (G) and penicillin/streptomycin (50units/ ml; 50 µg/ ml) 
(P/S) (details in appendix 3).  
Cell line MCF7HER2 was cultivated in DMEM/HER2 containing 4500mg/L Glucose and 
additional heat-inactivated foetal calf serum (10%) (FS), penicillin/streptomycin (50units/ 
ml; 50 µg/ ml) (P/S) and insulin (10mg/ml). Cells were incubated in T-75 flasks (Fisher) at 
37ºC in 5% CO2 atmosphere.  
Cells were washed twice with warm Hank-Buffered Saline solution (HBBS) and incubated 
in serum- and phenol free medium (DMEM/SS) overnight before any drug treatment was 
applied. 
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4.2.1.2 Counting of Cells 
Flasks were all seeded at 2x10
6
 cells.  Cells were trypsinised and neutralised with the 
equivalent amount of DMEM. The cell suspension was then transferred into a 50 ml 
centrifuge tube (Fisher) and centrifuged at 14000 rpm for 5 minutes. The supernatant was 
removed and the cell pellet resuspended in 1 ml of warm DMEM. 10 µl were removed, 
added to 90 µl of tryptan blue (1:10 dilution) in an Eppendorf Cup and thoroughly mixed. 
A small amount of this mixture was applied onto a haemocytometer. Cells in all four large 
squares were counted under light microscopy (figure 4.2). The average of the cell count 
was then multiplied by hundred (1:10 tryptan blue dilution).  
Figure 4.2: Neubauer haemocytometer 
 
Figure 4.2 shows a Neubauer haemocytometer. Cell suspension is placed on top of the 
grid. A cover slip is laid above and the haemocytometer is positioned under the light 
microscope. The cells are then counted in each of the 4 corner squares (marked with 1, 
2, 4 and 5). 
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4.2.2 Effect of steroid exposure and withdrawal on total Src kinase  
This experiment was conducted on all four cell lines to determine the effect of exposure 
and withdrawal of oestrogen on Src kinase activity. To deprive the breast cancer cell lines 
of hormones, charcoal-stripped foetal calf serum was used, supplying all the necessary 
growth factors, but holding insignificant amounts of steroid concentrations. Two million 
cells were seeded into 10 ml of DMEM and grown in T-75 flasks at 37 ºC in 5% CO2 
atmosphere. When the cells reached about 70% confluence, they were washed twice with 
warm HBBS before they were exposed to the different conditions. Each cell line was 
exposed to three different media in duplicates: DMEM containing 10% fetal calf serum 
(FM), serum free DMEM (SS) and steroid depleted DMEM containing 10% charcoal-
stripped serum (CS) (details in appendix 3). After 48 hours exposure, cell lysates were 
prepared and Western Blots were performed as described below. 
4.2.2.1 Cell lysis for Western Blotting 
After incubation with designated drug treatment medium and exposure time, the solution 
was removed and cells were carefully washed twice with ice-cold HBBS. Immediately 
before application, the lysis buffer was diluted 1:10 and 1 mM of phenylmethlysulfonyl 
fluoride (PMSF), a serine protease inhibitor, was added. The prepared buffer was stored on 
ice at all times. 500 µl of buffer was added to each flask and incubated on ice. After 5 
minutes, cells were scraped from the floor of the flask and removed. The cell lysate was 
transferred into a labelled 1.5 ml Eppendorf Cup. All samples were centrifuged at 14000 
rpm for 15 minutes at 4 ºC to separate the protein from cell debris. The protein containing 
supernatant is removed and stored at -70 ºC. The experiment for each cell line was 
performed twice. Therefore, there were four samples of each cell line available for Western 
Blotting. Western Blots for total Src on all four cell lines was carried out as described in 
method section in chapter 3. 
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4.2.3 Quantification of SRC mRNA expression in cell lines 
Materials used  for cell line RT-PCR are listed in appendix 2 
4.2.3.1 RNA isolation 
Two flasks of each cell line were grown till they reached 70% confluence. 2 mls of 
TRIZOL
®
 were added to each flask and incubated at room temperature for 5 minutes. 1 ml 
each was then pipetted into Eppendorf Cups and immediately frozen in -20ºC. Total 
mRNA was extracted using the TRIZOL® method according to manufacturer‘s protocol. 
RNA quantity and quality was assessed by UV spectrometry (GeneQuant machine) and by 
examination of rRNA bands after agarose gel electrophoresis. Only samples, which 
showed both 18S band and a stronger expressed 28S band, were included in this study 
(figure 2.1). 
4.2.3.2 cDNA synthesis 
To guarantee no other DNA was present, DNA-free DNAse treatment and removal reagent 
kit was added. Samples were incubated for 30 min at 37°C. To ensure the same amount of 
cDNA being used for quantification of mRNA, a starting concentration of 2000ng of tRNA 
was applied for each sample. Oligo (dt) primers (50ng) were used for First Strand cDNA 
Synthesis using SuperScript 
TM
 II RT according to manufacturer‘s instructions. Before 
using cDNA for PCR amplification, 2 units of RNase H were added to samples and 
incubated for 20 minutes at 37°C. Quality of cDNA was assessed by using a PCR control 
run with human ß–actin. Product bands were assessed by examination of agarose gel 
electrophoresis. Only samples, which showed equal product bands at 330 bp, were utilised 
(figure 2.2). 
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4.2.3.3 Quantification of mRNA 
Real-time quantative PCR was performed using an ABI Prism 7900 Sequence Detection 
System (Applied Biosystems, UK) and TaqMan® Gene Expression Assays (table 2.11, 
PCR chapter). For the TaqMan® Gene Expression Assays the manufacturer‘s protocol 
with recommended 40 rounds of amplification was applied. Thermal cycler condition were 
50°C for 2 min, 95°C for 10 min followed by 40x 95°C for 15 sec and 60°C for 1 min. 
Product melting curve analysis and gel electrophoresis experiments were used to ensure 
that only one product of the expected size was amplified. 
Negative controls (RNAse/DNAse free H2O and negative RTPCR sample) for each primer 
were included on every 96 well PCR plate (Applied Biosystems, UK). Quantitative values 
were obtained from the threshold cycle (Ct value) at which the increase TaqMan® probe 
fluorescent signal associated with an exponential increase of each individual PCR product 
reaching a fixed threshold value. Each individual primer had a fixed threshold Ct value. 
These fixed threshold values were used for every cDNA sample (table 2.1). 
As housekeeping gene, HPRT was used for evaluation of the different mRNA expression 
levels. Data were analysed as described in previous PCR chapter. All samples were 
measured in duplicates. 
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4.2.4 Stimulation and Inhibition of Src kinase, activated Src kinase, SFK 
members and downstream substrate Y861FAK 
Prior to any drug treatment all flasks were washed twice with HBBS and exposed to serum 
free DMEM (SS) overnight. 
4.2.4.1 Drugs 
- Epidermal Growth Factor 
Epidermal growth Factor (EGF) binds onto the Epidermal Growth Factor Receptor (HER1) 
causing its phosphorylation and activation of the growth factor receptor pathways. The cell 
line MDAMB 231, the only EGFR positive cell line, was stimulated with 10 nM EGF. 
This concentration was verified in previous studies performed in our group to be the most 
effective concentration. A stock solution of 1.6 µM was prepared and stored at -20 ºC 
(details in appendix 3). Exposure time to EGF was 30 minutes.  
- Heregulin α 
Heregulin α (HRG), a ligand for HER3 or HER4, binds to the HER3 or HER4 receptor 
resulting in its phosphorylation to form homo- or heterodimers with each other or trigger 
activation downstream signalling pathways. Cell lines MCF7 and MCF7HER2 are HER3 
positive and therefore treated with 10 nM HRG. As with EGF, this concentration was 
determined in previous studies. A stock solution of 1.42 µM was prepared and stored at -20 
ºC (details in appendix 3). Exposure time to HRG was 30 minutes.  
- Dasatinib 
Dasatinib (DASA), a small molecule ATP- competitive multikinase inhibitor, causes cell 
cycle arrest, blocks cell proliferation, induces apoptosis and inhibits metastasis. Dasatinib 
binds onto SH1 domain of Src and inhibits its kinase activity. Three cell lines were treated 
with 100 nM DASA. This concentration, used in previous prostate cancer cell line studies 
in our group, showed complete inhibition of phosphorylation and activation of Src and 
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downstream protein FAK (90). A stock solution of 10 mM was prepared and stored at -20 
ºC (details in appendix 3). Exposure time to DASA was 60 minutes.  
4.2.4.2 Drug Treatments 
This drug treatment experiment was only performed in duplicates on MCF7, MCF7HER2 
and MDAMB 231 breast cancer cell lines due to absence of total Src kinase expression in 
the cell line MDAMB 453 on Western Blotting. This was repeated twice. 
Two million cells were grown in T-75 flasks at 37 ºC in 5% CO2 atmosphere until they 
reached about 70% confluence.  
Table 4.2: Overview of different drug treatments, exposure time and concentration 
Flasks Flask  
No 
Stimulation Exposure Time & 
Drug Concentr. 
Inhibition Exposure Time & 
Drug Concentr. 
Cell line 1 & 2 - - - - 
Cell line 3 & 4 - - DASA 60 min & 100nM 
Cell line 5 & 6 EGF/ HRG 30 min & 10nM - - 
Cell line 7 & 8 EGF/ HRG 30 min & 10nM DASA 60 min & 100nM 
Table 4.2 displays the different prepared flask. Epidermal growth factor (EGF) or 
Heregulin (HRG) was used for stimulation depending on the cell line’s receptor status. 
Dasatinib (DASA) was applied for inhibition of Src kinase. Flask 1 & 2 (untreated= 
UT) were used as control flasks. 
After overnight incubation in serum free DMEM, the medium was removed and cells were 
washed twice with warm HBBS before 10 ml of correctly prepared media (table 4.2) were 
then applied. Cell lines were exposed to single or consecutive drug treatments: 10nM HRG 
or 10 nM EGF (Flask 5 & 6), 100 nM DASA (Flask 3 & 4) or a combination of both (Flask 
7 & 8). To ensure experimental uniformity, each flask had to contain the same 
concentration of BSA/PBS (HRG drug preparation), Acitic acid/BSA/PBS (EGF drug 
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preparation) and DMSO (DASA drug preparation) (table 4.3). Flasks 1 & 2 were incubated 
in fresh 10 ml of serum free medium for 60 min including 2 ml of DASA and 200 µl of 
HRG control.  
Table 4.3: Overview of contents of each flask 
Flask 
No 
Drug treatment and 
exposure time 
DASA 
1 nM 
DASA 
control 
HRG/EGF 
1 µM 
HRG/EGF 
control 
Serum free 
DMEM 
1 & 2 
 
UT 
(60 min) 
- 2 ml 
 
- 200 µl 
 
17.8 ml 
3 & 4 DASA 100 nM 
(60 min) 
2 ml 
 
- - 200 µl 
 
17.8 ml 
5 & 6 EGF/ HRG 10nM 
(30 min) 
 2 ml 
 
200 µl 
 
- 17.8 ml 
7 & 8  
 
EGF/ HRG 10 nM 
(30 min) 
and DASA 100 nM 
(60 min) 
 
 
2 ml 
 
 200 µl 
 
 
 19.8 ml 
 
18 ml 
Table 4.3: Overview of the different composition of drug treatments and controls for 
individual flasks. Dasatinib treatment: 2 µl of 10 mM stock concentration of dasatinib 
into 20 ml of serum free DMEM to achieve a concentration of 1 nM DASA. DASA 
control: 2 µl of DMSO into 20 ml of serum free DMEM. Heregulin treatment: 422 µl of 
HRG stock concentration was added to 176.4 µl of serum free DMEM to achieve a 
concentration of 1 µM HRG. HRG control: 0.1% BSA/PBS solution. EGF treatment: 
378 µl of EGF stock concentration was added to 228 µl of serum free DMEM to achieve 
a concentration of 1 µM of EGF. EGF control: 0.1% BSA/acetic acid plus PBS solution  
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4.2.4.3 Formation of Cell line Cell Pellets 
After incubation with designated drug treatment medium and exposure time, the solution 
was removed and cells were carefully washed twice with warm HBBS. 3 ml of trypsin was 
added to the flasks and incubated for 5 minutes at 37 ºC in 5% CO2 atmosphere. To 
inactivated trypsin was neutralised with the equivalent amount of DMEM. The 6 ml 
suspension was pipetted gently up and down to dislodge all cells, subsequently transferred 
into a 15 ml centrifuge tube (Fisher) and centrifuged at 10000 rpm for 10 minutes. This 
was followed by the supernatant being discarded and the cell pellet re-suspended in 10 ml 
of DMEM. Each centrifuge tube was placed next on ice and after the experiment was 
completed transferred to the in-house pathology department for formalin fixation, 
imbedding in individual paraffin wax-block and cut in sections, placed on salinised glass 
slides, ready for immunohistochemistry staining.  Each cell line experiment was repeated. 
Therefore 4 samples per cell line and drug treatment were available for analysis. 
4.2.4.4 Clot Formation of Cell line Cell Pellets for Immunohistochemistry 
10 ml of drug treated solution is transferred from the 15 ml centrifuge tube into 25 ml 
universal container (McQuilkin and Co) adding 15 ml of normal saline to wash the cells. 
The containers are placed in the centrifuge for 5 minutes at 1500 rpm. The supernatant is 
then carefully discarded leaving a cell button at the bottom of the universal container. 2-3 
drops of fridge stored human plasma is put on top of the cell button, combined with the cell 
pellet using a plastic pipette (Alpha laboratories) and subsequently mixed by moderate 
shaking of the container. Afterwards 1-2 drops of thrombin working solution is applied, 
gently agitated to allow a clot to form. Then formalin is added slowly to avoid 
fragmentation of the clot. Fixation of the clot in formalin occurs overnight before being 
placed into a correctly labelled cell block cassette and taken to histopathology for 
imbedding in a paraffin wax block. 
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4.2.4.5 Immunohistochemistry on Cell line Cell Pellets 
Indirect immunohistochemistry was performed with the following antibodies: c-Src, 
Y416Src, Y216Src, Lck and Y861FAK.  Reagents, solutions and methods used are 
described in method section of chapter 3. The protocol for antibody Y416Src had to be 
slightly modified due to expression variation. This was most likely caused by Lot change 
of the product. An overview of the primary antibodies used is given in the table below. 
Table 4.4: Overview of the primary antibodies used for cell pellet IHC staining 
Protein Antibody Antigen 
Retrieval 
H2O2 
Conc. 
Horse 
Serum 
Conc. 
Antibody 
Dilutions 
Incubation 
Time and 
Temp 
Total Src Rabbit 
Cell 
Signalling 
Citrate 
Buffer 
pH 6.0 
3% 1.5% 1:200 60 min at 
room temp 
Y416Src Rabbit 
Cell 
Signalling 
TE 
Buffer 
pH 9.0 
3% 5% 1:50 Overnight at 
4
o
C  
Y216Src Rabbit 
Santa Cruz 
Citrate 
Buffer 
pH 6.0 
3.0% 5% 1:25 Overnight at 
4
o
C 
Lck Rabbit 
Cell 
Signalling 
TE 
Buffer  
pH 8.0 
3.0% 5% 1:50 60 min at 
room temp 
Y861FAK Rabbit 
Invitrogen 
Citrate 
Buffer 
pH 6.0 
3.0% 5% 1:300 Overnight at 
4
o
C 
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Table 4.4 reveals details of the primary antibodies used to detect total Src, its activated 
forms (Y215, Y419), the SKF member protein Lck and activated downstream protein 
Y861FAK, a marker for Src activation. Further information is given regarding antibody 
source, antigen retrieval method, blocking reagent concentrations (H2O2 and Horse 
Serum), antibody dilutions, incubation time and temperature are all listed above. 
Citrate Buffer= 10mM Citrate buffer, TE Buffer= 1 mM EDTA, 5 mM Tris buffer at pH 
8.0 and pH 9.0. Both solutions were preheated in the microwave for 13.5 min to a 
temperature of 96
 o
C before slides were pressure cooked for 5 min with a cool down 
period of 20 min. 
Each IHC run had a negative and positive control, full section and tissue microarray 
control included to ensure no false positive or negative staining of the cell pellets. 
4.2.4.6 Immunohistochemistry Cell Pellet Scoring 
Each cell line cell pellet was scored according to the Histoscore-method, as already 
described in chapter 3. Protein expression was assessed at the nuclear, cytoplasmic and 
membrane location. 
Conformity of the two observers‘ scoring was again assessed by calculating intra- 
(variation in individual scoring) and inter- (variation between the observers) class 
coefficients- as described in the previous chapter. Comparison of both JE and BE scores 
generated ICCC scores between 0.80-0.96, as shown below in table 4.5. 
Table 4.5: ICCC scores for nuclear, cytoplasmic and membrane expression 
ICCC Nuclear Cytoplasm Membrane 
All antibodies 0.95 0.80 0.96 
Table 4.5: ICCC scores for all double-scores of nuclear, cytoplasmic and membrane 
protein expression. ICCC scores above 0.8 are considered as excellent 
Cell line pellets were independently scored by two observers (BE and JE) for nuclear, 
cytoplasmic and membrane staining of total Src, Y416Src, Y216Src, SFK member Lck and 
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Y861FAK. A semi-quantitative weighted histoscore method was applied. Agreement 
between scores was measured using inter-class correlation coefficients. 
ICCCs were performed to verify consistency between scorers. All nuclear, cytoplasmic and 
membrane double scores were analysed together, because of the small sample number. 
Scattered plots for these nuclear, cytoplasmic and membrane double-scores are displayed 
below. To confirm no bias between scorers was present Bland-Altman plots were 
constructed (figure 4.3). 
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Figure 4.3: Scattered Plots and Bland-Altman Plots for cell pellet double-scores 
 
 
 
 
 
 
 
 
Figure 4.3: Scattered plots and Bland-Altman plots for nuclear, cytoplasmic and 
membrane expression based on scorer-observer variation. The range and distribution of 
scores confirm appropriate scorer-observer correlation. 
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4.2.4.7 Statistical Analysis of Immunohistochemistry Staining 
For statistical analysis the same statistical software package (SPSS 15.0 Inc., Chicago, IL, 
USA) was used as in chapter 3.  
Basic descriptive statistics were performed to calculate frequencies, means, median and 
inter-quartile ranges for all the histoscores for each antibody. These values were then used 
to establish appropriate cut-off points to define with either low or expression of the protein. 
Correlations between expression of different proteins and a protein‘s expression level at a 
certain cellular compartment in different cell lines were evaluated with a general linear 
model via a univariate analysis using Post Hoc multiple comparisons for observed means. 
Equal variance was calculated with Dunnett‘s and Fisher‘s LSD test. Dunnett's test 
compares group means. Its goal is to identify groups whose means are significantly 
different from the mean of a reference group. It tests the null hypothesis that no group has 
its mean significantly different from the mean of the reference group. Fisher‘s LSD (Least 
Significant Difference) test was used to compare the mean of one group with the mean of 
another one. It is different to the Bonferroni and Dunnett methods. Fisher's LSD test does 
not account for multiple comparisons. It is basically a set of individual t-tests giving a 
more accurate value for the SD (significant difference). 
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4.3 Results 
4.3.1 Expression of Src kinase after Steroid Exposure and Withdrawal in 
the breast cancer cell lines 
Initially we investigated if Src kinase was expressed in all four breast cancer cell lines in 
order to conduct further inhibition and stimulation cell line experiments. 
The following breast cancer cell lines 
MCF7: ER positive/ HER2 negative 
MCF7HER2: ER positive/ HER2 positive (upregulated) 
MDAMB231: ER negative/ HER2 negative 
MDAMB453: ER negative/ HER2 positive 
were exposed for 48 hours to three different media with various steroid concentrations. 
This experiment highlighted that cell line MDAMB 453 did not express Src kinase in 
measurable concentrations (figure 4.4). The experiment was performed in duplicates. 
Western Blotting was repeated 4 times to verify this discovery. To strengthen this 
observation mRNA expression of SRC was measured in those cell lines. And again there 
was a marked difference between the ER negative/ HER2 positive (MDAMB453) cell line 
compared to the other three (p= 0.031, figure 4.5). 
Because of these findings, experiments on this cell line were halted at this point. 
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Figure 4.4: Western Blots for c-Src expression after steroid exposure and withdrawal 
 
Figure 4.4: All four cell lines were exposed to various culture media; FM: medium 
containing full foetal calf serum, SS: serum starved medium, CS: steroid depleted, 
charcoal-stripped medium. Src kinase expression was examined by Western Blotting. c-
Src is expressed at 60 kDa. β–tubulin was used as protein loading control (48 kDa). No 
expression of c-Src was detected in cell line MDAMB 453. 
Figure 4.5: SRC mRNA expression in different cell lines 
 
Figure 4.5 displays the mean mRNA expression of SRC in all four breast cancer cell 
lines (untreated, grown in full medium). There is a significant difference in Src 
expression between the cell line MDAMB453 and all others. 
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4.3.2 Drug stimulation and inhibition experiments in breast cancer cell 
lines 
MDAMB231, MCF7 and MCF7HER2 cell line were used to examine the effect of 
EGF/Heregulin and Src kinase inhibitor Dasatinib on protein expression of c-Src, 
Y419Src, Y215Src, Y861FAK and Lck and their cellular location in cell pellets. The same 
antibodies employed in the previous IHC chapter were used in these experiments. 
4.3.2.1 Differences in basal protein expression between cell lines in cell pellets 
Firstly we wanted to compare expression profiles of each individual cell line when 
untreated to investigate if there is a basal difference on protein expression present. 
c-Src expression 
There was no nuclear c-Src expression observed in MDAMB231 and MCF7, but a slight 
increased expression in the HER2 upregulated MCF7 cell line (difference p=0.005, figure 
4.6). 
The lowest c-Src expression in the cell cytoplasm was seen in MCF7 cell line, followed by 
the ER neg/HER2 neg cell line (MDAMB231) with no statistical difference regards 
expression (p=0.247). Again MCF7HER2 cell line had the highest cytoplasmic c-Src 
expression with a statistical difference of p<0.001 (MCF7) and p=0.003 (MDAMB231) 
(figure 4.6, picture 4.1). 
The highest membrane c-Src expression was noted in the ER negative (MDAMB231) 
(picture 4.1) compared to the ER positive cell line (MCF7) (p=0.001). MCF7HER2 had 
less c-Src expressed in the membrane compared to MDAMB231, with a significant 
difference of p=0.004. But there was no significant difference in expression between the 
ER positive cell lines (p=0.549) (figure 4.6) 
Nuclear and cytoplasmic c-Src expression was highest in HER2 upregulated ER positive 
cell line, whereas membrane c-Src expression most elevated in the ER negative cell line. 
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Least c-Src expression at all cellular locations was observed in the ER positive/HER2 
negative cell line (picture 4.1).  
Figure 4.6: Differences in basal nuclear, cytoplasmic and membrane c-Src expression 
 
 
 
Figure 4.6: Nuclear, cytoplasmic and membrane c-Src expression in the ER 
negative/HER2 negative cell line MDAMB231, ER positive/HER2 negative cell line 
MCF7 and ER positive/ HER2 positive (upregulated) MCF7HER2 cell line. Each figure 
demonstrates protein expression differences between those cell lines when untreated; º 
no significant statistical difference p value > 0.05,  * p< 0.05,  ** p< 0.01,  *** p< 
0.005. 
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Picture 4.1: IHC staining with c-Src on untreated cell line cell pellets 
 
 
 
 
 
 
 
Picture 4.1: IHC pictures from cell pellets of the cell line MDAMB231, MCF7 and 
MCF7HER2 stained with c-Src antibody (1:200, Cell Signalling); demonstrating the 
differences in staining intensity and distribution within the cells. Strongest membrane 
staining was seen in MDAMB231, strongest nuclear and cytoplasmic in MCF7HER2 
and weakest IHC staining of all cellular locations in MCF7 cell line. 
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Y419Src expression  
None of the three cell lines expressed Y419Src in the nucleus (Histoscore 0, p=1.0, picture 
4.2). 
Phosphorylated activated Y419Src was highest expressed in the cytoplasm in 
MDAMB231, followed by MCF7 and least in MCF7HER2 cell line. The only statistical 
significant expression difference was noticed between ER neg/HER2 neg and ER 
pos/HER2 pos cell lines (p=0.007, figure 4.7). 
Activated membrane Y419Src was again highest expressed in the ER neg/HER2 neg cell 
line. This time MCF7HER2 exhibit a higher protein expression than MCF7, but without 
any statistical significance (p=0.214, figure 4.7). The only noteworthy result between 
membrane Y419Src expression involved cell line MDAMB231 and MCF7 (p=0.014, 
figure 4.7) 
Figure 4.7: Differences in basal cytoplasmic and membrane Y419Src expression 
 
Figure 4.7: Cytoplasmic and membrane Y419Src expression in the ER negative/HER2 
negative cell line MDAMB231, ER positive/HER2 negative cell line MCF7 and ER 
positive/ HER2 positive (upregulated) MCF7HER2 cell line. Each figure demonstrates 
Y419Src protein expression differences seen in cell pellets obtained of those cell lines at 
an untreated phase; º no significant statistical difference p value > 0.05,  * p< 0.05,  ** 
p< 0.01,  *** p< 0.005. 
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Picture 4.2: IHC staining with Y416Src on untreated cell line cell pellets 
 
 
 
 
 
 
Picture 4.2: IHC pictures from cell pellets of the cell line MDAMB231, MCF7 and 
MCF7HER2 stained with Y416Src antibody (1:50, Cell Signalling); demonstrating the 
differences in staining intensity and distribution within the cells. Strongest cytoplasmic 
and membrane staining was seen in the ER neg/HER2 neg cell line (MDAMB231).  
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Y215Src expression 
Phosphorylated activated Y215Src expression showed no statistical difference in basal 
expression between all three cell lines in the nucleus and cytoplasm (table 4.6). Nuclear 
and cytoplasmic Y215Src expression pattern was equal in MDAMB231 and MCF7HER2, 
with least Y215Src protein expression in MCF7 (figure 4.8).  
However, membrane Y215Src expression showed a significant difference between ER 
negative to ER positive cell lines. MDAMB231 showed the least Y215Src membrane 
expression compared to MCF7HER2, which had the highest expression (p=0.006). There 
was no statistical difference in membrane expression between the two ER positive cell 
lines (p=0.495) 
Table 4.6: Statistical overview of expression differences with Y215Src antibody 
Nuc Y215Src (p value) MCF7  MCFHER2 
MDAMB231 0.391 0.961 
MCF7HER2 0.298  
Cytoplasmic Y215Src  MCF7  MCFHER2 
MDAMB231 0.402 0.839 
MCF7HER2 0.520  
Table 4.6 demonstrates that there was no statistically significant difference (p>0.05) 
between nuclear and cytoplasmic Y215Src expression within the three cell lines. 
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Figure 4.8: Basal Y215Src expression difference in cell line cell pellets 
  
 
Figure 4.8: Nuclear, cytoplasmic and membrane Y215Src expression in the ER 
negative/HER2 negative cell line MDAMB231, ER positive/HER2 negative cell line 
MCF7 and ER positive/ HER2 positive (upregulated) MCF7HER2 cell line. Each figure 
demonstrates protein expression differences between those cell lines when untreated. 
Same nuclear and cytoplasmic expression pattern is noted between the cell lines. 
Whereas membrane Y215Src expression is lowest in the ER neg/HER2 neg cell line 
compared to ER positive cell lines. º no significant statistical difference p value > 0.05,  
* p< 0.05,  ** p< 0.01,  *** p< 0.005. 
Chapter 4 Effects of Src inhibitor Dasatinib 248 
 
Picture 4.3: IHC staining with Y216Src antibody on untreated cell line cell pellets 
 
 
 
 
 
Figure 4.3: IHC pictures from cell pellets of the cell line MDAMB231, MCF7 and 
MCF7HER2 stained with Y216Src antibody (1:25, Santa Cruz); demonstrating the 
differences in staining intensity and distribution within the cells. Strongest membrane 
staining was observed in the ER pos/HER2 upregulated cell line (MCF7HER2).  There 
was no difference seen in Y215Src nuclear and cytoplasmic protein expression within 
those three cell lines. 
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Y861FAK expression 
Nuclear activated Y861FAK protein expression was observed highest in the ER 
positive/HER2 positive cell line (MCF7HER2), followed by the ER negative/ HER2 
negative (MDAMB231) and least detected in the MCF7 cell line. There was a statistically 
significant difference in expression noticed between MCF7HER2 and MDAMB231 
(p=0.003) and between MCF7HER2 and MCF7 (p<0.001). No significant expression 
difference was present between MDAMB231 and MCF7 (p=0.131, figure 4.9). 
Similar expression pattern between the cell lines was seen with cytoplasmic Y861FAK 
expression, although with lower histoscores. Highest cytoplasmic Y861FAK protein 
expression was found in MCF7HER2, followed by MDAMB231 and least detected in the 
MCF7 cell line. Statistically significant p-values were between MCF7HER2 and 
MDAMB231 (p=0.001) and between MCF7HER2 and MCF7 (p<0.001). No significant 
expression difference was again present between MDAMB231 and MCF7 cell line 
(p=0.330, figure 4.9). 
IHC picture 4.4 clearly shows a significantly lower membrane Y861FAK expression in the 
ER neg/HER2 neg cell line compared to ER positive cell lines (MDAMB231/MCF7 
p=0.026 and MDAMB231/MCF7HER2 p<0.001). 
MCF7HER2 had the highest nuclear, cytoplasmic and membrane Y861FAK protein 
expression. ER negative cell line expresses activated membrane Y861FAK in a smaller 
amount than ER positive cell lines. 
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Figure 4.9: Differences in basal expression of nuclear, cytoplasmic and membrane 
Y861FAK on cell pellets 
 
 
 
 
Figure 4.9: Nuclear, cytoplasmic and membrane Y861FAK expression in the ER 
negative/HER2 negative cell line MDAMB231, ER positive/HER2 negative cell line 
MCF7 and ER positive/ HER2 positive (upregulated) MCF7HER2 cell line. Each figure 
exhibits protein expression differences between those cell lines. Same nuclear and 
cytoplasmic expression pattern is noted within the three cell lines. Whereas membrane 
Y861FAK expression is lowest in the ER neg/HER2 neg cell line compared to ER 
positive cell lines. º no significant statistical difference p value > 0.05,  * p< 0.05,  ** 
p< 0.01,  *** p< 0.005. 
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Picture 4.4: IHC staining with Y861FAK on untreated cell line cell pellets 
 
 
 
 
Picture 4.4: IHC pictures from cell pellets of the cell line MDAMB231, MCF7 and 
MCF7HER2 stained with Y861FAK antibody (1:300, Invitrogen); demonstrating the 
differences in staining intensity and distribution within the cells. Strongest nuclear, 
cytoplasmic and membrane staining was observed in the ER pos/HER2 upregulated cell 
line (MCF7HER2). Least membrane staining was present in the ER neg/HER2 neg cell 
line. 
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Lck expression 
There was no nuclear, cytoplasmic or membrane Lck protein expression detected in 
MDAMB231 (ER neg/HER2 neg) and MCF7 (ER pos/HER2 neg) cell line (histoscores 0, 
figure 4.10). 
However, there was a small amount of nuclear Lck expression evident in the HER2 
upregulated ER positive cell line (MCF7HER2). A higher Lck protein expression was 
observed in the cytoplasm and membrane of the MCF7HER2 cells (figure 4.10, picture 
4.5). 
There was no statistical significant difference in nuclear and membrane protein expression 
within the three cell lines (table 4.7). The only significant differences were apparent in the 
cytoplasmic compartment between MCF7HER2 and the other cell lines (both p=0.012). 
Table 4.7: Statistical overview of basal expression of Lck in untreated cell lines 
Nuclear Lck (p value) MCF7  MCFHER2 
MDAMB231 1.0 0.490 
MCF7HER2 0.490  
Cytoplasmic Lck  MCF7  MCFHER2 
MDAMB231 1.0 0.012 
MCF7HER2 0.012  
Membrane Lck  MCF7  MCFHER2 
MDAMB231 1.0 0.490 
MCF7HER2 0.490  
Table 4.7 demonstrates that there was no statistically significant difference (p>0.05) 
between nuclear and membrane Lck expression within the three cell lines. Only 
cytoplasmic Lck expression in MCF7HER2 cell line was significantly different to the 
other cell lines’ protein expression. 
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Figure 4.10: Nuclear, cytoplasmic and membrane basal Lck expression in cell lines 
 
 
 
 
 
Figure 4.10: Nuclear, cytoplasmic and membrane Lck expression in the ER 
negative/HER2 negative cell line MDAMB231, ER positive/HER2 negative cell line 
MCF7 and ER positive/ HER2 positive (upregulated) MCF7HER2 cell line. There was 
no nuclear, cytoplasmic and membrane Lck expression detected in MDAMB231 and 
MCF7 cell line. The only significant expression difference was seen with MCF7HER2 in 
the cytoplasm; º no significant statistical difference p value > 0.05,  * p< 0.05,  ** p< 
0.01,  *** p< 0.005. 
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Picture 4.5: IHC staining with Lck antibody on untreated cell line cell pellets 
 
 
Picture 4.5: IHC pictures from cell pellets of the cell line MDAMB231, MCF7 and 
MCF7HER2 stained with Lck antibody (1:50, Cell Signalling); demonstrating the 
differences in staining intensity and distribution within the cells. Stromal staining was 
present in the MDAMB231 and MCF7 cell pellet. Strongest Lck staining was observed 
in the cytoplasm of MCF7HER2 cells. 
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4.3.2.2 Protein expression differences in cell lines after Inhibition and Stimulation 
Each cell line (depending on their HER status) was exposed for 30 min 10nM EGF or HRG, 
60 min 100nM of Src kinase inhibitor Dasatinib and a combination of both (details in 
appendix 3). After exposure cell pellets were created, imbedded in wax-blocks, cut to 
sections, placed on slides and baked at 56ºC ready for immunohistochemistry staining. 
Immunohistochemistry on all three cell lines was performed with four antibodies: c-Src, 
Y416Src, Y216Src- chosen by their significance regards patients‘ clinical outcome in 
previous IHC study, and Y861FAK- as a marker of downstream activation of Src. The same 
antibodies were used on those breast cancer patient tissue microarrays, described in previous 
chapter. 
 
MDAMB231 
Most significant changes in protein expression in this ER/HER2 negative cell line were 
observed with the Y416Src and Y861FAK antibody. 
 
c-Src was mainly expressed in the membrane, but with no statistically significant change in 
expression throughout the different drug treatments (all p values above >0.05, figure 4.11). 
Interestingly, nuclear and cytoplasmic c-Src seemed to have higher expression in the 
Dasatinib treated cell pellet compared to untreated MDAMB231 cells (c-Src nuc p=0.090 and 
c-Src cyto p=0.042, figure 4.11). 
 
There was no nuclear Y419Src protein expression seen in either cell lines, control cell pellet 
(UT= untreated) and different treatment exposures (figure 4.12).  
However, Y419Src expression in the cytoplasm was significantly higher after EGF 
stimulation (p=0.008, figure 4.12, picture 4.6 D) and significantly reduced after exposure to 
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Dasatinib (p=0.020, figure 4.12, picture 4.6 E) compared to cytoplasmic Y419Src expression 
in untreated control cells. Even more substantial was the difference on cytoplasmic Y419Src 
protein expression caused by the two divergent drug treatments (figure 4.12, p<0.001). No 
statistically significant difference was noted between untreated cells and cells treated with 
consecutive EGF and Dasatinib treatment (p=0.311). On the other hand there was a 
significant reduction on cytoplasmic Y419Src expression between the cells only stimulated 
with EGF and cells received the drug combination (p=0.002, picture 4.6 F). There was also no 
statistically significant difference in Y419Src expression in the cytoplasm present between 
MDAMB231 cells after only Dasatinib exposure and cells treated with the drug combination 
(EGF followed by Dasatinib) (p=0.121). 
An even more distinct reduction in Y419Src expression in the membrane (site of activation) 
was detected between MDAMB231 cells exposed to Dasatinib and untreated cells (p<0.001, 
picture 4.6 C), and cells stimulated with EGF (p<0.001) (figure 4.12, picture 4.6 D). There 
was no significant difference in expression between Dasatinib treatment and the combination 
of EGF/Dasatinib (p=0.925). In both cases the expression was nearly completed abolished 
(figure 4.12). No difference in protein expression was seen between untreated cells and cells 
exposed to 30 min of EGF (p=0.125). 
 
Y215Src was generally less expressed in the membrane compared to nucleus and cytoplasm 
(figure 4.13).  No statistically significant difference was observed between MDAMB231 
cells, which had no treatment and cells which received different drug treatments (table 4.8). 
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Table 4.8: Statistical analysis of drug treatment Y215Src expression differences 
Y215Src nuc 
P values  
UT EGF DASA 
EGF 0.695   
DASA 0.695 1.0  
ED 0.488 0.760 0.760 
Y215Src cyto UT EGF DASA 
EGF 0.938   
DASA 0.757 0.816  
ED 0.757 0.816 1.0 
Y215Src memb UT EGF DASA 
EGF 0.451   
DASA 0.297 0.761  
ED 0.897 0.545 0.368 
Table 4.8 illustrates non-significant associations between Y215Src nuc, Y215Src cyto and 
Y215Src membrane expression and their different drug treatments. 
Activated Y816FAK protein was mostly expressed in the nucleus of MDAMB231 cells 
(figure 4.14). Cells, which were exposed to 60 min Dasatinib, showed a significant reduction 
in nuclear Y861FAK expression compared to untreated control cells (p<0.001), EGF treated 
cells (p<0.001) and cells, which were exposed to both treatments (p<0.001) (figure 4.14). 
There was no significant difference noticed in nuclear Y861FAK protein expression between 
all other drug treatments (figure 4.14). 
A much greater response in cytoplasm Y861FAK expression was observed with EGF 
exposure (p=0.001) compared to untreated cells. Again MDAMB231, which were exposed to 
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Dasatinib treatment showed the lowest cytoplasmic Y861FAK expression compared to 
untreated cells (p=0.028), cells stimulated with EGF (p<0.001) and cells which received both 
drug treatments (p=0.012). A reduction in cytoplasmic Y861FAK was also detected when 
cells were exposed to Dasatinib after stimulation with EGF. A significant expression 
difference was noticed between cells only stimulated with EGF and cells with both drug 
treatments (p=0.001), but not compared to untreated cells (p=0.805). 
Membrane Y861FAK expression in MDAMB231 cells was elevated after EGF treatment and 
considerably decreased after Dasatinib exposure (p=0.010, figure 4.14). Membrane Y861FAK 
expression was also reduced in cells when EGF and Dasatinib treatment was combined 
compared to only EGF exposure (p=0.032). No statistically significant difference was 
achieved between cells with both treatments (ED) and only Dasatinib exposure (p=0.537, both 
membrane expressions were low) and between untreated cells (p=0.913). 
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Figure 4.11: Changes in c-Src expression in MDAMB231 after drug treatments 
   
Figure 4.12: Changes Y419Src expression in MDAMB231 after drug treatments  
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Figure 4.13: Changes Y215Src expression in MDAMB231 after drug treatments 
   
Figure 4.14: Changes Y861FAK expression in MDAMB231 after drug treatments  
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Figure 4.11-4.14: Overview of all protein expression variations for each of the four 
antibodies within the different cellular compartments after exposure to altered drug 
treatments. 4.11: Difference in nuclear, cytoplasmic and membrane c-Src expression 
after drug treatments; 4.12: Difference in cytoplasmic and membrane Y419Src 
expression after drug treatments; 4.13: Difference in nuclear, cytoplasmic and 
membrane Y215Src expression after drug treatments; 4.14: Difference in nuclear, 
cytoplasmic and membrane Y861FAK expression after drug treatments; 
UT= untreated control cells, EGF= epidermal growth factor (for stimulation of HER1), 
DASA= Dasatinib, Src kinase inhibitor; c-Src = total Src kinase, Y419Src = Src kinase 
phosphorylated at Tyrosine site 419, Y215Src = Src kinase phosphorylated at Tyrosine 
site Y215; c-Src nuc = c-Src nuclear expression, c-Src cyto = c-Src cytoplasmic 
expression, c-Src memb = c-Src membrane expression, Y416Src nuc = Y416Src nuclear 
expression, Y416Src cyto = Y416Src cytoplasmic expression, Y416Src memb = Y416Src 
membrane expression, Y215Src nuc = Y215Src nuclear expression, Y215Src cyto = 
Y215Src cytoplasmic expression, Y215Src memb = Y215Src membrane expression; ° 
insignificant p values (p > 0.05), * p values<0.05, ** p values <0.01, *** p values 
<0.005  
There is a significant reduction on Y419Src expression in the cytoplasm and membrane 
after MDAMB231 cells were treated with 100nM Dasatinib for 60 min. This phenomen 
wasn’t evident with the Y215Src antibody; no change in expression was seen after 
Heregulin or Dasatinib or both treatments However, the activated downstream protein 
FAK showed a similar effect as activated Y419Src. Its expression was also significantly 
inhibited after Dasatinib exposure.  
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Picture 4.6: Change of Y419Src staining after drug treatments 
 
 
 
 
 
 
Pictures 4.6: Immunohistochemistry with antibody Y416Src performed on MDAMB231 
cell pellets, displaying different protein expression pattern after altered drug 
treatments. 
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MCF7 
As already observed in the ER negative cell line, nuclear and cytoplasmic c-Src had the 
highest expression in the Dasatinib treated cell pellets compared to all other cell pellets 
(figure 4.15) (c-Src nuc UT/DASA p=0.010, HRG/DASA p=0.015, HD/DASA p=0.015). 
A proportionally greater difference in cytoplasmic c-Src expression was noted between 
untreated and Dasatinib exposed cells (c-Src cyto UT/DASA p=0.002, figure 4.15). 
c-Src was again mainly expressed in the membrane, though in this ER positive cell line 
with statistically significant changes in expression right through the different drug 
treatments (figure 4.15, picture 4.7 C-F).  
Cells activated with Heregulin exhibit the highest membrane c-Src expression compared to 
untreated (p=0.017), exposed to Dasatinib treatment (p=0.021) and cells treated with 
Heregulin followed by Dasatinib (p<0.001, figure 4.15, picture 4.7). Cells, which were 
exposed to both treatments, showed the lowest membrane c-Src expression; less than 
untreated cells (p=0.017) and cells with only Dasatinib treatment (p=0.014). There was no 
difference observed in membrane c-Src expression between untreated control cells and 
cells which received Dasatinib treatment (p=0.911). 
 
There was no nuclear Y419Src protein expression seen in the control cell pellet (UT) and 
the different treatment exposures (figure 4.16).  
The only statistically significant alteration in cytoplasmic Y419Src expression was 
detected after exposure to Dasatinib (p=0.033) compared to cytoplasmic Y419Src 
expression in untreated control cells. Dasatinib treated cell pellets had a decreased 
cytoplasmic expression compared to control cell pellets.  
A more considerable reduction in Y419Src expression was witnessed in the membrane. 
MCF7 cells exposed to Dasatinib retained hardly any detectable expression compared to 
untreated cells (p=0.001), and cells stimulated with HRG (p<0.001, figure 4.16). A 
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comparable effect was noticed with cells after combined drug treatments (HD) and 
untreated cells (p=0.001) as well as with cells only stimulated with HRG (p<0.001). 
There was no significant difference in membrane Y419Src expression between Dasatinib 
treatment and the combination of HRG/Dasatinib (p=0.951). In both cases the expression 
was nearly completed abolished (figure 4.16). No difference in protein expression was also 
seen between untreated cells and cells exposed to 30 min of 10nM HRG (p=0.134). A 
similar assessment was made in the ER negative cell line. 
 
There was no change in Y215Src protein expression observed in all three cellular 
compartments (figure 4.17) nor was there a statistically significant difference in nuclear, 
cytoplasmic and membrane Y215Src expression between MCF7 cells which had no 
treatment and cells which received different drug treatments (table 4.9). 
Chapter 4 Effects of Src inhibitor Dasatinib 265 
 
Table 4.9: Overview of statistical correlation between Y215Src expression and difference 
drug treatments 
Y215Src nuc 
P values  
UT HRG DASA 
HRG 0.965   
DASA 0.202 0.220  
HD 0.630 0.623 0.460 
Y215Src cyto UT HRG DASA 
HRG 0.918   
DASA 0.589 0.548  
HD 0.677 0.961 0.515 
Y215Src memb UT HRG DASA 
HRG 0.949   
DASA 0.348 0.417  
HD 0.516 0.582 0.816 
Table 4.9 highlights that there were only non-significant associations between Y215Src 
nuc, Y215Src cyto and Y215Src membrane expression and the different drug treatments. 
Activated Y816FAK protein was least expressed in the cytoplasm of MCF7 cells (figure 
4.18). The only statistically significant variation in cytoplasmic Y861FAK expression was 
seen between cells, which were exposed to 60 min Dasatinib and cells, which underwent 
both drug treatments (DASA/HD, p=0.013). Nevertheless there was noticeable decline in 
Y816FAK expression in the cytoplasm in ER positive cell line with Dasatinib treatment 
compared to the other cell pellets (figure 4.18). 
Most of the significant alterations in Y861FAK protein expression were present in the cell 
nucleus and membrane (figure 4.18).  
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Dasatinib treated cell pellets showed statistically significant fall in nuclear Y861FAK 
expression compared to untreated control cells (p=0.002), HRG treated cells (p=0.001) and 
cells, which were exposed to both treatments (p=0.001). There was no significant 
difference noticed in nuclear Y861FAK protein expression between all other drug 
treatments (figure 4.18). 
MCF7 cells, which were exposed to Dasatinib treatment, showed the lowest membrane 
Y861FAK expression compared to untreated cells (p<0.001), cells stimulated with HRG 
(p<0.001) and cells which received both drug treatments (p<0.001, figure 4.18).  
Heregulin stimulated cells had the highest membrane Y861FAK expression evaluated 
against all other treatment conditions (UT/HRG p<0.001, HRG/DASA p<0.001, 
HD/DASA p<0.001).  There was a slight, but statistically insignificant reduction noticed 
between membrane Y861FAK expression in untreated cells and cells, exposed to both drug 
treatments consecutively (p=0.558). 
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Figure 4.15: Changes in c-Src expression in MCF7 cell line after drug treatments 
   
Figure 4.16: Changes in Y419Src expression in MCF7 cell line after drug treatments 
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Figure 4.17: Changes in Y215Src expression in MCF7 cell line after drug treatments 
   
Figure 4.18: Changes in Y861FAK expression in MCF7 cell line after drug treatments 
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Figure 4.15-4.18: Overview of all protein expression variations for each of the four 
antibodies within the different cellular compartments after exposure to altered drug 
treatments in MCF7 cell line. 4.15: Difference in nuclear, cytoplasmic and membrane 
c-Src expression after drug treatments; 4.16: Difference in cytoplasmic and membrane 
Y419Src expression after drug treatments; 4.17: Difference in nuclear, cytoplasmic and 
membrane Y215Src expression after drug treatments; 4.18: Difference in nuclear, 
cytoplasmic and membrane Y861FAK expression after drug treatments. 
UT= untreated control cells, HRG= Heregulin (for stimulation of HER2/3), DASA= 
Dasatinib, Src kinase inhibitor; c-Src = total Src kinase, Y419Src = Src kinase 
phosphorylated at Tyrosine site 419, Y215Src = Src kinase phosphorylated at Tyrosine 
site Y215; c-Src nuc = c-Src nuclear expression, c-Src cyto = c-Src cytoplasmic 
expression, c-Src memb = c-Src membrane expression, Y416Src nuc = Y416Src nuclear 
expression, Y416Src cyto = Y416Src cytoplasmic expression, Y416Src memb = Y416Src 
membrane expression, Y215Src nuc = Y215Src nuclear expression, Y215Src cyto = 
Y215Src cytoplasmic expression, Y215Src memb = Y215Src membrane expression;  ° 
insignificant p values (p > 0.05), * p values<0.05, ** p values <0.01, *** p values 
<0.005  
There is a significant reduction on Y419Src expression in the cytoplasm and membrane 
after MCF7 cells were treated with 100nM Dasatinib for 60 min. Again no change in 
nuclear, cytoplasmic and membrane Y215Src expression was apparent. As seen within 
the ER negative cell line, activated downstream protein FAK showed a similar effect as 
activated Y419Src. Its expression was also significantly inhibited after Dasatinib 
exposure. 
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Picture 4.7: Changes in c-Src expression in MCF7 cell pellets after drug treatments 
 
 
 
 
 
 
Pictures 4.7: Immunohistochemistry with c-Src antibody performed on MCF7 cell 
pellets, demonstrating different protein expression pattern after altered drug treatments. 
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MCF7HER2 
The lowest c-Src protein expression was observed in the nucleus (figure 4.19). Again 
nuclear c-Src expression was highest in the Dasatinib treated cell pellets compared to all 
other MCF7HER2 cell pellets (figure 4.19), but with no significant p values for expression 
differences. MCF7HER2 cells treated with 10nM Heregulin followed by 100nM Dasatinib 
(HD) demonstrated the least cytoplasmic c-Src expression compared to untreated cells 
(p=0.004) and cells exposed to Dasatinib treatment (p=0.039). Surprisingly untreated 
control cells exhibit a higher cytoplasmic c-Src expression than cells exposed to Heregulin 
(p=0.012)  
Almost no change in membranous c-Src expression after stimulation with Heregulin and 
inhibition with Dasatinib or both was an unexpected finding, and differed to what was 
observed in the other cell lines. 
 
As mentioned before, there was again no nuclear Y419Src protein expression seen in the 
control cell pellet (UT) and the different treatment exposures (figure 4.20) of this cell line.  
There was a slight decrease in cytoplasmic Y419Src expression detected in cell pellets 
treated with Dasatinib, but without any statistically significant p value (figure 4.20). 
Assessment of Y419Src expression on the cellular membrane is the site of interest in all 
three cell lines: Once more there was a critical reduction in Y419Src expression witnessed 
in cell pellets after 60 min exposure to Dasatinib.  MCF7HER2 cells exposed to Dasatinib 
had the lowest membrane Y419Src expression compared to untreated cells (p=0.001) and 
cells stimulated with HRG (p<0.001, figure 4.20). Another significant reduction in 
Y419Src expression was detected in cell pellets which were treated with both drug 
treatments (HD) compared to untreated control cell pellets (p<0.001) and cell pellets after 
Heregulin exposure (p<0.001).  
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There was no significant difference in membrane Y419Src expression between Dasatinib 
treatment and the combination of HRG/Dasatinib (p=0.058). Balanced on the observations 
made in the other two cell lines, MCF7HER2 cell pellets showed a less extreme reduction 
in membrane Y419Src expression after Dasatinib treatment (figure 4.20).  
 
Yet again there was no change in Y215Src protein expression observed in all three cellular 
compartments (figure 4.21) nor was there a statistically significant difference in nuclear, 
cytoplasmic and membrane Y215Src expression between MCF7HER2 cells which had no 
treatment and cells which received different drug treatments (table 4.10). 
Table 4.10:  Statistical analysis of Y215Src expression changes after drug treatments 
Y215Src nuc 
P values  
UT HRG DASA 
HRG 0.570   
DASA 0.886 0.669  
HD 0.479 0.213 0.398 
Y215Src cyto UT HRG DASA 
HRG 0.214   
DASA 0.353 0.736  
HD 0.387 0.686 0.946 
Y215Src memb UT HRG DASA 
HRG 0.709   
DASA 0.314 0.516  
HD 0.459 0.709 0.779 
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Table 4.10 highlights that there were only non-significant associations between 
Y215Src nuc, Y215Src cyto and Y215Src membrane expression and the different drug 
treatments in the MCF7HER2 cell pellets. 
As observed in the other two cell lines, activated Y816FAK protein was least expressed in 
the cytoplasm of MCF7HER2 cell pellets (figure 4.22).  
Nuclear Y861FAK expression was significantly reduced in cell pellets, which were 
exposed to Dasatinib compared to untreated control cell pellets (p<0.001, picture 4.8 C), 
cell pellets after Heregulin stimulation (p<0.001, picture 4.8 D) and cell pellets after both 
drug treatments (p<0.001, picture 4.8 F, figure 4.22). Like with cytoplasmic c-Src 
expression, nuclear Y861FAK expression was found to be reduced in Heregulin stimulated 
cell pellets compared to untreated cell pellets (p=0.002). The same phenomenon is witness 
with cytoplasmic Y861FAK expression (p<0.001, figure 4.22). 
Dasatinib treated cell pellets showed statistically significant fall in cytoplasmic Y861FAK 
expression compared to untreated control cells (p<0.001), HRG treated cells (p=0.010) and 
cells, which were exposed to both treatments (p=0.010). There was a significant difference 
noticed in cytoplasmic Y861FAK protein expression in cell pellets exposed to both drug 
treatments and untreated cell pellets (p<0.001, figure 4.22). 
Dasatinib treatment again affected membrane Y861FAK expression greatly. Lowest 
Y861FAK expression was measured in Dasatinib treated MCF7HER2 cells compared to 
untreated cells (p<0.001, picture 4.8 C and E) and cells stimulated with HRG (p<0.001, 
picture 4.8 D).  
Different to the other cellular compartments, Heregulin had a stimulating effect on 
membrane Y861FAK expression. 
Cell pellets, which received both drug treatments exhibit less membrane Y861FAK 
expression compared to untreated cell pellet (p=0.002) and cell pellet after Heregulin 
stimulation (p<0.001).  
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There was a slight, but statistically insignificant reduction noticed between membrane 
Y861FAK expression in cells, treated with Dasatinib and cells, exposed to both drug 
treatments (p=0.159, figure 4.22). 
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Figure 4.19: c-Src expression in MCF7HER2 after drug treatments 
   
Figure 4.20: Y419Src expression in MCF7HER2 after drug treatments 
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Figure 4.21: Y215Src expression in MCF7HER2 after drug treatments 
   
Figure 4.22: Y861FAK in MCF7HER2 after drug treatments 
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Figure 4.19-4.22: Overview of all protein expression variations for each of the four 
antibodies within the different cellular compartments after exposure to altered drug 
treatments in MCF7HER2 cell line. 4.19: Difference in nuclear, cytoplasmic and 
membrane c-Src expression after drug treatments; 4.20: Difference in cytoplasmic and 
membrane Y419Src expression after drug treatments; 4.21: Difference in nuclear, 
cytoplasmic and membrane Y215Src expression after drug treatments; 4.22: Difference 
in nuclear, cytoplasmic and membrane Y861FAK expression after drug treatments. 
UT= untreated control cells, HRG= Heregulin (for stimulation of HER2/3), DASA= 
Dasatinib, Src kinase inhibitor; c-Src = total Src kinase, Y419Src = Src kinase 
phosphorylated at Tyrosine site 419, Y215Src = Src kinase phosphorylated at Tyrosine 
site Y215; c-Src nuc = c-Src nuclear expression, c-Src cyto = c-Src cytoplasmic 
expression, c-Src memb = c-Src membrane expression, Y416Src nuc = Y416Src nuclear 
expression, Y416Src cyto = Y416Src cytoplasmic expression, Y416Src memb = Y416Src 
membrane expression, Y215Src nuc = Y215Src nuclear expression, Y215Src cyto = 
Y215Src cytoplasmic expression, Y215Src memb = Y215Src membrane expression;  ° 
insignificant p values (p > 0.05), * p values<0.05, ** p values <0.01, *** p values 
<0.005  
There is a significant reduction on Y419Src expression in the membrane after 
MCF7HER2 cells were treated with 100nM Dasatinib for 60 min. No change in 
nuclear, cytoplasmic and membrane Y215Src expression was observed after Heregulin 
and Dasatinib or both treatments. However, the activated downstream protein FAK 
showed a similar effect as activated membrane Y419Src. Its expression was also 
significantly inhibited after Dasatinib exposure in the nuclear, cytoplasmic and 
membranous cell compartment.  
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Picture 4.8: IHC staining with Y861FAK on cell line cell pellets 
 
 
 
 
 
 
Pictures 4.8: Immunohistochemistry with Y861FAK antibody performed on 
MCF7HER2 cell pellets, demonstrating different protein expression pattern after 
altered drug treatments. 
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Lck 
The drug stimulation and inhibition experiment was only performed in the MCF7HER2 
cell line since the basal Lck protein expression was absent in the MDAMB231 and MCF7 
cell line (figure 4.10). 
Nuclear Lck expression was hardly detected in any of the cell pellets. No significant p 
value for variation in protein expression was therefore recorded (table 4.11). 
Cytoplasmic Lck expression was vaguely more marked (figure 4.23), but again there was 
no statistically significant difference in expression noticed (table 4.11). 
Cell pellets after Heregulin exposure showed a slight increased Lck expression in the 
membrane compared to untreated cell pellets, but once more without any statistically 
significant value (table 4.11). There was a faint decrease in membrane Lck expression in 
Dasatinib exposed cell pellets evident. This observation is based on lower histoscores other 
than significant p values (table 4.11, figure 4.23). 
 
Table 4.11: Statistical overview of nuclear, cytoplasmic and membrane Lck expression on 
cell line cell pellets after drug treatments 
Lck nuc 
P values  
UT HRG DASA 
HRG 0.374   
DASA 0.281 1.0  
HD 0.832 0.647 0.585 
Lck cyto UT HRG DASA 
HRG 0.529   
DASA 0.443 1.0  
HD 0.477 1.0 1.0 
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Lck memb UT HRG DASA 
HRG 0.379   
DASA 0.514 0.720  
HD 0.387 0.909 0.786 
Table 4.11 highlights that there were only non-significant associations between Lck 
nuc, Lck cyto and Lck membrane expression and the different drug treatments. 
Figure 4.23: Expression differences of Lck in cell pellets after drug treatments 
 
Figure 4.23 displays the differences in nuclear, cytoplasmic and membrane Lck 
expression after no treatment, exposure to Heregulin and Dasatinib or both 
treamtments. No significant protein expression changes are obvious. 
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Picture 4.9: IHC staining with Lck antibody on cell pellets 
 
 
 
 
 
 
 
 
 
 
Picture 4.9: Immunohistochemistry performed with Lck antibody on full section of 
normal breast tissue, invasive breast cancer TMA and cell pellet with various drug 
treatments in MCF7HER2 cell line. 
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4.4 Discussion 
Several studies in other tumours have consistently demonstrated the role of Src in the 
development and progression of cancer (114;210;212;214).  
A number of Src inhibitory agents are currently under investigations in pre-clinical and 
clinical studies to establish their efficacy as anti-proliferative and anti-invasive agents. 
Having found a negative impact of high Src expression and contrary results from its 
phosphorylation sites in our IHC cohort, we wanted to establish how exposure to a 
stimulant drug or/ and Dasatinib, a Src kinase inhibitor would influence Src protein 
expression, activation and cellular distribution. 
 
Activity of Dasatinib has been studied in various cell lines derived from different solid 
tumours (prostate, colon, lung, glioblastoma and others). Effects of Dasatinib on cell 
growth inhibition were also examined in 39 human breast cancer cell lines, categorised into 
luminal and basal subtypes based on the relative gene expression profiles of cytokeratins, 
using proliferation assays (169). Dasatinib inhibited cell growth of breast cancer cell lines 
representing both, luminal and basal breast cancer cell subtypes. It is a potent regulator of 
MDAMB231 breast cancer cell growth (164). This cell line represents the triple negative 
breast cancer type with poor prognosis, but with increased sensitivity to growth inhibitory 
effects of Dasatinib (169). 
We chose four cell lines representing the different breast cancer subgroups. Before we 
embarked on drug stimulation and inhibition experiments we investigated if c-Src kinase 
protein was expressed in all four cell lines through simple steroid depletion test. To our 
surprise cell line MDAMB453 did not express c-Src in measurable quantities for Western 
Blotting. To validate this finding further, we looked into SRC mRNA expression in this 
cell line, discovering that there was no detectable SRC mRNA present. Interestingly, Finn 
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et al. demonstrated that this cell line was resistant to high dose Dasatinib treatment due to 
unknown mechanism (169). We therefore proceeded with only three cell lines. 
 
Either overexpression or increased activity of Src can be responsible for oncogenesis. In 
colon carcinoma lysates, Src activity was elevated compared with normal human colon 
mucosa cells, which appeared to be as a result of increased kinase signalling by Src, rather 
than increased protein levels (213;214).  
To determine effects of inhibitors, reliable biomarkers for kinase activation must be found. 
Phospho-specific antibodies, targeting activated enzymes, are established tools to 
investigate molecular signalling pathways. When Src is activated, several downstream 
proteins are phosphorylated (e.g. paxillin at Tyr118, p130cas at Tyr410 and FAK at 
Tyr861). These potentially could act as biomarkers (167). The most reliable and applied 
indicator for Src activity is tyrosine site 419 (168). Activation at FAKY861 and Y419Src 
were both found to be decreased when hormone sensitive (LNCaP) and refractory 
(LNCaP-SDM) prostate cancer cell lines were exposed to Dasatinib (90).  A complete 
inhibition of Src activity in LNCaP cells was achieved with a concentration of 50 nM of 
Dasatinib. A slightly higher concentration (75nM) was needed for LNCaP-SDM. To 
ensure a definitive result could be achieved in our study, a concentration of 100 nM 
Dasatinib was selected. This was also based on a colon cancer in vitro study (167), 
demonstrating complete depletion of Src activation with this concentration. However, 
Dasatinib, used at concentrations of 100 nM and above, can inhibit multiple targets and 
therefore could be non-specific (164). Our investigations were focused on the effect of 
Dasatinib on Src kinase and Src activation (Y419Src, Y215Src and downstream protein 
Y861FAK). To suppress cell proliferation a higher concentration of Dasatinib would have 
been necessary. It also seems that not all cell lines utilise Src kinase family members in 
their proliferation signalling pathways (167). 
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Despite previous optimisation and application of the antibodies in the 
immunohistochemistry study, it was necessary to re-test antibody dilutions/ conditions on 
TMA, full section and control cell pellet slides due to the possibility of increased staining 
intensity on the more delicate cell pellets. A significant adjustment in Y416Src antibody 
dilution was required. This was most likely due to the article‘s Lot change by the company. 
c-Src and its activation sites Tyr419 and Tyr215, and Lck were investigated, because of 
their significant and contrary associations with clinical outcome of breast cancer patients 
examined in the previous IHC study. Antibody to Tyr861 of FAK, downstream substrate to 
Src and indicator for Src activation, was added as a control. 
 
Comparing basal expression of all three cell lines, we found that nuclear and cytoplasmic 
c-Src was highest expression in ER positive/HER2 upregulated cell line (MCF7HER2), 
which is in keeping with Src kinase being is over-expressed in HER2 over-expressed 
mammary cancers (124) promoting tumour development and progression in conjunction 
with the ER receptor. Another study demonstrates that HER2 over-expressing tumours 
showed increased levels of c-Src phosphorylation at Tyr215 and additionally up-regulating 
phosphorylation of downstream substrate FAK at Tyr861 (125). Similar we found that 
baseline Y861FAK expression, but only membrane Y215Src expression was highest in the 
untreated MCF7HER2 cell line compared to the other two.  
 
It is well established now that Src kinase plays an important role in promoting cancer cell 
motility (72). Activated Src kinase regulates the motility of cancer cell in building 
complexes with FAK followed by stimulation of other signalling proteins. 
FAK, also a non-receptor tyrosine kinase and downstream substrate to Src kinase, is 
mainly implicated in the regulation of cell motility, adhesion and anti-apoptotic signalling 
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(238). Growth factors can induce phosphorylation of FAK on a number of tyrosine sites, 
triggering distinct cell signals: Tyr397 in recruiting Src to focal adhesions, Tyr576 in up-
regulating FAK activity (239), Tyr925 in activating the Ras-mitogen-activated protein 
kinase pathway (240) and Tyr861 in Ras mediated transformation (241). Cells, which are 
deficient of FAK, are unresponsive to PDGF and EGF- mediated motility signals (242). 
Heregulin and activated HER2 can rearrange the cytoskeleton and increase the capability 
of breast cancer cells to metastasise without phosphorylation of FAK (243). Vadlamudi et 
al. demonstrated that Heregulin (10nM 30 min exposure) and HER2 signalling selectively 
upregulated phosphorylation of c-Src at Tyr215, increasing Src kinase activity and up-
regulating phosphorylation of FAK at Tyr861 (125).  
Interestingly we didn‘t observe a rise or decrease in Y215Src protein expression after 30 
min stimulation with 10 nM Heregulin nor when exposed to Dasatinib in all three cell 
lines. In spite of this, we saw a significant increase and decrease in Y861FAK expression 
on the membrane after the equivalent drug treatment. Our findings therefore support the 
hypothesis that Dasatinib selectively inhibits phosphorylation at Tyr419 and not 
phosphorylation site Y215Src. This needs to be investigated further, validating our results 
by repeating the experiment with cell lysis and Western Blotting. It would assure that the 
application of Dasatinib in the clinical setting would not be harmful and detrimental for 
patients, who express Y215Src in the nucleus or cytoplasm. Even more it would support 
the usage of Dasatinib in breast cancer patients based on our results. All three cell lines 
demonstrated a significant diminution of phosphorylated Y419Src and Y861FAK on the 
cellular membrane reducing Src activation leading to decreased cell proliferation and 
increased stabilisation of cellular adhesions. Demonstrating no expression difference and 
response to Dasatinib treatment at any cellular location, Y215Src would not be suitable as 
a prognostic nor predictive biomarker, despite cytoplasmic Y215Src expression being 
independent in uni- and multivariate analysis in the previous IHC study.  
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In our study, Y215Src and Y861FAK had a similar basal protein expression pattern. 
Nuclear and cytoplasmic expression of those proteins was lowest in the ER positive/HER2 
negative (MCF7) cell line, whereas membrane protein expression was lowest in the triple 
negative (MDAMB231) and highest in the ER positive/HER2 upregulated (MCF7HER2) 
cell line. This could imply that cellular location of these specific proteins influences 
cellular function inducing different expression profiles.  
Conversely, membrane expression of the classical Src activation site Y419 and c-Src was 
highest in MDAMB231. This could be the reason why this cell line is highly sensitive to 
Dasatinib treatment (169). We observed a near complete abolition of membrane Y419Src 
expression in MDAMB231 and MCF7 cells and a statistically significant reduction in 
MCF7HER2 cells after Dasatinib exposure. A comparable, but less radical pattern was 
noticed with membrane c-Src expression; Dasatinib treatment resulted in a significant 
reduction of membrane c-Src expression in MDAMB231 and MCF7 cells, but statistically 
non-significant in MCFHER2 cells. It would be of interest to establish if the up-regulated 
human epidermal growth factor receptor is the reason for the lethargic response to 
Dasatinib. This could be an indication to trial Dasatinib with Herceptin in HER2/c-Src 
positive patients. 
It also highlights that Y419Src would be a more suitable biomarker in predicting response 
to Dasatinib treatment, as various studies in other solid tumours have already suggested 
(90;168). Results from the previous IHC chapter draw attention to membrane Y419Src 
expression in invasive breast cancer patients and its association with poorer clinical 
outcome. The striking elimination of activated Y419Src expression on the cell membrane 
in all cell lines after Dasatinib treatment is supportive in justifying phase III clinical trials 
with this drug.  
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Interestingly, in MDAMB231 and MCF7 cells exposure to Dasatinib was followed by a 
significant increase in nuclear and cytoplasmic c-Src expression. A similar observation was 
made in LNCaP-SDM cells, where an increase in the dose of Dasatinib resulted in an 
increase in c-Src (90). With the knowledge that inactive Src is stored in the nucleus and 
cytoplasm, we hypothesise, that a rise in nuclear and/ or cytoplasmic c-Src expression 
might be a marker that treatment with Dasatinib could force Src kinase into a state of 
hibernation or senescence.  
 
Membranous expression of Lck in our IHC study was associated with no breast cancer 
related deaths. Therefore we were interested to study the effects of Dasatinib on SFK 
member Lck in our cell lines/ cell pellet experiment. Only cell line MCF7HER2 had 
quantifiable basal Lck protein expression. Again it raises the question of the role of human 
epidermal growth factors and their associations with SFK members in breast tumours. 
However, there was no detectable difference in Lck protein expression after any of the 
drug treatments. This is similar to results gained with Src activation site Y215. It‘s 
doubtful that these observed facts are related with each other. Yet Couture et al. reported, 
that Lck phosphorylated at tyrosine site 192 by Syk was corresponding with  
phosphorylated Y215Src (244). It would be of interest to perform IHC with an antibody for 
Tyr192 in our IHC cohort to investigate its correlation to Y215Src and association to 
clinical outcome. 
 
Our cell line studies revealed that Src kinase expression was not detected in MDAMB453 
cell line. Basal expression of activated Y419Src was highest in ER negative cell line. All 
cell line studies showed a significant decrease in Y419Src activation and phosphorylated 
downstream substrate Y861FAK after exposure to Src inhibitor Dasatinib.  
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Upregulated HER2 receptor seems to play a role in basal expression of Src and activated 
Src, their cellular distribution and response to drug treatments. A discordant effect on 
nuclear, cytoplasmic and membrane c-Src expression was observed in ER negative and ER 
positive cell line. No change in protein expression despite stimulation with HRG/EGF 
and/or inhibition with Dasatinib was witnessed with Y215Src and Lck expression. 
Our results support the use of Dasatinib as a reliable Src inhibitor for breast cancer 
patients.  Our results suggest a combination with Herceptin in HER2 over-expressing 
patients might be of benefit. Membrane expression of Y419Src could be a potential 
predictive biomarker to monitor response to Dasatinib treatment. These proposals have to 
be further validated in clinical trials. 
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Src kinase has been extensively investigated in in-vitro studies, mainly in colon carcinoma, 
and haematological malignancies. Src activation can occur via multiple mechanisms, e.g. 
de-/phosphorylation of different tyrosine sites, downstream activation via over-expressed 
EGFR receptors and/or interaction with many other cell signalling molecules. This 
activation of Src contributes significantly to the biological progression of tumours (83). 
Over the past few years Src inhibitors have been commercially developed and clinically 
trialled in CML, colon, pancreas and prostate cancer. Recently, without substantive 
translational research evidence, phase II and III clinical trials have opened and started 
recruitment of patients with advanced or metastatic breast cancer.  
 
With this project we aimed to enhance the current knowledge regards the role of Src and 
SFK members in human breast cancer and add significant findings to the current literature. 
During the course of this translational study we established Src and SFK expression in 
various human breast tissue samples, evaluated Src expression and activation in invasive 
breast cancer specimens and examined the impact of a Src inhibitor on those expression 
and activation sites in breast cancer cell lines to address their relevance in the clinical 
setting. 
 
Examining SFK mRNA expression in normal, non-malignant and malignant breast tissue 
we found all SFK members were expressed, but with different expression pattern. SRC and 
LYN were most highly expressed in non-malignant and malignant breast tissue samples, 
whereas FYN was highest expressed in the normal breast tissue specimens. FYN is known 
to be expressed in other normal tissue (194), but it‘s also likely that this finding is 
ambiguous because of the age difference of this cohort compared to the other two. SFK 
member LCK was higher expressed in ER negative compared to ER positive tumours. 
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SRC was the only SFK member, which was associated with clinical outcome. Breast 
cancer patients with high SRC mRNA expression had a shorter disease specific survival. 
Up till now there hasn‘t been a study which looked into mRNA expression of mammalian 
expressed SFK members in various breast tissue types, comparing and correlating the 
diverse expression levels and their significance to clinical parameters (e.g. ER status) and 
clinical outcome (e.g. disease specific survival).   
 
Due to small patient numbers in the malignant cohort (n=81) and unknown transcription 
from mRNA to protein synthesis and expression, we want to explore further expression of 
Src, Lyn and Lck proteins and their association with survival in a larger cohort. Cellular 
location and activation status of those proteins were able to be evaluated through indirect 
immunohistochemistry. Only a few studies (114;115;125;221;245) in the breast cancer 
related literature used this method to investigated if elevated protein expression and 
cellular distribution in clinical specimens were imperative. Only two other research groups 
related their findings to important aspects for clinicians like recurrence and/ or survival 
(115;116). None of these groups linked Src expression and activation to received adjuvant 
treatment, de-novo or acquired systemic treatment resistance. Parallel to this project, our 
group examined the role of SFK members in tamoxifen resistance in an unmixed ER 
positive cohort. No evidence was found to support a role for the Src family in de novo 
tamoxifen resistance. However, after 5 years of hormonal therapy, patients with high 
cytoplasmic c-Src expression in their breast tumours had a poorer clinical outcome. This 
result has raised several questions: 
Do patients with high cytoplasmic c-Src need to be selected for aromatase inhibitors?  
Do patients need to be selected for continuing endocrine therapy (> 5 years)? 
Do patients with advanced breast cancer and acquired endocrine resistance benefit from 
complementing a Src inhibitor to their systemic hormonal therapy? 
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Interestingly in our mixed cohort, it was also high expression of c-Src in the cytoplasm, 
which was associated with poorer clinical outcome.  
None of the phosphorylation sites of Src were able to be linked with acquired tamoxifen 
resistance and disease specific survival in the pure ER positive cohort. This differs 
significantly to our findings showing a strong association between Src activation and 
clinical outcome of breast cancer patients. 
 
It is well established in various cell lines derived from colon, lung or prostate tumours 
(90;212;214) that Dasatinib influences cell growth, proliferation and inhibits Src 
activation. With Src inhibitors currently being trialled in breast cancer it was necessary to 
explore what impact Dasatinib could have on the individual phosphorylation sites of Src 
and other SFK members. Various breast cancer cell lines were chosen to represent the 
different subgroup of breast cancer patients. To be able to compare results gained from 
IHC and cell line study and to draw conclusions, we investigated protein expression in cell 
line cell pellets with the same antibodies used for immunohistochemistry. No in vitro study 
in the currently literature has used this method to establish what influence drug treatments 
have on protein expression. The method of choice has always been Western Blotting. To 
strengthen our findings, Western Blotting from cell lysates, exposed to the same drug 
stimulation and inhibition, should be performed. 
Nevertheless it is encouraging that membrane Y419Src expression was significantly 
decreased in all cell lines after Dasatinib exposure implying that patients with increased 
activated (p419)Src kinase receiving Dasatinib would improve their clinical outcome and 
prolong their survival.  On the other hand we showed that expression of Y215Src stayed 
unchanged in all cell lines during exposure to different drug treatments. With the 
knowledge that patients, expressing nuclear and cytoplasmic Y215Src highly in their breast 
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cancer, have a better disease specific survival, it is reassuring that exposure/ administration 
of Dasatinib would not impact negatively on the clinical outcome of those patients. 
 
Due to the lack of Src mutation and gene amplification in the majority of tumours, it is 
only recently that Src kinase was accepted as a target for drug development. Mainly the 
increased enzyme activity in primary tumours and further rise in synchronous metastasis 
(213) has led to advance in molecular targeted therapy. 
Four compounds have shown to have sufficient potency and acceptable toxicity for the 
development as Src kinase inhibitors. Dasatinib has now been approved by NICE for the 
treatment of chronic myelogenous leukaemia (CML) partially based on a 95% complete 
haematological response rate for chronic-phase CML (246). 
Guided by preclinical studies, clinical trials are being conducted with Src inhibitors as 
monotherapy or in combination with cytotoxic chemotherapy, hormonal therapy and 
growth factor inhibitors. More than 50 trials of Src inhibitors are currently ongoing or 
about to open (189). In the beginning it was thought that Src inhibitors could be potent 
enough to be used for single agent therapy. However, cell lines studies showed that effects 
of Src inhibitors on cell proliferation was independent of Src kinase inhibition and more a 
result of inhibition of other tyrosine kinases (168);(185). Other preclinical studies report a 
limited affect of Src inhibitors on cell proliferation (83;188;247), questioning the benefit of 
their administration in the clinical setting. Following on from this, many contemporary 
trials explore the potential advantage of combining Src inhibitors with chemotherapy 
agents and other biological targeted molecules. 
Several questions still need to be answered: 
Is there a subgroup of tumours, which are uniquely susceptible to Src kinase inhibitors? 
Would membrane Y419Src expression be suitable as a validated biomarker for predicting 
response to all Src kinase inhibitors? 
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Is the role for Src kinase inhibitors more in the anti-invasive and anti-metastatic setting 
rather than anti-proliferative early stage of tumours? 
The ability of Src inhibitors to overcome resistance to standard therapies and tolerable 
toxicity profile (246) sends out hope that Src inhibitors in combination with cytotoxic 
anticancer drugs will be available as standard therapy for certain cancer patients. 
Within the next few years, ongoing research will provide answers regards Src kinase 
inhibitors‘ role in cancer treatment, just in time for the centennial anniversary of Rous‘s 
discovery of the sarcoma virus v-Src. 
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Appendices 
Appendix 1: Materials for mRNA expression of SKF members  
RNA extraction 
Reagents 
TRIZOL® (Invitrogen) 
Chloroform (Sigma) 
Isopropyl alcohol (Sigma) 
75% Ethanol (Fisher Scientific) 
RNAse/DNAse free Water (Promega) 
TBE (Tris-borate-EDTA) (Invitrogen) 
Agarose (Invitrogen) 
1Kb Plus DNA Ladder (Invitrogen) 
Bromophenol Blue loading solution (Promega) 
RT-PCR 
Reagents 
DNA Buffer*** (Applera) 
DNAse*** (Applera) 
DNA Inactivator Reagent (Applera) 
Oliga (dt) Primers (1:50) (Invitrogen) 
Random Primers (Hexamer) (1:60) (Invitrogen) 
5x First Strand Buffer (Invitrogen)** 
DTT (Invitrogen)** 
RNAse OUT (Invitrogen) 
SuperScript II Reverse Transcriptase (Invitrogen)** 
RNAse H (Applera) 
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Real time PCR 
Reagents 
PCR Buffer-Mg (VH Bio)* 
Enhancer Solution (VH Bio)* 
MolTaq enzyme (VH Bio)* 
10mM dNTP (VH Bio) 
Forward Primer (human ß-actin, 546-566, TM 68)  
GGTCACCCACACTGTGCCCAT   (Invitrogen) 
 
Reverse Primer (human ß-actin, 896-875, TM 68) 
GGATGCCACAGGACTCCATGC (Invitrogen) 
 
TaqMan® PCR 
Reagents 
TaqMan® Universal Master Mix (Applied Biosystems) 
Human HPRT1 endogenous control (VIC/TAMRA probe) (Applied Biosystems) 
Human GAPDH endogenous control (VIC/TAMRA probe) (Applied Biosystems) 
Src (Gene Expression Assay ID: Hs00178494_m1) (Applied Biosystems) 
Lck (Gene Expression Assay ID: Hs00176719_m1) (Applied Biosystems) 
Lyn (Gene Expression Assay ID: Hs00178427_m1) (Applied Biosystems) 
Yes (Gene Expression Assay ID: Hs00736972_m1) (Applied Biosystems) 
Fyn (Gene Expression Assay ID: Hs00176628_m1) (Applied Biosystems) 
Fgr (Gene Expression Assay ID: Hs00178340_m1) (Applied Biosystems) 
Hck (Gene Expression Assay ID: Hs00176654_m1) (Applied Biosystems) 
Blk (Gene Expression Assay ID: Hs00176441_m1) (Applied Biosystems) 
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Solutions 
MasterMix for RTPCR (per PCR tube) 
5x first strand buffer (4µl) 
DTT (2µl)  
RNase OUT (1µl) 
 
Master Mix for Real time PCR (per PCR tube) 
10x PCR buffer-Mg (2.5µl) 
10 mM dNTP (0.5µl) 
Enhancer solution (0.75µl) 
Forward primer ß-actin (0.5µl) 
Reverse primer ß-actin (0.5µl) 
Mol Taq (0.25µl) 
RNA/DNA free H2O (18µl) 
325 
 
Appendix 2: Materials for protein expression of SKF members 
Western Blotting 
Reagents 
 Bio-Rad Reagent (Bio-Rad Laboratories) 
 Bovine Serum Albumin (BSA) (Sigma) 
 Isopropanolol (Sigma-Aldrich 
 APS  (Sigma) 
 TEMED  (Sigma) 
 40% Acrylamide/Bis-Acrylamide  (Sigma) 
 Glycine  (Sigma) 
 Tris-HCL  (VWR) 
 Glycerol  (Sigma) 
 2-Mercaptoethanol  (Sigma) 
 Bromophenol Blue (0.05% w/v)  (Promega) 
 PVDF membrane  (BioRad) 
 100% Methanol  (Fisher Scientific) 
 Coomassie blue R250  (Sigma) 
 Acetic Acid Glacial  (BDH Laboratory Supplies)  
 TWEEN 20  (Sigma) 
 Marvel-dried skimmed milk  (Premier International Foods) 
 ECL+Plus: Solution A and B  (Amersham Biosciences) 
 HeLa cell lysates (Cell Signalling Technology) 
 NFkappaB cell lysates (Cell Signalling Technology) 
 Jurkat cell lysates (Cell Signalling Technology) 
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 Biotinylated Protein Ladder  (Cell Signalling Technology) 
 ß-actin antibody  (abcam) 
 ß-tubulin antibody  (abcam) 
 Total Src (60kDa) (mAb) (Cell Signalling Technology) 
 Anti-Src family negative regulatory site (pAb) (Invitrogen) 
 Clone 28 (mAb) (Invitrogen) 
 Y416 Src antibody (pAb) (Cell Signalling Technology) 
 Y216 Src antibody (pAb) (Santa Cruz) 
 Lyn (mAb) (BD Biosciences) 
 Lck (mAb) (Cell Signalling Technology) 
 Y861FAK (pAb) (Invitrogen) 
 Ki67 antigen MIB-1 (DAKO) 
 Anti-biotin HRP linked antibody (Cell Signalling Technology) 
 HRP-linked anti-rabbit IgG (Cell Signalling Technology) 
 Re-Blot Plus Strong Antibody Stripping Buffer  (Millipore) 
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Solutions and Buffers 
 
Resolving Gel (10%) (per 50 ml) 
Reagents  
40% Acrylamide/Bis-Acrylamide 6.25 ml 
0.5M EDTA 165 l 
2M Tris, pH 8.9 4.18 ml 
10% SDS 250 l 
dH2O 14.25 ml 
10% APS 150 l 
TEMED 15 l 
 
 
Stacking Gel (4.5 %) (per 50 ml) 
Excluding APS and TEDMED Stacking Gel can be made up and stored at 4 C 
Reagents  
40% Acrylamide/Bis-Acrylamide 5.63 ml 
0.5M EDTA 400 l 
1M Tris, pH 6.8 6.25 ml 
10% SDS 500 l 
dH2O 37.22 ml 
10% APS 30 l 
TEMED 10 l 
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1M Tris pH 6.8 
Dissolve 60.57 g Tris Base in ~400 ml distilled water 
pH to 6.8 with concentrated HCl 
Make up volume to 500 ml with distilled water 
 
2M Tris pH 8.9 
Dissolve 121.1 g Tris Base in ~400 ml distilled water 
pH to 8.9 with concentrated HCl 
Make up volume to 500 ml with distilled water 
 
0.5M EDTA 
Dissolve 18.6 g EDTA (mw 372.2 g/mol) in ~90 ml distilled water 
Add NaOH pellets or concentrated NaOH (alkaline conditions) until EDTA dissolves 
Make volume up to 100 ml with distilled water 
 
SDS Running Buffer (10x stronger) 
200mM Tris: 24.2 g 
2M Glycine: 144.1 g 
1% SDS: 10 g (100 ml of 10% SDS)  (check pH is ~8.3- but don‘t adjust) 
Make up to 1litre with distilled water 
 
SDS-PAGE Blotting Buffer 
Tris: 30 g 
Glycine: 95 g 
Make up to 1litre with distilled water   (for small proteins add 10-20% Methanol to buffer) 
329 
 
 
Transfer Buffer (10x stronger) 
248mM Tris: g 
1.3M Glycine: g 
20% Methanol 
Make up to 1litre with distilled water 
 
Stripping Buffer 
0.2M Glycine (pH 2.5): 7.51g 
1% SDS: 10 ml of 10% SDS 
 
Laemmli‘s sample reducing buffer 
Reagents  
0.5M Tris-HCL pH6.8 1.00 ml 
Glycerol 0.8 ml 
10% sodioum dodecyl sulphate 1.6 ml 
2-Mercaptoethanol 0.4 ml 
Bromophenol Blue (0.05 w/v) 0.2 ml 
dH2O 4.0 ml 
 
Coomasie Blue Stain 
1.25 g Coomassie Blue R250 
454 ml 50% Methanol 
46 ml Acetic acid  
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Destain 
25 ml Methanol 
37.5 ml Acetic Acid 
437.5 ml distilled water 
 
TBS (1 litre) (10x stronger) 
0.1M Tris/HCl pH 7.4 12.2 g 
1.5M NaCl 87.7 g 
 
TTBS (0.001% TBS) 
0.1M Tris/HCl pH 7.4 12.2 g 
1.5M NaCl 87.7 g 
1000 l TWEEN 20 per litre of TBS (1x) 
 
BLOTTO 
5g Marvel (5% Non-Fat Dry Milk) 
100ml TTBS 
 
Blocking Solution 
5g Marvel (5% Non-Fat Dry Milk) 
100ml TTBS 
331 
 
Antibody Dilutions and Concentrations 
Primary Antibodies 
Antibody Dilution Concentration 
Total Src 1:1000 0.86 µg/ml 
anti-Clone 28 1:1000 0.5 µg/ml  
Clone28 1:1000 * 
Y416Src 1:1000 0.04 µg/ml 
Y216Src 1:1000 0.2 µg/ml 
Lyn 1:200 1.25 µg/ml 
Lck  1:1000 0.038 µg/ml 
Y861FAK 1:500 * 
*No information provided by company 
 
Secondary Antibodies 
Secondary 
Antibody 
Primary 
Antibody 
Dilution Concentration 
Anti-biotin Biotin Ladder 1:1000 0.1 µg/ml 
Rabbit total Src 1:5000 0.02 µg/ml 
Rabbit anti-Clone28 1:5000 0.02 µg/ml 
Mouse Clone28 1:10000 0.01 µg/ml 
Rabbit Y416Src 1:5000 0.02 µg/ml 
Goat Y216Src 1:10000 0.01 µg/ml 
Mouse Lyn 1:10000 0.01 µg/ml 
Rabbit Lck 1:5000 0.02 µg/ml 
Rabbit Y861FAK 1:10000 0.01 µg/ml 
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Immunohistochemistry 
Reagents 
Antigen retrieval solution: Epitope Retrieval Buffer  (DAKO) 
Xylene (Fisher Scientific) 
Alcohol solutions (100%, 90%, 70%) (Fisher Scientific) 
H202  (VWR) 
Horse Serum (Vector Laboratories) 
Antibody dilutent (DAKO) 
DAKO kit (pen, AB solution, Envision) (DAKO) 
Chromagen 3,3‘-diaminobenzidine (DAB) (Vector Laboratories) 
Haematoxylin (VWR) 
DPX glue (VWR) 
Total Src (60kDa) (mAb) (Cell Signalling Technology) 
Anti-Src family negative regulatory site (pAb)- inactive YSrc530 (Invitrogen) 
Clone28 (mAb)- active YSrc530 (Invitrogen) 
Y416 Src antibody (pAb) (Cell Signalling Technology) 
Y216 Src antibody (pAb) (Santa Cruz) 
Lyn (mAb) (BD Biosciences) 
Lck (mAb) (Cell Signalling Technology) 
Ki67 antigen MIB-1 (mAb) (DAKO) 
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Solutions and Buffers 
Antigen retrieval buffer: 10 mM Cirate Buffer (pH 6.0): 
 
Reagents  
dH2O 990 ml 
Epitope Retrieval Buffer   10 ml 
 
H2O2 (4%) 
13.3 ml H2O2 + 386.7 ml dH2O 
 
Horse Serum (1.5 %) 
15 µl of HS/ ml TBS 
 
Horse Serum (5%) 
50 µl of HS/ ml TBS 
 
TBS Buffer diluted 
TBS (1 litre) (10x stronger) 
0.1M Tris/HCl pH 7.4 12.2 g 
1.5M NaCl 87.7 g 
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Scotts Tap Water Substitute 
Reagents 2 litres 
Magnesium sulphate (MgSO4, 7H20) 40g 
Sodium bicarbonate (NaHCO3) 7g 
 
 
DABO solution(chromagen 3,3‘-diaminobenzidine) 
Reagents  
DAB buffer 2 drops 
DAB substrate 4 drops 
DAB hydrogen peroxide 2 drops 
dH2O 5.0 ml 
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Antibody Dilutions and Concentrations 
Primary Antibodies 
Antibody Dilution Concentration 
Total Src 1:200 4.32 µg/ml 
antiClone28 1:1500 0.33 µg/ml 
Clone28 1:500 * 
Y416Src 1:2000 0.02 µg/ml 
Y216Src 1:25 8 µg/ml 
Lyn 1:5 50 µg/ml 
Lck 1:50 0.76 µg/ml 
Ki67 1:150 533.33 µg/ml 
*No information provided by company 
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Appendix 3: Materials for Dasatinib and cell line experiments 
Reagents 
Dulbecco‘s Modified Eagle Media (DMEM)1  (Invitrogen- 21969) 
Dulbecco‘s Modified Eagle Media (DMEM)2 (Invitrogen- 41966) 
Hank-Buffered Saline solution (HBBS) (Lonza) 
Phosphate Buffered Saline solution (PBS) (Invitrogen) 
DMSO-Freeze Medium (Sigma) 
Heat-inactivated fetal calf serum (Invitrogen) 
Heat-inactivated fetal calf serum (Charcoal stripped) (Invitrogen) 
L-glutamine (Invitrogen) 
Penicillin/Streptomycin (50 units/ml, 50 µl/ml) (Invitrogen 
Sodium Pyruvate (Invitrogen) 
Trypsin/EDTA solution (Lonza) 
Tryptan Blue (Lonza) 
Dasatinib (Src kinase inhibitor) (Bristol-Myers-Squip) 
Heregulin-α (Sigma H-5529) 
Epidermal Growth Factor (Sigma E-9644) 
Insulin (Sigma I-6634) 
Fresh Frozen Human Plasma (Local Blood bank) 
Bovine Alpha Thrombin (Cambridge Bioscience) 
10% buffered formal saline (‗formalin‘) (Genta Medical Formaldehyde) 
Normal physiological saline (0.9%) (Baxter, UKF7124) 
337 
 
Cell line Media and Buffer 
Full medium 
(FM) 
DMEM
1
 
(500ml) 
Foetal calf serum 
(10%)  
(50ml) 
L-glutamine 
(2mM) 
(5ml) 
Penicillin/Streptomycin 
(50units/ ml; 50 µg/ ml) 
(5ml) 
Serum free 
medium  
(SS) 
DMEM
1
 
(500ml) 
- L-glutamine 
(2mM) 
(5ml) 
Penicillin/Streptomycin 
(50units/ ml; 50 µg/ ml) 
(5ml) 
Charcoal 
strip medium 
(CS) 
DMEM
1
 
(500ml) 
Foetal calf serum 
(10%) been 
charcoal stripped 
(50ml) 
L-glutamine 
(2mM) 
(5ml) 
Penicillin/Streptomycin 
(50units/ ml; 50 µg/ ml) 
(5ml) 
HER2- 
medium 
(HER2) 
DMEM
2
 
(500ml)+  
4 mM  
L-glutamine 
Foetal calf serum 
(10%) 
(50ml) 
+ Insulin 
(10mg/ml) 
(750 µl) 
Penicillin/Streptomycin 
(50units/ ml; 50 µg/ ml) 
(5ml) 
Freeze 
medium 
DMEM
1
 DMSO (10%) - - 
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Stock Solutions for Drug Treatment 
All stock solutions were filtered through 0.2 µm filters before being aliquoted for longterm 
storage at -20 ºC. 
Insulin:  
100µl of glacial acitic acid was added to 10 ml dH2O, dissolving 100 mg of insulin powder 
in this solution. Final concentration: 10 mg/ml 
EGF:   
200 µl of glacial acitic acid containing 0.1% BSA was added to vial (0.2 mg of epidermal 
growth factor powder) to reach a concentration of 1 mg/ml. A final stock concentration of 
10 µg/ml (= 1.61 µM) was achieved in diluting this solution further with 20 ml of sterile 
PBS.  
HRG:  
10 mg of BSA was dissolved in 10 ml of sterile PBS. 5 ml of this solution was then added 
to the vial (50 µg Heregulin-α) to accomplish a stock solution of 10 µg/ml (= 1.42 µM). 
Dasatinib:  
24.8 mg of Dasatinib powder was dissolved in 124 µl of DMSO (Dasatinib soluble at 200 
mg/ml). To prepare a 10 mM stock solution, this suspension was further diluted in 4.96 ml 
of DMSO.  
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Drug treatment Dilution and Concentrations 
Drug Molecular 
weight 
(Dalton) 
Suspensed 
in 
Stock 
Concentration 
Final 
Concentration 
Epidermal Growth 
Factor (EGF) 
6200 HBBS and 
BSA/glacial acitic acid 
1.61 µM 10 nM 
Heregulin 
(HRG) 
7000 HBBS and BSA 1.42 µM 10 nM 
Dasatinib 
(DASA) 
488.01 
 
DMSO 10 mM 100 nM 
 
Solutions for cell pellet formation 
Thrombin Stock Solution:  
1ml of saline (0.9%) is added to 1 mg of thrombin and stored at 4-6 
º
C.  
Thrombin Working Solution for Formation of Cell pellet clots: 
1-2 drops of Thrombin stock solution is mixed with a further 1 ml of Saline (0.9%) 
 
